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Abstract 
Species in the Ganoderma lucidum species complex have been regarded as a 
supreme Chinese traditional medicine and are commonly called lingzhi. A hybrid 
was artificially bred by protoplast fusion of wild G, lucidum and cultivar G. tsugae. 
This study compared the performance of the hybrid and its parents in 
anti-proliferative effect of breast cancer cells. 
Hot water extracts of the two parents and their hybrid were prepared from 
different physiological stages obtained by both submerged fermentation and 
solid-state fermentation. These Ganoderma extracts showed anti-proliferative 
effects against breast cancer cell line MCF-7. The experiments were monitored 
using cytotoxicity MTT assay, Trypan blue cell viability assay and BrdU assay which 
measures DNA concentrations. Preparations from different physiological ages and 
strains did affect the efficacy of the anti-proliferation. The best I C 5 0 against MCF-7 
cells was: 0.236 mg/ml and 0.410 mg/ml for extracts prepared from vegetative 
biomass by submerged fermentation and fruiting body by solid-state fermentation of 
the artificial hybrid, respectively. Polysaccharide and terpene fractions of the hot 
water extracts from both vegetative biomass and fruiting body of these 3 lingzhi also 
showed anti-proliferative effects. Yet the reconstituted polysaccharide and terpene 
mixtures enhanced the anti-proliferative efficacies when compared to the hot water 
extracts. 
When the cancer cells were treated with lingzhi extracts, there was a common 
phenomenon that there was a first mitogenic phase followed by an anti-proliferative 
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phase. When the cultured medium collected after the mitogenic phase was used to 
incubate with fresh MCF-7 cells, immediate anti-proliferation was observed. This 
may imply that the mitogenic effect was due to the presence of growth factors, 
hormones or their analogues. As MCF-7 cells express both estrogen receptors 
(ERa and ERP), estrogenicities of the 3 strains were evaluated. Also, the 
anti-cancer potency of lingzhi was tested with another cell line MDA-MB-231 which 
is estrogen-independent and bears ERp. This is the first time that hot water extracts 
from G lucidum, G tsugae and their hybrid were found to bear estrogenicity by in 
vitro E-screen test, estrogen receptor competitor binding assays and pS2 mRNA 
expression assay by RT-PCR. Interestingly, biomass extracts did not compete for 
the ERa while fruiting body extracts showed competitive binding affinities to ER a 
and p. Among the polysaccharide and terpene preparations, only lingzhi terpene 
fractions showed positive results in in vitro E-screen test and estrogen receptor 
competitor binding assays. Unlike the case with MCF-7 cells, only the fruiting 
body extracts were able to inhibit the proliferation of MDA-MB-231 cells. Yet, the 
results imply that one or more estrogen-independent signal transduction pathways are 
involved to effect the anti-proliferation of breast cancer cells. 
The possible mechanisms of lingzhi in anti-proliferation efficacy were studied 
using mRNA expression assay by RT-PCR of anti-apoptotic gene Bcl-2, 
pro-apoptotic gene Bax and tumour suppressor gene p53. The p53 expression level 
was not affected by the hot water extracts of lingzhi. The deduced DNA content per 
cell showed a decreasing trend in the presence of lingzhi extracts in contrast to an 
increasing trend in the control with time. Instead, the bax/bcl-2 ratio was increased 
to different extents for at least 3-fold by lingzhi extracts leading to apoptosis. Thus, 
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lingzhi acted by up-regulation of Bax and down-regulation of Bcl-2 through a 
p53-indepentent pathway. 
In brief, this study showed a selected protoplast fusion hybrid of G lucidum and 
G. tsugae improved its potency in anti-proliferation of breast cancer cells. This is 
also the first report on the estrogenicity of lingzhi. This property might even be 
exploited further when lingzhi products are consumed commercially. This study 
also confirms the anti-proliferative effects of lingzhi against breast cancer cells 
which are either estrogen-dependent or estrogen-independent. The action 
mechanisms might involve cell cycle arrest and induction of apoptosis through the 
Bax and Bcl-2 system. Both the polysaccharide fraction and terpene fraction were 
effective in the anti-cancer property. However, the strain and physiological age 
affected the efficacy. Thus more basic researches are needed to support 
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1. Introduction 
1.1. Ganoderma species 
Laccate Ganoderma spp. are supreme traditional Chinese medicine with 
prevalent worldwide popularity (Berovic et al., 2003). In the Orient, Ganoderma 
spp. are regarded as the herb of longevity. These fungi have been used in folk 
medicine for hundreds of years, and strains are commercially cultivated for 
preparation of health products (Hseu et al, 1996). Classification of Ganoderma is 
shown in Table 1.1 (Chang and Milea, 2004). 
Table 1 • 1 Classification of Ganoderma (Chang and Miles, 2004). 
Classification of Ganoderma 




Family Ganodermaceae ~ 
Genus Ganoderma 
Species in the genus Ganoderma subgenus Ganoderma (or commonly called the 
Ganoderma lucidum species complex) are generally called "lingzhi" which refers to 
a group of fungi including G. lucidum, G. tsugae and G. sinense (Adaskaveg & 
Gilbertson, 1986; Zhao, 1989; Moncalvo & Ryvarden，1997; Lin, 2001). In the past, 
morphology is often used as a differentiation tool of classification of Ganoderma spp. 
as they can be characterized by its varnished, dark red/ shiny red/ purple basidiome 
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(common name: fruiting body) of a circular or kidney-shaped pileus and sometimes 
an eccentric-lateral stipe. Basidiospores are discharged from the basidiome (Mau et 
al., 2001). However, it is insufficient to clarify and distinguish taxa only by 
morphology (Chang and Miles, 2004). 
Ganoderma taxonomy is very complicated as there are over 290 taxonomic 
names published in this genus (Ryvarden, 2000). It is very often that multiple 
names were given to a single species (Buchanan, 2001) which may show similar or 
different morphology and medicinal values (Chang and Miles, 2004). Isolates used 
in pharmaceutical and medicinal studies and, consequently, commercially cultivated 
isolates are generally named G. lucidum. However, as used in the pharmaceutical 
literature, this name encompasses several laccate Ganoderma species which might 
differ in their bioactive compounds. The G. lucidum complex includes G. tsugae 
Murr., G. valesiacum Boud., G. oregonense Murr., G. resinaceum Boud., G. pfeifferi 
Bres” G. oerstedii (Fr.) Torr., G. ahmadii Stey, and several other taxa which are 
restricted to tropical areas (Hseu et al,, 1996). Some of these species are actually 
sexually compatible and bear highly similar or identical nucleotide sequences of 
nuclear ribosomal DNA and mitochondrial ribosomal DNA and other molecular 
properties (Moncalvo et al； 1997; Chen et al., 1999; Cheung, 2001; Hong et al., 
2002; Ma, 2002). Therefore, besides morphology, taxonomic approaches of 
biochemical tests, sequence analyses of ribosomal genes and spacers and rDNA 
analyses might be a more appropriate approach for classification (Mocalvo et al., 
1995 a and b; Gottlieb et al； 2000). 
Ganoderma is cultivated on solid substrates, stationary liquid medium or 
submerged cultivation for commercial exploitation (Berovic et al, 2003). In 2002, 
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the global production of Ganoderma lucidum was estimated to be 4900 - 5000 tons 
and at least 100 brands of G. lucidum products are sold in the market. The annual 
global turnover of G. lucidum products was estimated to be approximately US$2.16 
billion (Li et al., 2004). 
1.2. Bioactive components of Ganoderma spp. 
Different Ganoderma spp. differ in their bioactive compounds leading to 
different bioactivities (Hseu et al., 1996; Eo et al., 2000; Kim et al., 2000; Oh et al., 
2000). Two major categories of bioactive components in Ganoderma spp. are 
polysaccharides and terpenes (Lieu et al., 1993). Polysaccharides from G. lucidum 
were extensively reported to have anti-tumor effect (Wang et al., 2002). Terpenes 
extracted from Ganoderma spp. were reported to induce cytotoxic activity against 
tumor cells (Gan et al., 1998; Noda et al., 1997; Zhu et al., 1999; Min et al., 2000). 
1.2.1. Lingzhi polysaccharide 
Polysaccharides which can be wall polysaccharides or storage carbohydrates, 
are found to be pharmacologically active (Gao and Zhou, 2003). Preparation of 
polysaccharides can be extracted from pileus, spores or biomass produced by 
submerged fermentation (Berovic et al., 2003; Gao and Zhou, 2003). Solubilities of 
Ganoderma polysaccharides in water highly depend on molecular weight and water 
temperature. Hot water can increase extraction efficiency (Gao and Zhou, 2003) 
and low molecular weight polysaccharides generally have higher solubilities 
(Berovic et al., 2003). Nowadays over 100 types of polysaccharides have been 
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isolated from Ganoderma and most of them possess a molecular weight ranging from 
4 X 105 to 1 X 106 in primary structures (Su, 1991; Su et al； 1997). 
Heteropolysaccharides, /3-D-glucans and glycoprotein are components of 
polysaccharides and they are considered as the major contributors of bioactivities of 
Ganoderma spp. (Gao and Zhou, 2003). They have been revealed as effective 
anti-cancer substances with immunomodulatory effects and immunostimulatory 
effects (Habijanic et al., 2001; Kim et al., 1999; Mizushina et al., 1999; Wasser and 
Weiss, 1999). Lingzhi polysaccharide is also able to stimulate host immune 
response mediated by activation of lymphocytes and macrophages in secretion of 
anti-cancer cytokines such as TNF-a and interferon-y (Cao and Lin, 2004). Crude 
Ganoderma polysaccharide extract ganopoly enhanced host immune function via 
increased activity of effector cells such as T lymphocytes, macrophages and natural 
killer cells (Gao and Zhou, 2003). Lingzhi polysaccharide stated here is actually 
referred to ethanol-soluble polysaccharide. This ethanol fraction was firstly 
extracted by 85% ethanol which consisted of more components for 
immunostimulatory and cancer therapy (Habijani et al” 2001; Berovic et al., 2003). 
1.2.2. Terpenes 
Terpenes are specifically found in Ganoderma spp. but not all fiingi (Nishitoba 
et al., 1986). Terpenes are one of the largest classes of phytonutrients which are 
found in green foods, soy products and grains (Zhu et al., 1999). Ethanol, methanol 
and chloroform are commonly used in extraction of terpenes from Ganoderma spp. 
(Gao and Zhou, 2003). The extracts will then be further purified according to 
different methods (Kohda et al., 1985; Su, 1991). Over 119 terpenoids have been 
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isolated from the pilei and mycelia of G. lucidum. They include highly oxidized 
lanostane-type terpenoids such as ganoderic and lucidenic acids, ganodermic acids, 
ganoderenic acids, lucidone, ganoderal and ganoderols (Chen and Yu, 1990; Kim 
and Kim, 1999; Lin and Shiao, 1988; Ma et al, 2002; Shiao et aL, 1988; Wasser and 
Weis, 1999). Terpenes function as antioxidants, protecting lipids, blood and other 
body fluids from attack by free radical oxygen species (Lin, et al； 2003; Zhu et al., 
1999). Also, Min et aL (2000) and Noda et al. (1997) have reported the anti-cancer 
property of lingzhi terpenes. Terpenes synthesize precursor molecules which then 
undergo extensive and subtle alterations for controlling systems in human, often in 
fatty tissues as diverse as meiosis, carbohydrate metabolism, fat storage, muscle 
growth, immune function and nerve cell membrane chemistry (Lin et al., 2003). 
They can pass through cell membranes because of their high lipophilicity and affect 
DNA transcription which in turn alters protein synthesis (Gao and Zhou, 2003). 
1,3. Ganoderma spp. as Chinese traditional medicine 
Lingzhi has been used solely or in combination with other Chinese traditional 
medicine for a long history (Chang and Miles, 2004). It has been used as ancient 
folk medicine for treatment of promoting agility, lengthening life span, relieving 
hepatopathy, nephritis, hyperlipemia, arthritis and asthma (Chang and But, 1986; 
Jong and Birmingham, 1992). It has also been used to treat hepatitis, neurasthenia, 
hypercholesterolemia, bronchitis and cancer (Cao and Lin, 2004; Lin et aL, 1995; 
Yang et al, 2000). Eo et al (1999) revealed that water and methanol extracted 
substances from Ganoderma lucidum contained antiviral activities. Its acidic 
protein-bound polysaccharide was identified to contain antiherpetic activities with 
enhancement in combination with acyclovir and interferons (Oh et aL, 2000; Kim et 
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al., 2000). Isolated ganoderiol F and ganodermanontriol from methanol extract of 
pileus of Ganoderma lucidum were found to act as anti-HIV-1 agents and ganoderic 
acids and ganoderiols were moderately active inhibitors against HIV-1 protease 
(El-Mekkawy et al., 1998). Anti-angiogenic activity of Ganoderma lucidum and its 
inhibition of the inducible nitric oxide production were reported by Song et al. 
(2004). 
Ganoderma lucidum is becoming more popular in treating cancer for its safety 
to consume without genotoxic chromosomal breakage in in vitro test nor cytotoxic 
effect in in vivo test revealed by Chiu et al (2000). Hu et al. (2002) reported that 
alcoholic extract of Ganoderma lucidum induced apoptosis in MCF-7 breast cancer 
cell through up-regulation of Bax. Jiang et al (2004) revealed the anti-proliferative 
effect and induction of apoptosis in PC-3 human prostate cancer cells via 
enhancement of Bax/Bcl-2 ratio. Also, Cheung et a\. (2000) demonstrated that 
Ganoderma lucidum extract is effective in induction of neuronal differentiation of 
PC 12 cells and prevented nerve growth factor-dependent PC 12 neurons from 
apoptosis which is mediated by ras/extracellular signal-regulated kinase (Erk) and 
cAMP-response element binding protein. 
1.4. Artificial hybridisation of Ganoderma lucidum and GL tsugae 
Ganoderma lucidum and G. tsugae are species of Ganoderma lucidum species 
complex mentioned in previous section. General growth conditions of Ganoderma 
lucidum are summarized in Table 1.2. 
6 
Table 1.2 General growth conditions of Ganoderma spp. (Stamets, 1993; Chen, 
1999; Lin, 1996; Chang and Miles, 2004). 
Temperature Mycelial growth ranges 15 - 35^C 
Optimum mycelial growth temperature 24 - 25 °C 
Primordia initiation 18 - 25 
Fruiting body development 20 - 25 °C 
Substrate water content 60 - 65% 
Relative humidity Mycelial running 60 - 70% 
Fruiting development 70 - 85% 
Air Good ventilation is necessary during fructification period 
pH value 5.0 - 5.5 
Light Primordial initiation 500- 1000 lux 
Fruiting body development 750- 1500 lux 
J  
The growth temperature range of G. lucidum is wider than that of G. tsugae 
(Adaskaveg and Gilbertson, 1986)，and this study aims at expanding the growth 
temperature of cultivar G. tsugae by artificially introducing wild germplasm of 
another lingzhi G. lucidum by protoplast fusion which brings two genomes in the 
same cytoplasm (Lau 1985; Zhao 1994; Hanson & Howell 2002; Yoo et al. 2002). 
These two medicinal fungi are found to show different medicinal potencies and their 
bioactive components including polysaccharides, terpenes and immunomodulatory 
protein LZ-8 (Yen and Wu, 1999; Cheung et al., 2000; Chiu et al., 2000b; Lin, 2001; 
Hu et al., 2002; Jiang, et al., 2004). In nature, these fungi grow in different 
geographical areas and defend their own territories as G. tsugae can only fruit at 
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lower temperature (Zhao, 1989; Moncalvo and Ryvarden, 1997; Cheung, 2001; Ma, 
2002). Bred isolates with expanded high and low temperature tolerance will 
significantly reduce the investment and miming cost of mushroom production. 
1.4.1. Protoplast isolation and fusion of Ganoderma tsugae and G lucidum 
Protoplast fusion technique is advantageous for introducing one or more 
polygenic traits and traits with unknown genetic mechanisms for crossing the 
reproduction barrier of two biological species. A number of studies reported that 
protoplast fusion in edible and medicinal mushroom for artificial breeding has been 
carried out in laboratory studies but real application has not been reported (Zhao, 
1994). This may indicate that problems arise in using laboratory isolates which 
may be auxotropic mutants in experimental design to render commercial exploitation, 
decrease quality of the artificial hybrid such as sterility, poor growth, poor fruiting 
and failure in generating hybrids (Lau, 1985; Zhao, 1994; Yanai et aL, 1995; Yoo et 
al., 2002). No study has attempted to carry out protoplast fusion of G. lucidum and 
G. tsugae of which both are lingzhi. This study tested the validity of 
biotechnological breeding scheme with G. lucidum and G. tsugae. 
1.5, Breast cancer 
Breast cancer is the most common cancer in American women and the second 
leading cause of death after lung cancer. According to World Health Organization, 
more than 1.2 million people will be diagnosed with breast cancer this year 
worldwide (WHO, 2005). In 2004, 217,440 new breast cancer cases were 
diagnosed in US where 215,990 were female cases and 1,450 for male cases 
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(Ghafoor et al., 2004). The American Cancer Society estimates that approximately 
211,240 women in the United States will be diagnosed invasive breast cancer in 2005. 
Another 58,490 women will be diagnosed with in situ breast cancer which is the very 
early form of the disease. There would be 1 out of 8 women develop breast cancer 
over the course of a lifetime. Also, an estimated of 1,690 cases will be diagnosed in 
men in 2005 (Ghafoor et al, 2004). 
Cancers is a disease derived from a single cell which has undergone mutation. 
Initial mutation will cause division of cells which in turn leads to production of a 
genetically homogenous clone. Additional mutations then occur and further 
enhance the cells' growth potential. These mutations give rise to subclones within 
tumor with differing properties so that most tumors are heterogeneous (MacDonald 
and Ford, 1997). Tumors can be divided into two main categories, benign or 
malignant. For benign tumors, they are rarely life threatening which grow within a 
well-defined capsule that limits their size, and the characteristics of the origin cell 
would be maintained. However, malignant tumors are not the case. They invade 
surrounding tissues and spread to different areas of the body to generate further 
growths or metastases. Therefore it is often most life threatening as different clones 
within a tumor will have different abilities to metastasize (MacDonald and Ford, 
1997). 
1.5.1. Anti-tumor effects of natural substances against breast cancer cell 
MCF-7 
The MCF-7 cell line was developed at Michigan Cancer Foundation in early 
1970s. It was derived from a woman in the late stages of metastatic mammary 
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carcinoma (Soule et al” 1973). Non-invasive estrogen responsive MCF-7 cells are 
often used as a model for study of anti-cancer drugs, steroid hormone biochemistry, 
toxicology and the effects of estrogens on target tissues (Karin, 2003). It is an 
epithelial cell with cellular products of insulin-like growth factor binding proteins 
BP-2, BP-4 and BP-5 (Sugarman et al., 1985; Takahashi and Suzuki, 1993)，and it 
has been reported to express both ER a and (3 (Burow et al., 2000; Pratt and Pollak, 
1993; van Dijk et al., 1997). The stemline chromosome numbers range from 
hypertriploidy to hypotetraploidy with 2S component occurring at 1% (Huguet et al., 
1994). Marker chromosomes of 29 to 34 per S metaphase and 24 to 28 markers 
occurred in at least 30% of cells. One large submetacentric (Ml) and 3 large 
subtelocentric (M2, M3 and M4) markers were recognizable in over 80% of 
metaphases generally (Lee et al., 1996). 
A number of studies reported that various natural substances inhibited MCF-7 
breast cancer cells growth through different pathways and mechanisms. A widely 
used Chinese herb Huanglian exerted anti-proliferative effect on MCF-7 cells via 
reduction of interferon-/? (IFN-|(3) and tumor necrosis factor -a (TNP-a) (Kang et al., 
2005). Duncan et al. (2005) demonstrated that genistein and docosahexaenoic acid 
(DHA) inhibits the growth of MCF-7 cells through regulation of HMG-CoA 
reductase. Brassica oleracea juice markedly reduced DNA synthesis in MCF-7 
cells (Brandi et al； 2005). A cytotoxic plant alkaloid ellipticine induced apoptotis 
in MCF-7 cells and G2/M phase arrest associated with markedly increase in protein 
levels of p53 (Kuo et al, 2005). Spinasterol from Pueraria roots showed strong 
anti-proliferative effect on MCF-7 cell but its mechanism requires further 
investigation (Jeon et al., 2005). Ganoderma lucidum ethanol extract induced 
apoptosis by up-regulation of Bax and cell cycle arrest which is mediated by 
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up-regulation of p21 and down-regulation of cyclin D1 (Hu et al., 2002). At 
present, no study has been reported for water extract preparation in treating MCF-7 
breast cancer cells. 
1.5.2. Anti-tumor effects of natural substances against breast cancer cell line 
MDA-MB-231 
Invasive breast cancer cell line MDA-MB-231 is an estrogen-independent with 
epidermal growth factor and transforming growth factor a expression (Bates et al., 
1990). It is derived from an aneuploid female with chromosome counts in 
near-triploid range (Siciliano et al., 1979). Normal chromosomes of N8 and N15 
were absent (Huguet et al., 1994). Unassignable chromosomes in addition to the 
majority of autosomes are noted from 11 stable rearranged marker chromosomes 
(Satya-Prakash et al., 1981). MDA-MB-231 cells have been reported to express ER 
13 only (Dotzlaw et al., 1996; Burow et al, 2000). 
Some studies reported that various natural substances possess growth inhibitory 
effect on MDA-MB-231 breast cancer cells. Medicinal plant of Rheum palmatum, 
holarrhena flaibunda and Bangladeshi displayed anti-proliferative effect of 
MDA-MB-231 cells (Abrue et al, 1999; Campbell et al” 2002; Lambertini et al” 
2004; Rowlands et al., 2002). Also, curcumin of spic turmeric induced apoptosis in 
this invasive breast cancer cell line through down-regulation of JNK activation (Li et 
al., 1999; Somasundaram et al, 2002). Sliva et al (2002) reported that water 
extracts of Ganoderma lucidum spore and fruiting body suppresses motility of 
MDA-MB-231 cells but no anti-proliferative effect was demonstrated. 
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Some substances used to treat the above breast cancer cells as hormone 
replacement therapy. Phytochemicals soyasapogenol A and B inhibit both MCF-7 
and MDA-MB-231 breast cancer cells but on the other hand increased the 
estrogen-responsive gene pS2 mRNA expression (Rowlands et al., 2002). Another 
widely studied phytoestrogen genistein also exerted similar effects towards MCF-7 
and MDA-MB-231 cells but proliferative effect was observed at low concentrations 
(10-5-10-8 M) and anti-proliferative effect at high concentrations (IC'^ -IO"^ M) (Wang 
et al., 1996). Wang et al. (1996) also demonstrated the competitive effect of 
genistein with estradiol in binding with ER a and P of a 50% inhibition 
concentration of 5 x 10'^ M and stimulation of pS2 mRNA expression such that 
genistein has been commonly recognized as a phytoestrogen. 
1.5.3. Anti-proliferation of cancer 
1.5.3.1. Cell cycle arrest 
DNA replication and equally distribution to daughter cells are essential in cell 
division (King, 2000). These processes of DNA synthesis and mitosis are separated 
by gaps during which RNA and protein are made and the cell reorganizes itself for 
the next round of division. The first gap (Gl) is sometimes divided to include a GO 
phase in order to differentiate cells from those preparing to enter the next phase of 
the cycle (King, 2000). Differentiation takes cell out of the cell cycle and can be 
represented as an exit from Gl (King, 2000). In first gap phase Gl, DNA 
replication (S) and the second gap phase G2 together make up interphase which the 
period from the end of one nuclear division to the start of the next step of mitosis 
(MacDonald and Ford, 1997; King, 2000). In complex events leading to cancer 
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formation, chromosomal DNA changes occur and generate DNA contents per cell 
that are simple multiples of those in diploid cells. Regulation is essential in 
monitoring the cells in amplification of their DNA and other macromolecules which 
reorganize their interphase chromatin into chromosomes prior to mitosis (King, 
2000). Therefore checkpoints are present to traverse for accurate cell reproduction. 
The G1 checkpoint ensures adequate machinery for future events and accurate 
transmission of genetic information (King, 2000). The G2 checkpoints ensures the 
elimination of damaged cells that may have escaped G1 control or have not 
accurately duplicated their DNA and the M phase spindle assembly checkpoint 
monitors accurate chromosome alignment and retraction into the two daughter cells 
(MacDonald and Ford, 1997; King, 2000). An important tumor suppressor gene 
p53 functions as a cell cycle checkpoint protein by transactivation of genes which 
encode proteins with growth suppressing activities and it exerts its function during 
the G1 phase of the cycle (MacDonald and Ford, 1997). Increase in p53 level in 
response to DNA damage will in turn cause arrest of the cell cycle during G1 and 
give the cell time to repair its DNA. If repair is not possible, p53 induces 
programmed cell death (MacDonald and Ford, 1997). 
1.5.3.2. Cell death 
There are two functions of cell death: tissue remodeling and removal of 
damaged cells that might otherwise harm the rest of the body (King, 2000). Cells 
developed a method for detecting such DNA duplication defects and committing 
suicide in order to prevent unwanted consequences (King, 2000). In carcinogenesis, 
unregulated proliferation or decreased cell death will generate a tumor and the 
objective of cancer treatments is to achieve anti-proliferation of cancer cells 
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(MacDonald and Ford, 1997; King, 2000). There are two types of cell death, 
apoptosis and necrosis. 
Necrosis is the consequences of gross injury to the cells (King, 2000). This is 
an uncontrolled and passive process resulted from extreme changes in the cell. Cell 
lysis is accompanied by an inflammatory response associated with cell damage. 
Cells become leaky, release macromolecules and rapidly disintegrate, thereby 
inducing inflammation in necrosis. Smear of degraded DNA usually seen in necrotic 
cells (King, 2000). It is commonly seen in central regions of solid tumors as poor 
supply of nutrient leading to disruption of energy-dependent, membrane-mediated 
ion channels (MacDonald and Ford, 1997). Increase in cell volume results, and loss 
of membrane integrity leads to the release of lysosomal lytic enzymes such as 
proteases and nucleases (MacDonald and Ford, 1997). 
Apoptosis requires mRNA and protein syntheses (King, 2000). It is an active 
process as opposed to an unplanned process induced by cell injury. Also, apoptotic 
cells are recognized by phagocytes and removed before they disintegrate. As a 
result, there is no surrounding tissue damage or induction of inflammatory responses 
(MacDonald and Ford, 1997). Apoptotic cells show a very characteristic 
morphology with condensation of nuclear chromatin, cell shrinkage and loss of 
positional organization of organelles in the cytoplasm. Electrophoresis of DNA 
extracted from apoptotic cells shows a characteristic laddering pattern of 
oligonucleosomal fragments resulting from intemucleosomal chromatin cleavage by 
endogenous endonucleases (MacDonald and Ford, 1997). Apoptosis is not 
confined to regressing tumors. It is a balance between proliferation and death that 
determines whether a tumor increases in size or becomes smaller. It is also 
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important in determining response to treatments like chemotherapy and radiation 
(King, 2000). 
All essential signals happen outside the nucleus for apoptosis. Induction phase 
ends with the activation of a family of proteases called caspases. These caspases 
alter mitochondrial function in order to release cytochrome C into the cytoplasm and 
in turn activates additional caspases and initiates the final degradation phase. 
Release of cytochrome C leads to formation of mitochondrial membrane pores such 
that apoptosis results (Cory and Adams, 2002). 
The p53, Bcl-2 and Bax are proteins involved in apoptosis (Cory and Adams, 
2002; King, 2000; MacDonald and Ford, 1997; Vousden and Lu, 2002). The p53 
gene is a tumor suppressor gene which locates on the short arm of chromosome 17 
(MacDonald and Ford, 1997). It is primarily located in nucleus but can be detected 
in cytoplasm in G1 and also following DNA synthesis. Induction of p53 leads to an 
irreversible inhibition of cell growth which most decisively acts by activating 
apoptosis (Vousden and Lu, 2002). The tumor suppressor p53 is an important 
component of cellular machinery which responds to genotoxic stresses particularly 
DNA damage. Also, it maintains genomic integrity by arresting the cell cycle or by 
inducing apoptosis (Ko and Prives, 1996; Levine, 1997). Tumor suppressor p53 
protein is found in low level in normal cells because of its short half-life (Levin, 
1997). Double-stranded breaks formed by 7-irradiation and DNA-repair 
intermediates formed by UV irradiation of DNA damage induce p53 levels. 
Although not always, substantial evidence that much of the biological activity ofp53 
is mediated through its regulation of gene transcription (Buckbinder et al., 1995; 
Miyashita and Reed, 1995; Owen-Schaub et al, 1995). 
15 
Up-regulation of Bax is one of the events whereby p53 induces apoptosis. Bax 
gene is known to be transcriptionally regulated by p53 during induction of apoptosis 
(Buckbinder et al., 1995; Miyashita and Reed, 1995). It is a pro-apoptotic Bcl-2 
family member that binds to the anti-apoptotic Bcl-2 family member which in turn 
binds to the anti-apoptotic Bcl-2 protein. This binding will antagonize the Bcl-2 
function to block apoptosis (Cory and Adams, 2002). Bcl-2 is important for its 
anti-apoptotic function (Miysashita and Reed, 1994; Germain et al., 1993). p53 
may mediate down-regulation of Bcl-2 by binding to silence Bcl-2 (Haldar et al., 
1994). 
Estrogen was found to be able to up-regulate Bcl-2 expression in MCF-7 cells 
(Perillo et al., 2000). Estrogen was reported for its control of cell proliferation in 
normal and transformed mammary epithelial cells where expression of immediate 
and delayed hormone-responsive genes was induced (Altucci et al., 1996; Berthois et 
al., 1989). Bcl-2 prevents apoptosis as it inhibit plasma membrane blebbing, 
nuclear condensation and DNA endonucleolytic cleavage which are all classical 
characteristics of programmed cell death after its overexpression (Hockenbery et aL, 
1990), Estrogen inhibits apoptosis in mammary gland and breast cancer cell 
MCF-7 which express functional estrogen receptor by an increase of Bcl-2 mRNA 
level (Ferguson and Anderson, 1981; Kyprianou et aL, 1991; Texixeirs et al., 1995). 
Comparison of apoptosis against necrosis is shown in Table 1.3 below. 
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Table 1.3 Comparison between apoptosis and necrosis (King, 2000). 
Apoptosis Necrosis 
Causes Remodeling of tissue, cell Hypoxia, nutrient shortage, 
turnover, DNA damage, changes in pH and 
growth signals withdrawal temperature 
Morphology 
Affected cells Single Groups  
Cell volume Decreased Increased 
Chromatin Dense Fragmented  
Lysosomes Intact Abnormal  
Mitochondria Normal Abnormal  
Inflammatory response No Yes  
Cell fate Apoptotic bodies Lysis  
Molecular changes 
Gene activity Required Not required  
DNA cleavage Specific Random  
Intracellular Ca^^ Increased No change  
Ion pumps Retained Lost  
1.5.4. Anti-proliferative assays 
— There are a number of assays in determination of anti-proliferation in vitro. 
Three of them which are widely used are MTT, Trypan blue cell viability and BrdU 
assays. 
1.5.4.1. MTT assay 
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliiim bromide] assay was 
firstly described by Mosmaim in 1983. It is based on the ability of a mitochondrial 
dehydrogenate enzyme from viable cells to cleave the tetrazolium rings of pale 
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yellow MTT to form a dark blue formazan crystals which is highly impermeable to 
cell membranes and thus, resulting in its accumulation in healthy cells (Florian et al., 
1999). The cells are then solubilized by addition of detergent and resulted in 
liberation of solubilized crystals. The number of surviving cells will be directly 
proportional to the level of formazan product accumulated and the color can then be 
quantified by simple colorimetric assay (Florian et al., 1999). 
1.5.4.2. Trypan blue cell viability assay 
Percentage of Trypan Blue cell viability assay assesses the cell viability as 
viable cells exclude Trypan blue while dead cells are stained by this dye (Wiley et al., 
1995). This assay measurement is also useful for determining whether cells in 
culture have escaped breakage or disruption (Wright et al., 1992) and in assessment 
of apoptosis (Wiley et al., 1995). The staining procedure is simple and 
determination of percentage of viable cells only requires a light microscope. 
1.5.4.3. BrdU assay 
This assay employs the incorporation of newly synthesized DNA, and 
bromodeoxyuridine (BrdU) is an analogue to DNA base thymidine and competes 
with that base for uptake during the synthesis of DNA. So only those cells that 
have been actively synthesising DNA will take up BrdU which is then quantified to 
give a measurement of cell proliferation (Gratzner, 1982). This method must be 
detected by BrdU-specific antibody conjugated to a reporter system such as 
fluorochrome or enzyme in immunohistochemistry indirectly (Gratzner, 1982). 
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MTT assay is based on the mitochondrial dehydrogenase enzyme in viable cells 
to cleave tetrazolium rings of yellow MTT and form a dark blue formazan crystals 
which is highly impermeable to cell membranes which resulting in accumulation in 
healthy cells whereas cell viability assay employed conventional hemocytometer 
counting of stained dye by trypan blue (Florian et al., 1999). BrdU assay employs 
the incorporation of bromodeoxyuridine (BrdU) into newly synthesized DNA and 
provides a measurement of cell proliferation (Gratzner, 1982). MTT assay allows 
simple, fast, reliable and accurate results compared to cell viability assay as only 
subsample of cells would be counted in cell viability assay. However, MTT is toxic 
to human (Scudiero et al., 1988). BrdU assay has been proved as a very useful too 
for the study of cell kinetics and avoid using hazardous radioisotopes. However, it 
is an indirect method which requires BrdU-specific antibody conjugated to a reporter 
system suitable for use in immunohistochemistry. Also, this assay requires 
extensive processing of samples at predetermined time points and therefore, no 
continuous monitoring of a single sample can be performed (Eriksson et al., 1998; 
Barinaga, 1998; Kempermann and Gage, 1999). In conclusion, MTT assay is the 
best assay among the three assays after comparison and therefore, MTT assay would 
be used primarily for discussion. 
1.6. Endocrine system and hormones 
Endocrine system is a complex system of glands which produce and secrete 
hormones (Benassayag, 2002). A hormone is a chemical released from an 
endocrine gland into the blood. It travels in the blood stream to target organs where 
they stimulate a response. Because of this they have earned the name chemical 
messengers. Hormones travel to all parts of the body but only affect certain cells. 
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The effect of hormones can be rapid, like adrenaline for example. It can also be very 
slow as in the case of growth hormone. There are a number of different glands 

















































































































































































































































































































































































































































































































































































































































































































































































Hormones are signaling molecules synthesized within the body that regulate and 
coordinate physiological and metabolic functions by acting on receptors located on 
or in target cells (Spener, 2002). They can be produced by specialized secretory 
cells that are either localized in secretory glands or within organs that have other 
primary functions. Hormone also exhibits specificity (i.e., correct effects on correct 
cells) which is a sort of lock and key mechanism (Cooper and Kavlock，1997). 
Hormones are categorized into three structural groups; they are peptides and proteins, 
steroids and amino acid derivatives (Kavlock et al., 1996). 
Peptide and protein hormones are products of translation. They vary 
considerably in size and post-translational modifications, ranging from peptides as 
short as three amino acids to large multisubunit glycoproteins (Cooper and Kavlock, 
1997). Many protein hormones are synthesized as prohormones then proteolytically 
clipped to generate their mature form. In other cases, the hormone is originally 
embedded within the sequence of a larger precursor then released by multiple 
proteolytic cleavages (Kavlock et al., 1996). 
Steroids are lipids and, more specifically, derivatives of cholesterol. Examples 
include the sex steroids such as testosterone and adrenal steroids such as Cortisol. 
Steroid hormones are typically eliminated by inactivating metabolic transformations 
and excretion in urine or bile (Cooper and Kavlock, 1997). 
For amino acid derivatives, there are two groups of hormones derived from 
tyrosine. They are thyroid hormones and catecholamines. Two other amino acids 
are used for synthesis of hormones: Tryptophan is the precursor to serotonin and the 
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pineal hormone melatonin, and glutamic acid is converted to histamine (Kavlock et 
al； 1996). 
Most women suffer from menopause disturbing symptoms such as hot flushes, 
night sweats, tension, insomnia, diminished interest in sex, irritability or depression. 
Other symptoms such as fatigue, palpitations, dizziness and headaches may also 
appear. Ovaries no longer producing normal amounts of estrogen which is the 
dominant female hormone may account for the disturbing symptoms associated with 
menopause arise. These symptoms may also result if the normal functioning of the 
ovaries was being interfered. Lack of a normal hormonal balance may also bring 
severe backache which is caused by thinning of the bones (Murkies et al., 1998). 
Due to the importance of estrogen to women, estrogen would be selected for further 
study. 
1.6.1. Estrogen 
Estrogens are polycylic molecules that are rigid and asymmetrical. Specific 
2-D structural features of estrogen deemed important for potency include a 
unsaturated A-ring, a D-ring, substitution by a hydroxy group in the 1 - a - and /or 11-
曰-positions, and a hydrophobic backbone. It appears that any combination of these 
structural alerts results in xenoestrogenic activity (Benassayag et al” 2002). 
Estrogen influences a number of enzymes and contributes on growth and 
differentiation of target organs through several growth factors (Lauritzen, 2000). 
Biosynthesis of estrogens involves a series of enzymatic steps and the biological 
action of estrogens in our body is regulated by the concentration of estrogen in 
23 
circulation, the intracellular conversion into more or less active derivatives and the 
estrogen receptor concentration in target tissues (Pari, 2000). The estrogenic or 
antiestrogenic activity of any chemical depends on the ability of the compound to 
interact with the estrogen receptor (Lorenzo, 2003). 
1.6.2. Estrogen receptors 
Estrogen actions are mediated by binding to specific nuclear estrogen receptors 
(ERs), which act as ligand-inducible transcription factors. These factors regulate 
the expression of target genes that finally producing specific proteins (Benassayag et 
al., 2002; Lauritzen, 2000). ER belongs to nuclear receptor superfamily of steroid 
and thyroid hormones, vitamin D，retinoids and prostanoids (Wahli and Martinez, 
1991; Beato et al., 1995; Mangelsdorf et al, 1995). Two sub-types of ER are 
known to date, the ER a and ER (3. ER a gene is located at chromosome 6 of 
6q25.1 (Menasce et al., 1993). It extends over more than 140 kb which contains 
eight exons and encodes a protein of 595 amino acids with a predicted molecular 
weight of 66,182 Dalton (Pari, 2000) and the molecular structure is shown in Figure 
1.1. — 
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Figure 1.1 ER a gene with an open reading frame begins in the middle of the first 
exon. The protein composed of 595 amino acids is organized into 
functional domains A-F. The A/B region consists of a 
ligand-independent transactivation function, AF-1, which is required 
for maximal ER function. Region C composed of DNA-binding 
domain domain which determines the specificity of target gene 
activation. Domain E contains the hormone-binding domain together 
with a ligand-dependent transcription activation function, AF-2 (Pari, 
2000). 
N-terminal A/B contains a ligand-independent transactivation function, AF-1, 
which is required for maximal ER function (Tom et al., 1989). Region C which is 
characterized by a helix-loop-helix structure stabilized by two zinc atom that 
contains with the DNA-binding domain which determines the specificity of target 
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gene activation (Daniellian et al., 1992; Green and Chambon, 1987; Kumar et al,, 
1986; Pierrat et al, 1994; Webster et al., 1988; Ylikomi et al., 1992). Interaction 
between these domains is necessary and important for estrogen-dependent activation 
of gene transcription (Truss and Beato, 1993). Firstly, estrogen binds to 
ligand-binding domain in region E and dissociation of heat shock proteins would be 
induced followed by formation of stable ER homodimers (Gordon and Notides, 1988; 
Linstedt et al.’ 1989; Kumar and Chambon, 1986; Smith and Toft, 1993). Secondly, 
the hormone-activated ER dimmer interacts through the DNA-binding domain with 
regulatory DNA enhancer sequences and specific ER-binding DNA sequences was 
identified in the 5' region of several estrogen-inducible target genes (Seiler-Tuyns et 
al., 1986; Martinez and Wahli, 1989). These estrogen-inducible target genes are 
called estrogen response element (ERE) and are characterized by a 13-base pair 
palindrome with 5-bp stems separated by a 3-bp spacer and a consensus sequence of 
GGTCAimnTGACC (Klein et al., 1986; Klock et al., 1987). Finally, the 
E2-ER-ERE complex is postulated to promote the dissociation or inactivation of 
corepressor proteins and the recruitment of coactivator proteins with the most of 
interaction with AF-2 domain (Horwitz et al., 1998). This protein-DNA complex 
contains the nucleus of a preinitiation complex to which RNA polymerase II and 
other basal transcription factors can bind efficiently to activate high levels of gene 
transcription (Bagchi et al., 1992; Ptashne, 1998; Ptashne et al., 1997). 
Several factors regulate the transcriptional activity of ER such as the nature of 
the ligand, the phosphorylation-state of the receptor and interactions with coactivator 
proteins (Beato et al., 1995; Katzenellenbogen et al., 1996). The action of 
estrogens is antagonized by anti-estrogens which bind to ER in a competitive maimer 
against E2, but on the other hand fail to effectively activate gene transcription 
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(Wakeling and Bowler, 1988; Berry et al., 1990，Jordan and Murphy, 1990; Montano 
et al., 1996). A second ER gene was identified in 1996. It is located in 
chromosome 14 of 14q22-24 and designated ER l3 where as the classical ER gene 
was termed ER a (Kuiper et al., 1996; Mosselman et al., 1996). ER a and ER (3 
share a basic three-domain structure with N-terminal domain (A/B domain) which is 
highly immunogenic and comprises sites for interaction with proteins involved in 
transcriptional activation (Enmark and Gustafsson, 1996). Also, it possesses a 
central DNA-binding domain C and ligand-binding domain E/F domain. The 
highest degree of homology between ER a and ER is in the DNA-binding domain 
with 95% identity of amino acid sequence. On the other hand the homologies of 
A/B and E/F donmains are less than 20% and 60% respectively (Kuiler et al., 1996). 
ER a and ER (3 binds to estradiol with high affinity and specificity. Also, they both 
activate transcription of reporter genes containing estrogen response elements in a 
hormone-dependent manner (Kuiper et al., 1996; Tremblay et al., 1997; Barkhem et 
al., 1998). It was assumed that ER-mediated gene transcription required binding of 
E2 to ER as well as interaction of ER with ERE in 1980s (Pari, 2000). Subsequent 
work discovered that neither hormone binding nor receptor-DNA contact is essential 
and that at least two alternate pathways exist for ER-mediated gene transcription and 
this is revealed in Figure 1.2. 
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Figure 1.2 Schematic representation of different pathways of ER-mediated gene 
transcription, (a) classical pathway involves both binding of E2 to ER 
followed by interaction with ERE resulting in hormone-induced gene 
transactivation (arrow), (b) ERE-independent pathway that ER 
interacts with another transcription factor and bound to its respective 
response element, (c) E2-independent pathway involves interaction of 
intermediary factors with receptor and transcription factor and transfer 
of activation signal to transcription complex 
The first pathway other than the classical pathway is that ER interacts 
synergistically with another transcription factor. This may explain Ez-induced 
expression of certain genes with identifiable EREs. Nuclear receptors acts with 
other transcription factors to give synergistic effect and this can be demonstrated by 
two mechanisms. The first one is cooperative binding of both proteins to DNA and 
the second mechanism is intermediary factors that interact with receptor and 
transcription factor and transfer of activation signal to transcription initation complex 
(Bastian and Nordeen, 1991). The second pathway is achieved by peptide growth 
factors and protein kinase activators which can stimulate ER mediated gene 
transcription in an Ei-independent manner. These factors can activate ER through 
phosphorylation in the absence of hormone (Pari, 2000). 
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1.6.3. Estrogen action 
Estrogens affect the growth, differentiation and function of tissues of the female 
reproductive system (i.e. uterus, ovary and breast)，as well as non-reproductive 
tissues such as bone and the cardiovascular system (Turner et al., 1994; White et al., 
1995). Both receptors have a distinct tissue distribution and play a distinct tissue 
distribution and play a distinct role in physiology (Mueller, 2002). Table 1.5 shows 
the estrogen actions on classical and non-classical target organs and Table 1.6 shows 
the distribution of ER a and & in our body (Gustafsson, 1999). 
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Table 1.5 Estrogen actions on classical and non-classical target organs in human 
body (Diel et al., 2002). 
Classic targets Non-classic targets 
Ovary Kidney 
Vagina Islets of Langerhanus 
Uterus Liver 
Mammary gland Bone 
Adrenal gland Cardiovascular system 
Prostate Macrophages 
Pituitary gland Thymocytes 
Hypothalamus Lymphoid cells 





Table 1.6 Distribution of ER a and (3 in human body (Gustafsson, 1999). 
ERa ER/5 
Central Nervous System \f 
Cardiovascular System V 
Breast V \f 
Liver \f X 
Gastrointestinal Tract X sf 
Urogenital Tract 
Bone V \f 
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Three mechanisms of estrogen action have been identified at cellular level. The 
first one is that: estrogen regulates the expression of target genes by binding to 
nuclear ER as mentioned in section 1.8.3. The second mechanism is that: estrogen 
mediates cell functions via non-genomic pathways modulated by interaction with cell 
membrane ER. Cell fractionation, ligand binding and immunohistochemical studies 
have demonstrated the existence of a cell membrane ER (Pappas et al., 1995). 
Membrane and nuclear receptors were similar for both mass and affinity for E2. 
However, the number of membrane ER a was only three percent of the nuclear ER a 
density and the corresponding number for membrane ER was only two percent 
(Razandi et al., 1999). It is obvious that the great majority of receptors are nuclear 
but some ER proteins appear to undergo post-translational modification by lipid 
addition or glycosylation targeted to the cell membrane. Lastly, the third 
mechanism is estrogen which is metabolized to catechol estrogens, which may be 
carcinogenic (Pari, 2000). 
Estrogen plays a role at various stage of life beginning with oocyte maturation 
and embryonic development (Hou et al., 1993; Hou et al., 1996) and it is mitogenic 
for several cell types with the major estrogen target tissues, particularly epithelial 
cells of the mammary gland, uterus and vagina. 
ER a and jS are also expressed in malignant tissue with concentrations different 
from those found in corresponding normal tissue. Breast cancer can be 
characterized by a high level of ER a expression (Vollmer et al., 1990). Research 
of ER-positive breast cancer cell lines revealed that E2 increased the rate of cell 
proliferation by two mechanisms, i.e. by recruiting noncycling cells from GO state 
into cell cycle and by shortening the overall cell cycle time due to a reduction in 
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length of G1 phase (Hou et al., 1996). Reports of anti-estrogen support this by 
treating MCF-7 cells which leaded to growth arrest with a reduction in proportion of 
cells in S phase and a concomitant increase in the percentage of cells (Taylor et al., 
1983; Wakeling et al., 1989). Decrease in cell proliferation rate can be negated by 
simultaneous or subsequent addition of E2 providing support for the concept that 
anti-estrogens inhibit cell proliferation by competitive inhibition of estrogen-induced 
mitogenic signaling (Sutherland et al., 1983). 
1.6.4. Estrogenicity assays 
An endocrine disrupter or anti-estrogen is advantageous in treating cancer. 
Regulatory agencies and scientific community have put a lot of effort in 
identification of estrogenic potential of synthetic and natural compounds. For this 
reason, several in vitro and in vivo assays were developed for testing of 
estrogenicity of compounds (Shelby et al., 1996). 
These are 4 most common in vitro assays (Fong et al., 2000; Jorgensen et al., 
2000; Karin, 2003). They are recombinant yeast assay determining ER 
binding-dependent transcriptional and translational activity, E-screen assay measures 
the cell proliferation of estrogen sensitive cells, estrogen receptor competitor binding 
assay measures the hinging affinity of a sample for ER and lastly, pS2 mRNA 
expression assay which studies the expression of an estrogen-responsive gene. One 
of the in vivo assays is uterotrophic assay (Fong et al., 2000). 
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1.6.4.1. Recombinant yeast assay 
No endogenous steroid hormone receptor is present in yeast cell (Metzger et al., 
1988) and human ER was discovered to be able to function in yeast (Metzger et al., 
1988). Receptor structure and function of selected ligands as well as the activity of 
selected ligands are then studied using recombinant yeast strain Saccharomyces 
cerevisiae (Zacharewski, 1997). 
Routledge and Sumpter (1996) first published the recombinant yeast estrogen 
screen which has been prevalently used for rapid screening of estrogenic compounds. 
These assays mediate the ER function by modulating the rate of transcription of its 
target cell genes. 
This assay is based on the ability of a compound to activate ER-dependent 
transcriptional activity and so, reporter gene expression is a result of molecular 
cascade of events implicated in receptor activation and indicates the estrogenic 
activity of a compound (Karin, 2003). Yeast cells are stably transfected with 
human estrogen receptor a gene together with expression plasmids estrogen 
responsive elements and lac-Z reporter gene encoding for the enzyme 
jS-galactosidase (Routledge and Sumpter, 1996). Cells are incubated with a test 
compound for 3 days. Compound displaying estrogenic activity would bind to the 
estrogen receptor, transcription of lac-Z reporter genes resulted. /5 -galactosidase 
activity is measured colorimetrically as it metabolizes yellow chlorophenol red-/5 
-D-galactopyranoside into chlorophenol red. Result is expressed in activity ratio 
compared to ITjS-estradiol (Fong et al., 2000; Harris et al, 1997; Hamblen et al., 
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2003). Estrogen as an estrogenic reference is assayed with samples in parallel and 
the estrogenic activity of the sample is compared to the estrogen standard. 
To determine the relative potency in agonism studies, induction can be 
compared to the induction by a reference estrogen. On the other hand when 
dose-response data are generated, E C 5 0 for the test substance can be determined and 
compared with that for the reference of estrogen. In antagonism studies, reference 
estrogen together with the test substance are simultaneously added to the cells while 
only reference estrogen is added to control cells. Estrogen antagonism is measured 
by the difference in the induction of reporter gene product in the presence and 
absence of the test substance (Fong et al.’ 2000). 
For anti-estrogenic activity, estrogen is added at a concentration that exerts a 
maximal response. The inhibition of estrogen induced color change by the 
compounds is then determined (Routledge and Sumpter, 1997; Sohoni and Sumpter, 
1998). 
Absence of endogenous steroid hormone receptors and resulting lack of 
complex interactions between ER and other receptors accounts for the weakness of 
this assay (Routledge and Sumpter, 1996). Since ER is transfected into the cell, no 
consideration was made based on the effect of mutant or variant receptors which are 
known to be present in receptor-positive cell lines such as MCF-7 cells (Sluyser, 
1992; Pfeffer et al., 1996). One important note in disadvantages of this assay is that 
active transport mechanisms in yeast cell wall may differ from those found in 
mammalian cells which may in turn affect the activity of some test compounds 
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(Legler et al, 2002a). Furthermore, yeast cells have to grow in steroid hormone free 
medium in order to ensure low background levels. 
1.6.4.2. E-screen assay 
MCF-7 cells are extensively used for the study of estrogenic compounds. 
Lippman et al. (1976) discovered the estrogen responsive cell growth of MCF-7 cells 
and Soto et al. (1992) developed the E-screen assay which employs the proliferation 
of MCF-7 cells which gives a response to estrogen. Proliferation of MCF-7 human 
breast cancer cells as a response to estrogen is measured in E-screen assay. This 
assay is based on three premises: (i) charcoal-dextran treated serum added to the 
medium inhibit the proliferation of MCF-7 cells, (ii) estrogen induces cell 
proliferation by opposing this inhibitory effect, and (iii) non-estrogenic substances do 
not neutralize the inhibitory signal present in serum (Soto et al” 1992, 1995; 
Sonnenschein et al” 1996; Zacharewski, 1997). A standardized number of MCF-7 
cells are seeded in each well and allowed to attach for 24 hours, and then the medium 
is changed. Cells are then allowed to proliferate for 4 - 6 days in the presence of 
medium containing serum rendered estrogenless by charcoal-dextran adsorption, 
along with a range of concentrations of the compound being tested. After 
incubation, several methods can be used for quantification. Cells can be lysed and 
nuclei counted on a Coulter counter. The E-screen then compares the number of 
cells present following incubation in the presence or absence of the test substance 
(Soto et al., 1992, 1998). The end point of this assay has been modified by Komer 
et al. (1998) who utilized a colorimetric end point which is measured by MTT assays 
rather than counting cells or nuclei. Firstly, the inhibition of estrogen action by the 
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compound is tested with a range of concentrations of presumptive antagonist added 
to the medium containing the minimal dose of estrogen which induces maximal 
proliferation. An assumption is made that a compound inhibits estrogen action via 
receptor-mediated phenomenon. In other words, increasing estrogen concentration 
can reverse it. Secondly, the minimum dose of the antagonist required for 
maximum inhibition is studied for a range of doses of estrogen (Soto et al, 1998). 
However, it has been shown that the E-screen may not be as estrogen specific as 
assumed, since a range of non-estrogenic substances has been found to influence the 
proliferation of MCF-7 cells such as mitogens, cytokines, growth factors, nutrients 
and hormones other than estrogens (Osborne et al； 1990; van der Burg et al., 1992; 
Dickson and Lippman，1995; Jones et al” 1998; Diel et al, 1999; Ando et al, 2002). 
In addition, considerable inter-laboratory variability has been observed in test results 
from the E-screen. Furthermore, the E-screen is more time consuming than the 
other assays and is thus considered impractical for extensive monitoring studies 
(Fong et al., 2000; Karin, 2003). Finally, false positive results may occur in 
determinations of estrogenic compounds and false negatives may also result for 
cytotoxic substances and gereral growth inhibitors (Karin, 2003). 
1.6.4.3. Estrogen receptor competitor binding assay 
Competitive binding assay is based on the binding action of test compounds to 
ER. This assay is well established and has been prevalently used to determine 
ER-ligand interactions. ER binding assay can be performed with receptors obtained 
from cytosolic or nuclear extracts of various mammalian and other vertebrate tissues 
(Ankley at al., 1998; Karin, 2003). 
36 
There are two types of ER binding assays, radiolabelled and non-raidolabelled 
(Fong et al., 2000). Most ER binding assays based on the quantification of the 
ability of a test compound to compete with radiolabelled 17/5-estradiol ([^H]E2) for 
binding to the ER. High-speed centrifugal fraction of rat uterine cytosol or cell 
extract is incubated with excess [^ H]E2 and various concentrations of unlabelled test 
compounds in a typical competitive hormone binding assay. Compounds will 
displace a fraction of [ H]E2 from receptor in a concentration dependent manner if 
they compete with [^ H]E2 for receptor binding. The higher the concentration of the 
competitor, the more [ H]E2 is displace from ER (Gray et al., 1997). 
For non-radioactive method, fluorescent polarization (Bolger et al., 1998) or 
enzyme-linked receptor assays (Seifert et al., 1999) have been reported. However, 
these methods have not been widely used for environmental samples (Karin, 2003). 
I C 5 0 is denoted for the concentration at which a 50% decrease in binding of estrogen 
to the receptor resulted from incubation with the testing compound. Relative 
binding affinity can also be used for expression as result which is the ratio between 
the IC50 of the test compound to estrogen (Soto et al., 1998). Schematic diagram is 
shown in Figure 1.4. 
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Figure 1.3 Schematic diagram showing the principle of estrogen receptor 
competitor binding assay. 
This assay is important for characterizing a compound as a ligand to ER (Fong 
et al., 2000; Karin, 2003). However, ER binding does not determine the ligand as 
an agonist or an antagonist (Karin, 2003). Furthermore, the ability of a compound 
to activate the molecular cascade of events in gene transcription and protein 
synthesis associated with adverse effects is not studied in this assay (Karin, 2003) 
and non-competitive displacement may result from high concentrations of competitor 
ligand (Zacharewski, 1997; Jobling, 1998). 
ER binding assays are significantly less sensitive that other in vitro assays 
although these tests are fast (Karin, 2003). Furthermore, binding assays are not 
easily amenable to automation which limiting their utility as a screening tool (Fong 
et al； 2000; Karin, 2003). Also, the binding of a substance to ER is only indicative 
that it may act as a xenoestrogen and some studies suggested that ER binding may be 
a poor predictor of more complex in vitro and in vivo response (Karin, 2003; 
Villeneuve et al., 1998). 
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1.6.4.4. Endogenous estrogen-regulated gene expression assay 
This assay is based on quantification of estrogen-induced changes in the 
expression levels of endogenous genes either in cultured cells or in selected tissues 
from exposed animals. Identification of estrogenic compounds via induction of 
vitellogenin in trout hepatocyte cultures was measured by Petit et al. (1997). 
Regulation of different signaling pathways as well as genes that are regulated 
directly by ER can be studied through gene expression assay (Jorgensen et al., 2000). 
Also, effects derived from both test compound and its metabolites are detected 
including tissue specific effect (Jorgensen et al., 2000). 
This assay is done by using estrogen-dependent breast cancer MCF-7 cells and 
differentiate expression in gene are assayed by reverse transcriptase-polymerase 
chain reaction (RT-PCR). Expression levels are subsequently quantified by Bio-rad 
Gel Doc imaging. Induction or repression of endogenous estrogen-regulated 
marker genes in human breast cancer MCF-7 cells were studied in this assay (Fong et 
al.’ 2000). The three commonly used marker genes are pS2, transforming growth 
fact 13 3 (TGFi33) and monoamine oxidase A (Jorgensen et al., 2000). 
1.6.4.4.1. Transforming growth factor (3 3 
TGF/5 3 expression is regulated by estradiol in MCF-7 cells by repression (Bates 
et al., 1988). Tissue specific expression of TGFjSS has been demonstrated by 
Takahashi et al. (1994). The expression is regulated by nonestrogenic compounds 
(Dannecker et al., 1996) and it is necessary to include additional marker genes for 
verification. TGFjS 3 inhibits the growth of MCF-7 cells and secretion of TGFjS 3 is 
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induced by antiestrogens (Knabbe et al., 1987) but it was only slightly increased after 
exposure to a high concentration of partial antiestrogen 4-OH-TAM (Jorgense et al., 
2000). 
1.6.4.4.2. Monoamine oxidase A 
Monoamine oxidase A (MAO-A) gene encodes one of the two monoamine 
oxidase proteins. Expression and activity of MAO genes (A and B) have been 
studied for both in vivo and in vitro systems (Ma et al., 1993; Ma et al., 1995; 
Holschneider et al., 1998). Correlation between mood changes and estradiol levels 
which may be mediated through the activity of monoamine exidase in in vivo 
systems was studied (Klaiber et al., 1996; Klaiber et al,, 1997; Chakravorty et al., 
1997). Sarabia and Liehr (1998) demonstrated that expression of MAO-B may be 
induced by estrogen in hamster kidneys but on the other hand, Ma et al. (1995), 
Holschneider et al (1998) and Jorgensen et al. (2000) observed that activity and 
expression of MAO-A are inversely correlated between in vivo and in vitro to 
estradiol concentration respectively. 
1.6.4.4.3. pS2 
pS2 mRNA expression level is a prevalently used indicator of estrogenicity and 
the translation product of pS2 mRNA is also induced in MCF-7 cell in response to 
estrogen which makes it an ideal model to study estrogen-regulated gene expression 
(Jakowlew et al, 1984; Kim et al., 2000). pS2 gene is the prototype of an 
estrogen-responsive gene which expresses by regulation at transcriptional level 
through ER binding to an ERE (estrogen response element) in the pS2 promoter 
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(Sewack and Hansen, 1997). It is a 9 kDa encoded pS2 protein which is a peptide 
of trefoil family which is involved in regulation of proliferation and activation of 
Ras/MEK/MAP-kniase signal transcduction pathway by direct interaction with 
epidermal growth factor receptor (Rio, 1997; Taupin et al., 1999). Nonestrogenic 
compounds could not induce pS2 expression in MCF-7 cells (Jorgensen et al., 2000). 
The human pS2 gene possesses an imperfect estrogen response element (ERE) which 
contributes for its estrogen-dependent regulation (Berry et al； 1989). Further, 
Jorgensen et al. (2000) demonstrated the high correlation of estrogen concentrations 
with pS2 gene expression. This result suggested that this system employing the 
marker gene pS2 was the most sensitive in detection of estrogenic compound among 
this assay. 
It is essential that protocols of PGR amplification of cDNA synthesized from 
different RNA samples do not introduce significant variation (Jorgensen et al., 2000). 
This assay is more time consuming and less suited for large-scale screening of 
chemical compounds comparing to other more simple in vitro assays described 
before (Fong et al； 2000; Jorgensen et al., 2000). 
1.6.4.5. Uterotrophic assay 
Rodent uterotropic assay is one of the most extensively used in vivo assays for 
estrogenicity assay in which the stimulation of uterine growth is determined (Connor 
et al., 1996; Reel et al., 1996). In a typical uterotropic assay, immature female rats 
with 21 - 22 day old or ovariectomized adult female rats of 6-8 weeks old are treated 
for 3 days orally or subcutaneously with the testing compounds. The animals are 
sacrificed on day 4 and the absolute uterus weights are determined (Diel et al., 2002). 
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The treatment period may be shorter or extended up to 14 to even 28 days. The 
choice of the species of animal is not a critical variable as it has been proved that a 
similar sensitivity of rats and mice to a variety of different chemicals (Jefferson and 
Newbold, 2000). The design of this assay is suitable for investigating potential 
antiestrogenic properties of testing chemicals as they may reduce or abolish the 
uterotrophic response to estradiol (Kangas, 1992). However, this system is time 
consuming and variation among individuals could be significant. Also, the 
physiological response of the tested animal is still far apart from the human body 
(Fong et al., 2000; Jefferson and Newbold, 2000; Kangas, 1992; Karin, 2003). 
1.6.4.6. Comparison of in vitro and in vivo assays 
Although in vitro assays are faster and simpler for screening of potential 
estrogenic compounds, there are a lot of drawbacks compared to in vivo systems. In 
vivo assays allow detection of multiple mechanisms such as bioavailability 
toxicokinetic, metabolism and cross talk between biological pathways where as in 
vitro assays are only mechanism-specific (Zacharewski, 1997). In vitro assays may 
lead to false negatives for compounds that are bioactivated and overestimate the 
potency for a compound readily inactivated in vivo. In other words, in vitro 
systems are limited in their abilities to mimic whole animal metabolism (Soto et al., 
1995; Sohoni and Sumpter, 1998; Andersen et al., 1999; Legler et al., 1999; Tyler et 
al., 2000; Layton et al., 2002) and the complex processes of uptake, binding to 
carrier proteins, transport, targeting and disposition of compounds in whole animals 
are not taken into account in in vitro assays (Zacharewski, 1997). Also, 
bioaccumulation and homeostatic controls are not mimicked by in vitro tests as they 
could not reveal compounds that possess anti-estrogenic responses in vivo by 
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modifying endogenous estrogen levels mediated by the effects on hypothatlamus or 
pituitary (Karin, 2003). Integration of estrogenic effects of in vivo assays may 
occur by different mechanisms in multiple tissues simultaneously (Karin, 2003). In 
other words, in vivo studies are essential for linking exposure to biologically relevant 
effect. However, in vivo studies are impractical for routine, high throughput 
determination of large scale samples (Fong et al., 2000; Karin, 2003). Generally 
speaking, in vivo studies are more laborious, time consuming and costly compared to 
in vitro assays. Also, they may involve a large number of animals. Moreover, 
significant inter-individual variations always exist in responses. Utilization of in 
vitro assays circumvents much of the inter-individual, seasonal and temporal 
variability which can complicate interpretation of in vivo responses (Fong et al., 
2000; Karin, 2003). Furthermore, in vitro assays avoid ethical issues associated 
with whole animal studies. In conclusion, in vitro assays are better for primarily 
screening of potential estrogenic compounds and combination of in vitro and in vivo 
assays is suggested in determination of estrogenic activity of samples (Fong et al., 
2000; Karin, 2003). In vitro and in vivo assays measure different end points at 
different levels of biological complexity of estrogen action. No single assay can be 
regarded as ideal for monitoring the estrogenic activity. They all have advantages 

























































































































































































































































































































































































































































1.7. Aim of study 
This study aims to improve the cultivar G. tsugae strain by introducing wild 
germplasm of G. lucidum using protoplast fusion. The improvement was then 
assessed in the following aspect: a. extension of growth temperatures; b. growth rates 
and fruiting yield; and c. anti-proliferative effect on breast cancer cells. The success 
of this breeding programme exemplifies an application of biotechnology in 
commercial mushroom exploitation. 
1.7.1. Objectives 
In order to achieve the aim of this study, the following experiments were carried 
out in order to: 
• carry out protoplast fusion, screening and selection for an improved Ganoderma 
strain as an artificial hybrid of G. tsugae and G. lucidum; 
• evaluate the anti-proliferative efficacy of G. lucidum, G. tsugae and the bred 
isolate on estrogen-dependent breast cancer cells MCF-7 and 
estrogen-independent breast cancer cells MDA-MB-231 ； 
• determine the optimal physiological stage of Ganoderma species for the best 
anti-cancer bioactivity against breast cancer cells; 
• prepare different fractions of the hot water extracts of Ganoderma for this 
anti-cancer bioactivity and compare and contrast their efficacies; 
• as a pioneer study reveal the estrogenicity of G. lucidum, G. tsugae and the bred 
isolate; As a result, this study revealed the estrogen-independent pathway for 
anti-cancer effect of Ganoderma., 
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• last but not the least unveil the myth of lingzhi, a supreme traditional Chinese 
medicine, in anti-cancer bioactivity against breast cancer. 
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2. Methodology 
2.1. Fungal culture 
Cultivar Ganoderma tsugae Murr. (PI) was provided by Peninsular Innovations 
Limited and G. lucidum (W. Curt.: Fr.) P. Karst. (P2) were used (Cheung, 2001; Ma, 
2002). The identities of the two parents were confirmed by sequence analyses of 
nuclear ribosomal DNA repeat (ITSl, 5.8S and ITS2) and mitochondrial small 
subunit of ribosomal DNA (Mt-SSU-rDNA) and mating compatibility test (Cheung, 
2001; Ma, 2002). These cultures were maintained at complete medium plates at 
room temperature in darkness. 
2.2. Artificial hybridisation of Ganoderma tsugae and G. lucidium 
2.2.1. Protoplast isolation of Ganoderma tsugae and G lucidum 
Ganoderma tsuage and Ganoderma lucidum were cultured on PDA medium 
plates at 25�C for about 1 week. Then the mycelium was blended (Blender cup, 
high speed for 1 minute) and transferred into complete medium liquid medium 
consisting of 0.5 g MgSCU.THiO，0.46 g KH2PO4, 1 g K2HPO4, 2 g peptone, 20 g 
D-glucose per 1 liter volume and cultured for 3 days to a log phase at 28°C in 
darkness at 120 rpm. The actively growing mycelia were harvested by filtration 
through autoclaved nickel sieve of 1 mm in diameter and were rinsed with an 
osmotic buffer (0.6 M mannitol solution) (Sigma, M-9546) (Zhao, 1994; Cheung, 
2001). The harvested mycelia were weighted and suspended in filter-sterilized 2% 
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lytic enzyme solution containing 10 mg/ml Novozyme (Sigma, V-2010) dissolved in 
osmotic buffer to enzymatically remove the fungal cell wall (Cheung, 2001). 
Digestion of cell walls was allowed to proceed for 2.5 hours for G. tsuage at 30 
with shaking at 100 rpm and 2 hours for G. lucidum with the same incubation 
conditions. Hyphal fragments were removed by filtration through a column of 
cotton packed up to the 1 ml mark of a 10-ml syringe. Isolated protoplasts were 
washed twice with 0.6 M maimitol solution by centrifugation (5500 x g, lOmin) and 
finally suspended in the same osmotic stabilizer (Zhao, 1994; Cheung, 2001). 
Protoplast yield was quantified with a hemacytometer under phase contrast light 
microscopy. 
2.2.2. Protoplast fusion of Ganoderma tsugae and G lucidum 
Approximately 5.0 x 10^  protoplasts from each parent were combined in a 
screw-capped tube (Falcon, cat. no. 352096) and centrifuged (5500 x g, 5min). 0.5 
ml fusogen of 30% (w/v) containing polyethylene glycol (Sigma, MW 3350, 
P-95904), 0.05M CaCh and 0.05M glycine (pH was adjusted to 8 with O.OIM NaOH) 
were added. The protoplast suspension was then mixed by rolling the tube gently 
for 10 minutes at 30°C in darkness (Zhao 1994). A second 0.5 ml of fUsogen was 
added, and the fusion mixture was mixed again by rolling gently. Following 
incubation at 30°C for 10 minutes, the suspension was diluted with 4 ml 0.6M 
maimitol gently. Protoplasts were collected by centrifugation and suspended in 5 
ml 0.6M maimitol. Concentrations of protoplasts were determined by a 
hemacytometer. About 2000 protoplasts were plated on regeneration minimal 
medium consisting of 4 g D-glucose, 4 g yeast extract, 10 g malt extract and 15 g 
agar in 0.6 M maimitol per 1 L volume for regeneration of cell wall (Lau, 1985; Zhao, 
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1994; Cheung, 2001). After incubation at 28°C in darkness for 3 - 5 days, 100 
visible colonies were picked and transferred to CM as putative hybrid isolates. 
2,3, Screening and selection of hybrid 
2.3.1. Temperature screening 
Screening and selection of hybrid were primarily done by temperature screening. 
The putative hybrids were cultured in 24-well plates on complete medium and 
incubated at two growth temperatures (18 and 37°C) for 3 days in selection for 
fast-growing isolates. The two parents were examined in parallel. Three 
replicates were done for each isolate and isolates with faster growth rates at both 
temperatures were selected for further analyses. 
2.3.2. DNA fingerprint by Arbitrarily-primed polymerase chain reaction 
2.3.2.1. Extraction of genomic DNA 
Isolates with faster growth rates were selected to proceed to DNA fingerprinting. 
Genomic DNA was extracted using DNA extraction kit of NucleoSpin® Plant 
(Macherey & Nagel，740570250) and protocol was provided by supplier. About 
100 mg of fresh mycelia of each parent and the putative hybrids were weighed. 
Then 200 [xl cell lysis buffer CI were added to the mycelia. The sample was 
homogenized and vortex mixed briefly. The mixture was incubated at 60°C for 30 
minutes followed by centrifugation at 14,000 x g for 5 minutes. The clear lysate 
was collected and 300 jul buffer C4 premixed with 200 fxl ethanol were added to each 
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sample. Then the mixture was loaded to a new tube with NucleoSpin� Filter 
column and was brought to centrifugation for 1 minute at 14,000 x g. The 
flow-through was discarded. This step was repeated until all the lysate has passed 
through the column. Then, 400 buffer CW were added to the column followed 
by centrifugation for 1 minute at 14,000 x g. Flowthrough was discarded. Next, 
700 /xl buffer C5 were added to the column and centrifuged for 1 minute at 14,000 x 
g and flowthrough was discarded. Another 200 /xl buffer C5 were added to the 
column again, and the whole tube was brought for centrifugation at 14,000 x g for 2 
minutes in order to remove buffer C5 completely and dry the silica membrane of the 
column. The column was then placed into a new 1.5 ml centrifuge tube and 100 fil 
elution buffer CE, which was preheated to 70°C, were transferred onto the membrane 
of the column. The tube was incubated at room temperature for 5 minutes. After 
the incubation, the tube was centrifuged for 1 minute at 14,000 x g for elution of the 
DNA. 
2.3.2.2. Arbitrarily-primed polymerase chain reaction 
Putative identification of the hybrid was carried out using arbitrarily-primed 
polymerase chain reaction (Chiu et al. 1993, 1996). The arbitrary primers used in 
this study are: EcoRI ext, TAGGCGTATCACGAGGCCCT; ITS5, 
5‘-AAGTAAAAGTCGTAACAA-3‘； and TGF，5'-AGGCTCCGATAG-3‘ (Welsh 
& McClelland 1990; Williams et al 1990; Chiu et al 1993, 1996). Then, 10 jtil of 
reaction mixture containing IX Reaction Buffer, 3.5 mM MgCl�，0.2 mM dNTPs, 10 
pM primers, 1.5U Taq DNA polymerase (Thermoprime Plus), about 300 ng DNA 
and ultra pure water were prepared. The thermal program consisted of 2 
low-stringency cycles of 94°C for 2 min, 35°C for 1 min and 72°C for 2 min, 
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followed by 35 high-stringency cycles of 94°C for 2 min, 55°C for 1 min and 72°C 
for 2 min with the last extension time lengthened to 10 min with the use of thermal 
cycler PTOIOOTM (MJ Research, Inc.). DNA fingerprints were resolved by 
agarose gel electrophoresis, and images were captured using a gel documentation 
system (BIO-RAD Gel Doc 1000). 
2.3.2.3. Gel electrophoresis 
Agarose gel of 2% (0.8 g of agarose (Ordinary Electrophoresis Grade; Beijing) 
dissolved in 40 ml of Ix TBE buffer) was set. Then, 1 [i\ loading buffer (30% 
Glycerol, 0.25% Bromophenol Blue, 0.25% Xylene Cyanole) was mixed with 2 of 
each PCR sample, and 1 |il of GeneRuler™ lOObp DNA Ladder Plus, ready-to-use 
(MBI Fermentas) together with 4 |il deionized water as DNA size marker was run in 
parallel. Samples were loaded into wells of the solidified gel. They were allowed 
to run at 120V for 25 minutes. It was visualized using ethidium bromide staining. 
Gel image was captured using a gel documentation system (BIORAD Gel Doc 
1000). 
2.4. Confirmation tests 
2.4.1. Somatic incompatibility test 
Mycelia of plate culture of putative hybrids were paired with the parents in 
complete medium plate in the somatic incompatibility test (Chiu et al., 1998; Cheung 
2001). After 2 week incubation at 25°C in darkness, the plate was checked for the 
presence of barrier inbetween the colonies of the putative hybrid and its parents. 
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2.4.2. DNA fingerprinting by speciHc polymerase chain reaction 
2.4.2.1. Specific Polymerase Chain Reaction (PGR) 
The nuclear ribosomal DNA (ITSl, 5.8s and ITS2) and mitochondrial ribosomal 
DNA were amplified using fungal-specific primers ITSl and ITS2, MSI and MS2 
respectively (White et al 1990; Cheung 2001; Ma 2002). House keeping gene 
tubulin was also under study using primer TGF. Another set of primer PSIL 
forward and backward primers designed from Pleurotus sajor-caju laccase 1 (Gene 
bank no. AJ507324) was also used in studying the DNA fingerprinting of parents and 
hybrid. The primer sequences are as follows: 
Table 2.1 The primers used for DNA fingerprints. 
Primer Sequence Amplification 
product (bp) 
ITS 1 5 '-TCCTCCGCTTATTGATATGC-3 ‘ 700 
ITS 2 5'-GGAAGTAAAAGTCGTAACAAGG-3’ 
MS 1 5 ‘ -C AGC AGTC AAGAATATT AGTC AATG-3 ‘ 2500 
MS 2 5'-GCGGATTATCGAATTAAATAAC-3， 
TGF forward 5'-AGGTGTCGGACACCGTCGT-3’ 200 
TGF backward 5 '-GCAGGCAAGTCGTGATACCC-3 ’ 
PSIL forward 5'-GAATGCGGTGCTTCCTACTG-3‘ 591 
PSIL backward 5'-CCGACAGCTAAAGCGGGTAT-3‘ 
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A reaction mixture containing IX Reaction Buffer, 3.5 mM MgCl2, 0.2 mM 
dNTPs, 10 pM primers, 1.5U Taq DNA polymerase (Thermoprime Plus) and about 
100 ng DNA was prepared, and ultra pure water was used to make up the volume to 
10 /xL Specific PGR program consisted of 95�C for 1 min; 58�C for 1 min and 70�C 
for 1 min for 39 cycles with the last extension time lengthened to 10 min (Cheung, 
2001; Ma, 2002). For another set of primer PSIL the annealing temperature was 
lowered to 45°C. PCR products were resolved by 2% agarose gel electrophoresis, 
and images were captured using a gel documentation system (BIO-RAD Gel Doc 
1000). The band of the expected size was cut from the gel and purified by a 
GENECLEAN® SPIN Kit (Qbiogene，Canada). 
2.4.2.2. Purification of PCR products 
PCR product band from ethidium bromide-stained agarose gel was excised 
using a razor blade under minimal 310 nm UV exposure. Then 5 fig DNA or a 
maximum of 300 mg agarose gel were transferred to a spin filter of the 
GENECLEAN® SPIN Kit (Q-Bio gene, 1101-600). Next 400 fil were added to 
each spin filter followed by heating at 55®C for 5 min and inverting the spin filter in 
every minute. This was to elute out the DNA from the agarose gel and prevent the 
binding of DNA with the filter instead of the proprietary silica matrix and chaotropic 
binding salt. The spin filter was brought to centrifugation at 14,000 x g for 1 min. 
Flow-through was discarded and 500 /xl of NEW Wash from the kit were added to 
the filter to further remove remaining contaminants. It was then centrifuged for 
another 30 seconds and flow-through was discarded again. The pellet was dried 
after spinning for 2 more minutes at 14,000 x g. The filter was then transferred to a 
fresh catch tube. Then 10 (xl elution solution were added to the filter, and the tube 
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was gently shaken. In order to elute out the DNA, the tube was spun for 30 seconds 
and another 5 /xl elution solution were added to improve the recovery efficiency. 
Afterwards it was spun down for 30 seconds again, and the filter was then discarded 
and purified DNA was collected. 
2.4.2.3. Cycle-sequencing 
Cycle sequencing mixture consisting of 1 |LI1 forward primer of the target gene, 1 
[il dRhodamine Terminator, 4 (PE Applied Biosystems, 403042) and purified 
DNA template together with ultrapure water in order to make up to a final volume of 
10 |LIL The thermal profile was: 36 cycles of DNA denaturation at 95°C for 30 s, 
annealing at 50°C for 30 s and extension at 70°C for 1 min. 
2.4.2.4. Sequencing 
The cycle-sequencing products were precipitated by 26 |j,l of 95% ethanol with 
3 M sodium acetate (pH 5.2) (Sigma, S-8625). Then all cycle sequencing products 
were added to 0.6 ml PGR tube followed by incubation in ice for 15 minutes for 
precipitation. Then the mixture was centrifuged at 14,000 x g for 25 minutes. The 
supernatant was discarded after centrifligation. The pellet was washed with 200 [il 
70% ethanol. The mixture was then vortex mixed and centrifuged at 14,000 x g for 
20 minutes. Supernatant was discarded again, and the pellet was vacuum dried for 
2 minutes. Then 12 /xl Hi-Dye Formamide (Applied Biosystem, 4311320) were 
added to each tube containing the pellet. The pellet was resuspended by vortex 
mixing, and a pellet was formed by spinning down the suspension. The mixture 
was then denatured at 95°C for 2 minutes using thermal cycler PTC-IOOTM (MJ 
54 
Research, Inc.). After the denaturing step, the tubes were placed in ice bath 
immediately for 5 minutes to prevent fusion of DNA strands. The mixture was 
centrifuged, and the supernatant was pipetted out as a template for ABI Prism 3100 
Genetic Analyser (PE Biosystems). 
2.4.2.5. Sequence analysis 
The sequence generated by the ABI Prism 3100 Genetic Analyser was 
processed by the software Sequencing Analysis version 3.0 (PE Biosystems). 
Sequences were aligned used web tool ClustalW and phylogenetic trees were 
constructed by UPGMA (unweighted pair-group method using arithmetic averages) 
and neighbor-joining provided by MEGA (Molecular Evolutionary Genetics 
Analysis, version 3，2003). 
For PSIL, specific forward and backward primers were designed for specific 
PGR reaction of genomic DNAs of both parents and hybrid using PrimerExpress 2.0 
(Perkin-Elmer). Several parameters were considered as primers should be 23 - 28 
nucleotide long, the GC content of the primers was within the range of 50 - 70 %, 
and a Tm of at least 65°C and whenever possible, the Tm should be greater than 70°C. 
The forward primer of PSIL designed was 5'- ATTGACTGCCATGCGCTCA -3' 
and backward 5，- GGAAGCTCTGTCTCGCCATC -3，with a target amplicon of 280 
base pairs. 
After specific PGR with conditions stated in section 2.4.6.1, the PCR products 
of PSIL were purified and sequenced as stated in sections 2.4.6.2, 2.4.6.3 and 2.4.6.4. 
The sequence generated by the ABI Prism 3100 Genetic Analyser was again 
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processed by the software Sequencing Analysis version 3.0 (PE Biosystems). 
Sequences were aligned used web tool ClustalW and phylogenetic trees were 
constructed by UPGMA and neighbor-joining (unweighted pair-group method using 
arithmetic averages) provided by MEGA (Molecular Evolutionary Genetics Analysis, 
version 3，2003). 
2.5. Characterisation of the selected hybrid 
2.5.1. Scanning electron microscopy (SEM) 
2.5.1.1. Preparation of specimens for scanning electron microscopy 
The specimens were fixed in 2.5% glutaraldehyde fixative in PBS (O.IM PBS 
consisting of 36 ml stock solution of 7.10 g anhydrous Na2HP04 / 250 ml and 14 ml 
stock solution of 3.90g NaHyPCU • 2H2O /125 ml of pH 7.2) for 4 hours at 4�C under 
vacuum. Afterwards, they were washed twice with PBS at room temperature for 5 -
10 minutes in order to displace the fixative. Then, 50, 70, 85, 95 and 100% ethanol 
were used for up serial dehydration with each step lasted for 10 minutes. Step using 
95% ethanol was repeated twice, and three times for 100% ethanol. The specimens 
were dried by liquid carbon dioxide using critical point dryer (LADD 28002) and 
were then coated with alloy of gold and palladium by a sputter coater for 30 minutes 
(Edwards SI SOB). Coated specimens were examined with a scanning electron 
microscope (JSM-5300, JOEL). 
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2.5.1.2. Cytological Studies of pileus, stipe and spores of G. lucidum, G. tsugae and 
hybrid 
Structures of pileus, stipe and spores of G. lucidum, G. tsugae and hybrid were 
examined under SEM. Basidiomes were cultivated in mushroom cultivation complex, 
The Chinese University of Hong Kong (CUHK). Spores were collected from a 
matured basidiome whereas its pileus and stipe were separated. Both pileus and stipe 
were cut horizontally and longitudinally. The structures of hymenophores, 
basidiospores and stipes were examined. 
2.5.2. Temperature effect 
The selected hybrid and the parents were cultured at 5 different temperatures 
(18, 25，30’ 37 and 40°C) in complete medium plates. The radius of a mycelilal 
colony was measured after 5-day incubation. 
2.5.3. Submerged fermentation 
Mycelia of G. lucidum, G. tsugae and one selected hybrid were cultured in 250 
ml complete liquid medium. Air-lift benchtop fermenter (BioEnginerring Type 
KLF W. no. 12250) was used for submerged fermentation of G. lucidum, G. tsugae 
and hybrid. Complete medium of 0.5 g MgSCU.THzO, 0.46 g K H 2 P O 4 , 1 g K 2 H P O 4 , 
2 g peptone, 20 g D-glucose per 1 L was prepared. In-situ sterilization was carried 
out at 121°C for 30 minutes. The temperature was adjusted to 28°C. After 
inoculation, the fermentor was incubated at 28�C at 200 rpm for 5 days at 28°C. 
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Mycelia and filtrate were harvested, freeze-dried and weighted as biomass and 
filtrate respectively. Submerged cultivation was carried out three times for each of 
the 3 strains, G. lucidum, G. tsugae and the hybrid. 
2.5.4. Fruiting test 
Similarly, G. lucidum, G. tsugae and one selected hybrid were brought to 
fruiting tests. Fruiting tests were carried out in the mushroom cultivation complex, 
Department of Biology, The Chinese University of Hong Kong (CUHK) for 
experimental production with 30 bags per isolate. Autoclavable plastic bags were 
used for fruiting trial with each bag contained 500 g of a novel formulated fruiting 
substrate, consisting of (%，w/w): sawdust, 60; milled coconut fibre, 20; wheat bran, 
14; sucrose, 5; (agricultural grade) and lime, 1% (modified from Chiu et al,, 1998， 
2000a). Mycelial running was carried out at 28°C in darkness. The compost was 
then transferred to a fruiting environmental chamber in the mushroom cultivation 
complex, CUHK after it was completely colonized. Basidiomes were induced by a 
photoperiod of 12 h light 12 h dark, incubation at 28°C and relative humidity of 85% 
or above. 
2,6, Bioactive components of G lucidum, G tsugae and hybrid 
2.6.1. Sample preparation 
Pileus and stipe were collected after the harvest of fruiting bodies. Biomass 
and filtrate were collected by submerged fermentation using air-lift fermenter. 
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Pileus, stipe, biomass and filtrate were freeze-dried and stored in desiccators until 
use. 
2.6.2. Lingzhi polysaccharide 
The extraction method of lingzhi polysaccharide was described by Berovic et al. 
(2003). In brief, 0.5 g of mycelium (biomass) and pileus of the Ganoderma 
lucidum, G. tsugae and hybrid were freeze dried and rinsed with 85% ethanol in order 
to eliminate low-molecular components. The first fraction of intracellular 
polysaccharides was extracted with hot water at 100�C for 3 hours. Then the 
samples were brought to filtration through Whatman GF/C filter and filtrate was 
collected. The collected filtrate was concentrated by freeze-drying, and then 
resuspended in ultra pure water. Lingzhi polysaccharide was then precipitated by 
96% ethanol. 
2.6.3. Terpenes 
Firstly, 0.1 g freeze-dried biomass or pileus was homogenized and saponified 
with 0.5 ml saturated aqueous potassium hydroxide (Sigma, P-6310). Then 8 ml of 
absolute ethanol were added to each sample in a screw-capped tube followed by 
incubation at 85°C for 30 minutes. The unsaponificable matter was extracted with 
20 ml hexane. Then the sample was diluted with 12 ml water and shaken at 200 rpm 
for 1 hour. The hexane extract was collected and rotary dried. The dried extract 
was weighed, resuspended in 1 ml diethyl ether (HPCL grade) and analysed by 
GC-MSD (GC，Aglient Technologies Network, 6890N; MSD, Aligent Technologies, 
5973N). Sample was injected by Hewlett Packard (HP) 7673 automatic injector 
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into a HP 6890 series gas chromatograph (Atlanta, GA) connected to mass selective 
detector at 62.5 kN m \ AHP-5 MS column of 5 % phenyl methyl silicone (0.25 mm 
X 30 m X 25 fim film thickness) was used, and putative identification of the terpenes 
was analyzed by matching the mass spectra of the resolved peaks with the stored 
spectra in the library (NIST 98.1). The carrier gas was helium at flow rate 50 
ml/min. GC operating conditions are shown below. 
Table 2.2 The temperature profile for gas chromatography analysis of terpenes. 
Rate (°C/min) Temperature (°C) Time (min) 
- 150 5 
5 300 10 
Post run 200 
Total run time 45 min 
2.7. Effect of extracts against breast cancer cell lines 
2.7.1. Cell culture 
The human MCF-7 and MDA-MB-231 breast cancer cell lines were obtained 
from ATCC (Manassas, VA). MCF-7 cells were maintained in Minimum Essential 
Medium (MEM) (Gibco BRL, cat. 61100-061) supplemented with 2.2 g sodium 
bicarbonate (Sigma, S-6014), 1:100 sodium pyruvate solution (Gibco BRL, cat. 
11360-070) and 1:100 MEM Non-essential amino acid solution (Gibco BRL, cat. 
11140-050) per L medium together with 10% fetal bovine serum (FBS) (Gem Cell, 
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cat. 100-500) in a humidified incubator at 37�C and 5% CO2. MDA-MB-231 breast 
cancer cells were cultured in RPMI Medium 1640 (Gibco BRL, cat. 11875-036) 
supplemented with 2 g sodium bicarbonate per L medium and 10% fetal bovine 
serum (FBS) (Gem Cell, cat. 100-500) in a humidified incubator at 37�C and 5% 
C O 2 . 
2.7.2. Lingzhi Extract preparation 
Firstly 100 ml ultra pure water were added to 1 g freeze dried stipe, filtrate, 
pileus or biomass. Hot water extracts were prepared by autoclaving the extracts at 
121°C for 20 minutes at 1 KPa pressure. The extracts were aliquoted into separate 
vials and stored at -20°C. Each vial was wanned at 2>TC before use. 
2.7.3. Optimization of cell density 
The optimal cell density of each cell line was determined by growth curve 
analysis using MTT assay and cell viability test. 
2.7.3.1. MTT assay 
Cell proliferation was studied by the tetrazolium salt method which based on the 
ability of live cells to convert tetrazolium salt into purple formazan. The follow cell 
densities were seeded in 96 well plates: 1x10^ 2x10^ 4x10^ and 8xlO^/welL The 
medium was replaced with fresh medium after overnight incubation. The cells were 
harvested at indicated times of 24，48，72 and 96 hours. At the end of the indicated 
periods, 15 of 5 mg/ml thiazolyl blue terazolium bromide (Sigma, M-5655) 
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solution were added to each well, and the plates were further incubated for 2.5 hours 
at 37°C. The medium was removed and 80 jil MTT solubilization solution (10% 
Triton, 90% isopropanol with 10% IN HCl) were added to each well to dissolve the 
water-insoluble purple formazan crystals. The absorbance at wavelength 570 nm 
was measured with a microplate reader (Molecular Devices, spectra Max 250). All 
the measurements were performed in 5 replicates. The growth curve was plotted 
with data shown at mean 土 SD. 
2.7.3.2. Trypan blue cell viability assay 
Cells were cultured in 96-well plate with cell density of 1x10^ 2xl04，4x10"^  and 
8xl04/ml. The medium was replaced with fresh medium after overnight incubation. 
The cells were harvested at indicated times of 24，48, 72 and 96 hours. At the end 
of the indicated periods, medium was removed, and 25 |il 0.25% Trysin-EDTA 
(Gibco BRL, 15400-054) were added to each well and incubated for 2 minutes. 
Then 25 \xl 0.4% Trypan Blue solution (Sigma, T-8154) were added to each well 
after the incubation. The cell suspension was loaded to the counting chamber of a 
hemocytometer and the number of unstained cells was counted. The growth curve 
was plotted with data shown in mean 土 SD. 
2.7.3.3. BrdU assay 
Cells were cultured in 96-well plate with cell density of 1x1 O*，2x10^  4x1 O^  and 
8xl04/ml in a 96-well tissue culture grade with flat and clear bottom multi well plate 
(Iwaki, cat. no. 3860-096) in 100 |iL medium. Medium was removed on the next 
day and replaced with 150 |LI1 medium. The cells were then incubated in the 
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humidified incubator supplemented with 5% CO2 at 37°C. Cells were harvested at 
the end of the incubation period (i.e. 24，48’ 72 and 96 hours). At the specified 
incubation period, 15 nl/well BrdU labeling solution were added to give a final 
concentration of 10 loM BrdU labeling solution. The cells were reincubated for 
additional 2 hours at 37°C. The labeling medium was removed after the 2-hour 
incubation by tapping off the plate. Then 200 lul/well FixDenat were added to each 
well and the cells were incubated for 30 minutes at room temperature. The 
FixDenat solution was removed thoroughly by flicking off and tapping again. 
Afterwards, 100 |il/well Anti-BrdU-POD working solution was added to the cells 
followed by incubation for about 30 minutes at room temperature. The antibody 
conjugate was then removed by flicking off and the cells were rinsed three times 
with 200 |il/well washing solution. The Washing solution was left in the well for 3 
minutes during each washing step which may help to reduce background and 
increase precision. The Washing solution was removed by tapping and the clear 
bottom was then sealed with a black adhesive foil, and 100 jal/well Substrate solution 
was added to each well using a multi-channel pipetteman. All wells were started 
within a minimum period of time and incubated at room temperature for at least 3 
minutes on a shaker. In order to avoid burning out of substrate, samples were 
quantified within 10 minutes after adding the reagent, and the light emission was 
measured in a microplate luminometer (ML3000; Microliter® Plate luminometer). 
2.7.3.4. Growth curve of MCF-7 
The growth curves of MCF-7 are shown in Figures 2.1，2.2，2.4. The 
correlation of MTT and cell viability assay is shown in Figure 2.3 and correlation of 
MTT and BrdU assay is shown in Figure 2.5. From Figures 2.1，2.2 and 2.4，3 x 
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lO^cells/ml was found to be the optimum cell density of MCF-7 cells. From the 
correlation analysis, the R^ of the 4 cell densities were all above 0.8 for both MTT 
and cell viability assay and also BrdU assay. Therefore, MTT assay would be used 
as the primary screening assay for convenience. 
2.7.3.5. Growth curve of MDA-MB-231 
The growth curves of MDA-MB-231 are shown in Figures 2.6 and 2.7，and Figure 
2.8 shows the correlation of MTT and cell viability assay. The determined optimal 
cell density for MDA-MB-231 cells was 2 x lO'^ cells/ml. 
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Figure 2.1 Growth curves of MCF-7 cells determined by MTT assay. Cell 
densities of 1x10^ 2x10^ 4x10^ and 8xlO^/welL The medium was 
replaced with fresh medium after overnight incubation. The cells 
were harvested at indicated times of 24，48，72 and 96 hours. 
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Figure 2.2 Growth curves of MCF-7 cells determined by Trypan blue cell 
viability assay. Cells were cultured in 96-well plate with cell 
density of 1x1 (A 2x10^ 4x10^ and SxloVml. The medium was 
replaced with fresh medium after overnight incubation. The cells 
were harvested at indicated times of 24, 48, 72 and 96 hours. 
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Figure 2.3 Correlation of growth curves derived from MTT assay and cell 
viability assay. R of the four cell densities are above 0.8. 
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Figure 2.4 Growth curves of MCF-7 cells determined by BrdU assay. Cells 
were cultured in 96-well plate with cell density of lxlO\ 2x10^ 4x1。斗 
and 8xl04/ml. The medium was replaced with fresh medium after 
overnight incubation. The cells were harvested at indicated times of 
24, 48, 72 and 96 hours 
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Figure 2.5 Correlation of growth curves derived from MTT assay and BrdU 
assay. R^ of the four cell densities are above 0.8. 
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Figure 2.6 Growth curves of MDA-MB-231 determined by MTT assay. Cell 
densities of 1x10^ 2x10^ 4x10^ and SxloVwell. The medium was 
replaced with fresh medium after overnight incubation. The cells 
were harvested at indicated times of 24, 48, 72 and 96 hours. 
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Figure 2.7 Growth curves of MDA-MB-231 determined by Trypan blue cell 
viability assay. Cell densities of 1x10^ 2x10^ 4x10^ and 8xlO^/well. 
The medium was replaced with fresh medium after overnight 
incubation. The cells were harvested at indicated times of 24, 48，72 
and 96 hours. 
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Figure 2.8 Correlation of growth curves of MDA-MB-231 derived from MTT 
assay and cell viability assay. R^ of the cell densities are above 0.8. 
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2.7.4. Anti-proliferative effect of extracts on MCF-7 cells 
2.7.4.1. MTT assay 
MCF-7 cells were cultured in 96-well plate with cell density of 3xl0Vwell and 
incubated overnight. Then medium was removed and replaced with medium with 
stipe, filtrate, pileus and biomass extracts of two parents and hybrid with 
concentrations of 1，0.5，0.25, 0.125, 0.0625 mg/ml and incubated for indicated times 
of 24，48, 72 and 96 hours as mentioned in section 2.7.3.1. All the measurements 
were performed in 5 replicates and presented in percentage of inhibition which was 
calculated by the following formula: 
0/ r-- ControlABs-SampleABs 、 ， … 。 ， 
% of inhibition = X 100% ControlABs 
The experiment has been repeated for three times and representative data were 
presented. I C 5 0 was calculated using EPA Probit analysis programme used for 
calculating LC/EC values version 1.5. Samples with the lowest I C 5 0 values would 
be proceeded to trypan blue cell viability assay and BrdU assay. 
2.7.4.2. Trypan blue cell viability assay 
Trypan blue cell viability assay mentioned in section 2.7.3.2 was used to study 
cytotoxicity of the extracts to the cells. In brief, MCF-7 cells were cultured in 
96-well plate with a cell density of 3x10 /well and incubated overnight. Then they 
were treated with pileus and biomass extracts of two parents and hybrid with 
concentrations of 1，0.5，0.25，0.125, 0.0625 mg/ml for indicated times of 24，48，72 
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and 96 hours. All the measurements were performed in 5 replicates and presented 
in percentage of inhibition which was calculated by the following formula: 
Viable cell no. Viable cell no. 
in Control _ in Sample cell 
% of mortality = X 100% 
Viable cell no. 
in Control 
2.7.4.3. BrdU assay 
The DNA replication assay was done using BrdU assay kit. MCF-7 cells were 
seeded at a density of 3xl0Vwell in a 96-well tissue culture grade with flat and clear 
bottom multi well plate (Iwaki, cat. no. 3860-096) in 100 pL medium. Medium was 
removed on the next day and replaced with 150 \i\ medium in the presence of various 
concentrations of pileus or biomass extracts of the two parents and hybrids. The 
cells were then incubated in the humidified incubator supplemented with 5% CO2 at 
37°C. Cells were harvested at the end of the incubation period (i.e. day 1, 2，3 and 4) 
and the procedure has been mentioned in section 2.7.3.4. All the measurements 
were performed in 5 replicates and presented in percentage of inhibition which was 
calculated by the following formula: 
DNA content in Control - DNA content in Sample % of mortality = — X 100% DNA content in Control 
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2.7.5. Study of cultured medium effect of biomass and pileus extracts on 
MCF-7 cells 
2.7.5.1. Cultured medium effect of biomass and pileus extracts 
MCF-7 cells of 3 x 10^  cells per ml were first treated with biomass and pileus 
extracts for two days. Then the medium was collected and filter sterilized. The 
filter sterilized medium was then added to newly seeded MCF-7 cells (procedure 
mentioned in 2 . 7 . 4 . 1 ) again to study for anti-proliferative effect. I C 5 0 was 
calculated using EPA Probit analysis programme used for calculating LC/EC values 
version 1.5. 
2.7.6. mRNA expression assay (RT-PCR) 
2.7.6.1. Effect of extract on gene expression 
MCF-7 cells were seeded at a density of 9 x lO'^  cells/well in 6-well plate. 
They were incubated with MEM supplemented with 10% FBS and maintained in 5% 
C O 2 in air at 37°C. Medium was changed on the next day, and 1 mg/ml pileus or 
biomass extract of G. lucidum, G. tsugae and hybrid was added to the well. Cells 
were harvested at Day 4 and RNA extraction was carried out afterwards. 
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2.7.6.2. Time effect of extract on gene expression 
MCF-7 cells were seeded at a density of 9 x cells per well in 6-well plate. 
They were incubated with MEM supplemented with 10% FBS and maintained in 5% 
CO2 in air at 37®C. Medium was removed and replaced with medium together with 
1 mg/ml pileus extract of hybrid. Cells were harvested at Day 0，2 and 4 (i.e. 0, 48 
and 96 hours) and RNA extraction was conducted afterwards. 
2.7.6.3. Isolation of RNA 
Total RNA was isolated using TRIzol reagent (Invitrogen, 15596-018). Then, 1 
ml TriPure Isolation Reagent was added to each well. Next, the cell suspension was 
harvested and transferred to 1.5 ml eppendoff. Then 200 [i\ chloroform were added 
to each sample tube followed by vortex mixing vigorously for 15 seconds. The 
mixture was then kept on ice until centrifugation was carried out at 14,000 x g for 15 
minutes at 4°C. The supernatant was transferred into a new eppendoff tube and the 
RNA was precipitated with 500 [x\ of isopropanol. The precipitated RNA was 
collected by centrifugation at 14,000 x g for 10 minutes at 4°C again. Supernatant 
was discarded after precipitation and the RNA pellet was washed by 1 ml 70% 
ethanol. Then the ethanol was removed by centrifugation at 14,000 x g for 10 
minutes at 4°C and the pellet was dried in a DNA Speed Vac (Eppendrof, 
Concentrator 5301) for 15 minutes. The pellet was resuspended in 20 |il dimethyl 
pyrocarbonate (DEPC) (Sigma, D-5758) treated ultra pure water. The quantity and 
purity of RNA were determined by spectrophotometry. 
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2.7.6.4. Quantification and qualification of DNA and RNA by spectrophotometry 
Nucleic acids were quantified by spectrophotometry and 2 |Ltl of sample were 
added into 198 \x[ of water using a 96 multi well plate for measuring UV absorbance. 
OD260 of 1 was taken to correspond to approximately 4 |Lig/|il RNA. The quality of 
nucleic acids was determined by the ratio of OD260 and OD280. For pure RNA, the 
ratio of OD260/OD280 is around 2. 
2.7.6.5. First strand cDNA synthesis 
Firstly, 1 |ig of total RNA was mixed with 1 |il of oligo(dT)i2-i8 (10 pmol/jil) 
together with 1 |li1 PCR grade dNTPs mix (Invitrogen, 10297-117) and made up to 
the volume of 10 i^l with DEPC-treated water, which was RNase-free. The reaction 
mixture was incubated at 65°C for 5 minutes using a thermal cycler PTC-IOOTM (MJ 
Research, Inc.). At the end of the incubation period, the mixture was chilled on ice 
for at least 1 minute. After chilling, 4 |il 5X RT buffer, 2 0.1 M dithiothreitol 
(DTT) (purchased with M-MLV Reverse Transcriptase), 1 [iL RNaseOUT 
Recombinant RNase inhibitor (Invitrogen, 10777-019) were added to each reaction 
mixture. Then the mixture was incubated at 42°C for 2 minutes and chilled on ice 
again afterwards. Then 1 \x\ of M-MLV Reverse Transcriptase (Invitrogen, 
28025-021) was added and the mixture was further incubated at 42°C for 50 minutes. 
The reaction was terminated at 70°C for 15 minutes. The cDNA synthesized was 
stored at -20°C until use. 
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2.7.6.6. Amplification of cDNA 
Semi-quantification of apoptotic genes was carried out using RT-PCR and the 
method was modified from Zhang et al. (1999). Reaction mixture containing IX 
Reaction Buffer, 3.5 mM MgCl]，0.2 mM dNTPs, 10 pM primers, 1.5U Taq DNA 
polymerase (Thermoprime Plus) was prepared together with about 100 ng DNA and 
ultra pure water was added to make up the volume to 10 i^l. Specific PGR profile 
was 95�C for 1 min; 58�C for 1 min and 70�C for 1 min for 30 cycles followed by 
extension for 10 min. The primer sets used for PGR amplification are as follows: 
Table 2.3 Primer sets for RT-PCR analyses of apoptotic genes (Zhang et al., 
1999; Oh and Chung, 2004). 
Primer Sequence Amplification 
product (bp) 
Qj-actin forward 5 '-GGAGCAATGATCTTGATCTT -3， 204 
a-actin forward 5,-CCTTCTGGGCATGGAGTCCT-3， 
Bcl-2 forward 5'-GGTGCCACCTGTGGTCCACCTG-3' — 459 
Bcl-2 backward 5'-CTTCACTTGTGGCCCAGATGG-3' 
Bax forward 5'-CAGCTCTGAGCAGATCATGAAGACA-3‘ 538 
Bax backward 5 '-GCCCATCTTCTTCCAGATGGTGAGC-3 ’ 
p53 forward 5'-CTGAGGTTGGCTCTGACTGTACCA-3' 591 
p53 backward 5'-CTCATTCAGCTCTCGGAACATCTC-3' 
74 
After PGR, amplification products were resolved by 2% agarose gel 
electrophoresis, and images were captured using a gel documentation system 
(BIO-RAD Gel Doc 1000). The amount of specific gene expression was 
normalized by comparing the intensity of the target gene to that of the amplified 
a-actin from the same batch of cDNA sample. The % volume intensity of each 
target bands would be calculated using BIORAD Gel Doc 1000 for comparison. 
2.7.7. Effect of biomass and pileus lingzhi polysaccharides and terpenes on 
MCF-7 cells 
MCF-7 cells were cultured in 96-well plate with a cell density of 3xl0Vwell and 
incubated overnight. Then medium was removed and replaced with medium with 
stipe, filtrate, pileus and biomass extracts of two parents and hybrid with 
concentrations equivalent to the amount of lingzhi polysaccharide and terpenes 
presented in extracts and incubated for indicated times of 24, 48，72 and 96 hours as 
mentioned in section 2.7.4.1. All the measurements were performed in 5 replicates. 
Experiment has been repeated for three times and representative data were presented. 
I C 5 0 was calculated using EPA Probit analysis programme used for calculating 
LC/EC values version 1.5. 
2.7.7.1. Effect of reconstitution of lingzhi polysaccharide and terpenes on MCF-7 
cells 
Lingzhi polysaccharide and terpenes were added together to study for any 
additive effect on inhibition of MCF-7 cells. MCF-7 cells were cultured in 96-well 
plate with cell density of 3xl0Vwell and incubated overnight. Then medium was 
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removed and replaced with medium with stipe, filtrate, pileus and biomass extracts 
of two parents and hybrid with concentrations equivalent to the amount of lingzhi 
polysaccharide and terpenes presented in extracts and incubated for indicated times 
of 24，48，72 and 96 hours as mentioned in section 2.7.4.1. All the measurements 
were performed in 5 replicates. Experiment has been repeated for three times and 
representative data were presented. I C 5 0 was calculated using EPA Probit analysis 
programme used for calculating LC/EC values version 1.5. 
2.7.8. Effect of biomass and pileus extracts on MDA-MB-231 cells 
The effects of pileus and biomass extracts on MDA-MD-231 were also studied 
using MTT assay and cell viability assay. MDA-MB-231 cells were seeded at 
2xl0^/well in 96-well plates, and observation was monitored in 4 days as stated in 
sections 2.7.4.1 and 2.7.4.2. 
2.8. Estrogenicity assay 
2.8.1. E-screen test 
The assay was modified from the method described by Oh and Chung (2004). 
MCF-7 cells were cultured in depletion of steroids with the use of 10% charcoal 
dextran Fetal Bovine Serum (CDFBS) (Hyclone, SH30068.03) for two days. Then 
two sets of MCF-7 cells were seeded into 24-well plates at a density of 3 x lO"^  cells 
per well in 10% CDFBS and incubated in 5% CO2 in air at 37°C. P-estradiol was 
used as standard (Sigma, E-2758) and pileus extract, biomass extract, terpene and 
lingzhi polysaccharide preparation of the two parents and the selected hybrid were 
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added to the medium at a range of concentrations of 1，0.5, 0.25, 0.125，0.0625 
mg/ml. The assay was terminated after 96 hours by removing media from the well. 
MTT and cell viability assay were conducted based on the procedures mentioned in 
2.7.4.1 and 2.7.4.2 respectively. The cell proliferative response was defined as 
relative proliferation effect (RPE) of MCF-7 cells. It is calculated according to 
RPE = S/E X 100 where S = proliferation of samples and E = proliferation of 
positive control (10 nM E2). 
2.8.2. Estrogen receptor competitor binding assay 
The procedure was based on the instruction manual of the Estrogen receptor-a 
competitor Assays, Red (Invitrogen, P-3029) and Estrogen receptor-p competitor 
Assays, Red (Invitorgen, P-3032). The biomass extract, pileus extract and terpenes 
extracted from biomass and pileus of the two parents and the selected hybrid, and 
p-estradiol as standard (Sigma, E-2758) was diluted to a 2X concentration using ER 
Red Assay Buffer serially. 2X ER/Fluormone™ EL Red Complex was prepared to 
a final concentration of 30 nM estrogen receptor-a or 60 nM estrogen-P and 2 nM 
Fluormone™ EL Red in ER Red Assay Buffer. 20 |il of the prepared sample or 
丁 Ivi 
standard were dispensed to each well and 20 |j,1 of 2X ER/Fluormone EL Red 
Complex were added to the well. The solution was mixed by pipetting up and 
down for at least 3 times. The plate was covered by aluminum foil to protect from 
light and incubated at room temperature for 2 hours. The fluorescence polarization 
was measured using automated multifunctional monochromator reader 
(Tecan-B017554). Data were plotted as % of ER/Fluormone™ EL Red Complex 
remaining. 
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2.8.3. pS2 mRNA expression assay 
The assay was modified from the method described by Oh and Chung (2004). 
MCF-7 cells were cultured in depletion of steroids with the use of 10% charcoal 
dextran fetal bovine serum (CDFBS) (Hyclone, SH30068.03) for two days. Then 
MCF-7 cells were seeded into 6-well plates at a density of 9 x cells/well in 10% 
CDFBS and incubated in 5% CO2 in air at 37°C. The medium was replaced with 
fresh medium supplemented with 10% CDFBS with addition of |3-estradiol as 
standard (Sigma, E-2758) and pileus extract or biomass extract. The plate was 
incubated for 96 hours. Thereafter the medium was removed and the cells were 
scraped from the plate to examine the amounts of pS2 mRNA. Total RNA was 
purified with TRIzol reagent described in sections 2.7.6.3 and 2.7.6.4. RT was 
carried out based on the protocol described in section 2.7.6.5. cDNA was amplified 
using primers of pS2 with forward primer 5 '-CATGGAGAACAAGGTGATCTG-3 ‘ 
and backward primer 5 '-CAGAAGCGTGTCTGAGGTGTC-3 ‘ (Oh and Chung, 
2004) with an amplicon of 336 base pairs. Amplification was performed using 
thermal cycler PTC-IOOTM (MJ Research, Inc.) with thermal profile of 30 cycles at 
95°C for 1 min; 58°C for 1 min and 70°C for 1 min with the last extension time 
lengthened to 10 min. PCR products were separated by electrophoresis in 2% 
agarose gel and stained with ethidium bromide and visualized under UV light as 
mentioned in section 2.3.4. The amount of mRNA was semi-quantified by 
comparing the banding intensity with the expression level of the house keeping gene 
a-actin from the same sample of cDNA. The % volume intensity of each target 
bands would be calculated using BIORAD Gel Doc 1000. 
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DNA microarray analysis 
2.9.1. mRNA purification 
mRNA was isolated using purification Kit (SuperrArray, GA-002) and protocol 
was provided by the supplier. MCF-7 cells were seeded in 100 mm culture dish 
with the optimal seeding density found in section 2.7.3.4. Medium was then 
removed after one night incubation and replaced with medium for control and 1 
mg/ml water extracts of the hybrid biomass or pileus for treatment. After 4-day 
treatment period, the cells were collected by trypsinization and centrifuged at 4°C for 
5 min. Cells were then washed with ice-cold PBS (pH 7.4) and cell pellet was 
collected by centrifuged at 4°C for 5 min again. The tube was flicked with finger 
for loosening of cell pellet followed by addition of 1 ml lysis buffer. Lysate was then 
transferred into a 1.5 ml RNase-free eppendorf tube. The lysate was pipetted up 
and down several times for homogenization. On the other hand 100 jd Oligo-dT 
beads were resuspended thoroughly and transferred to an RNase free 1.5ml tube. 
The tube was then placed on a magnetic stand. The supernatant was completely 
removed after the bead suspension was cleared. Afterwards the tube was removed 
from the stand the beads were washed with 100 jul lysis buffer by mixing thoroughly 
again. The beads were let stand until the cell lysate was prepared. After the 
preparation and removal of the magnetic bead from stand, cell lysate was added to 
each tube. The tube were mixed by rotating at room temperature for 5 min. The 
tube was placed on magnetic stand for 2 min afterwards and the supernatant was 
removed after the solution was cleared. The bead was then washed twice with 1 ml 
Lysis Buffer A and once with 1 ml Washing Buffer B at room temperature by mixing 
well with the use of magnetic stand as described above. After the removal of the 
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final wash, 25 /xl Elution Buffer was added to the tube and mixed well afterwards. 
The tube was incubated at 70�C for 2 min. The tube was placed on the magnetic 
stand and the supernatant was transferred to a new RNase-free tube once the solution 
was cleared. The yield and purity of the RNA were quantified by 
spectrophotometry with measurement of absorbance at 260 run and ratio between 
absorbencies at 260 and 280 nm, respectively. A 1:20 or more dilution of mRNA 
was prepared, and the mRNA concentration was calculated by 
mRNA] in mg/ml = A260 x 0.04 x dilution factor 
2.9.2. RT and LPR (Linear Polymerase Reaction) labeling 
The AmpoLabelling-LPR Kit (SuperArray, L-03) was used and the protocol 
was provided by supplier. An annealing mixture was prepared by adding 0.3 fig 
RNA into a PCR tube containing 1 /xl RT primer and RNase-free water was used in 
order to make up the volume to 10 jttl. The mixture was then undergone reaction in 
a thermal cycler at 70°C for 3 min and cooled to 37°C holding for 10 min afterwards. 
RT cocktail was prepared as a mixture of 4 /xl Buffer BL，4 /xl RNase-free water, 1 jLil 
RNase inhibitor and 1 jitl reverse transcriptase for each sample. Then, 10 fil of the 
RT cocktail were added to the annealing mixture with gentle mixing after the 
reaction. The mixture was placed into a thermal cycler again with temperature set 
at 37�C for 25 min followed by heating at 85�C for 5 min and the reaction was hold 
at 4°C until next step. Linear Polymerase Reaction (LPR) cocktail was prepared 
with a mixture of 18 /xl buffer L，9 /xl Buffer AF, 2 /xl Biotin-16-dUTP and 1 /xl DNA 
polymerase for each sample. RT mixture was mixed with 30 /xl of the LPR cocktail 
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after the completion of RT reaction with gentle mixing and the mixture was then 
placed in the thermal cycler with the following temperature profile: 85°C, 5 min; 30 
cycles of (85°C, 1 min, 50°C, 1 min, 72°C, 1 min); then 72�C，5 min. After all, the 
cDNA probe was denatured by setting the temperature at 94°C for 2 min and chilled 
on ice until next step. 
2.9.3. Pre-hybridization 
The GEArray Q Series Human Signal Transduction in Cancer Gene Array 
(SuperArray, HS-044) was used in this study. The array membrane was pre-wet by 
adding roughly 5 ml deionized water to the hybridization tube which was placed 
inverted while preparing GEAprehyb. The GEAhyb Hybridization Solution was 
warmed to 60°C and the bottle was inverted several times to allow complete 
dissolution of the buffer components. Sheared salmon sperm DNA was heated at 
100�C for 5 min and immediately chilled on ice afterwards. The heat-denatured 
salmon sperm DNA was added to the pre-warmed GEZhyb hybridization solution to 
a final concentration of 100 /xm/ml and the GEAprehyb solution was kept at 60°C 
until used. The deionized water was discarded from the hybridization tube and 2 ml 
of GEAprehyb solution was added followed by vortex gently for a few seconds. 
The tube was then placed inside the hybridization cylinder and pre-hybridization was 
performed in the hybridization oven at 60�C for 1 to 2 hours with continuous 
agitation at 5 to 10 rpm. 
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3. Results 
3.1, Artificial hybridisation of Ganoderma tsugae and G lucidium 
3.1.1. Protoplast isolation and fusion of Ganoderma tsugae and G lucidum 
Protoplasts were released from G. lucidum and G. tsugae at yields of 5.34 x 10^  
and 5.56 x 10^  protoplasts cells per ml. The protoplast regeneration efficiency of 
protoplast cell after fusion was 4.9 土 1.8 %• Both large and small regenerated 
mycelial colonies were observed and isolated for hybrid screening. 
3.2, Screening and selection of hybrid 
3.2.1. Temperature screening 
Regenerated mycelial colonies were processed to primary temperature screening. 
The radii of regenerated mycelial colonies are shown in Figure 3.1a and 3.1b for 
growing temperatures at 18�C and 37°C respectively. Putative hybrids 1, 7, 18, 25 
and 26 were found to grow significantly faster than both G. tsugae and G. lucidum 
at 18°C, and the growth rates of isolates 7 and 18 were found significantly faster 
than both parents at 37°C. Cultivar G. tsugae did not show obvious visible growth 
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Figure 3.1 Primary temperature screening for the fast growers of the putative 
hybrids of the protoplast fusion mixture at (a) 18°C and (b) 3TC. 
Growth was measured by the colony radius (cm) after 5 days. Each 
set of data is represented by the mean 士 standard deviation of triplicates. 
Ranking is by Tukey test at 5% probability. 
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3.2.2. DNA fingerprint by Arbitrarily-primed polymerase chain reaction 
The identity of the putative hybrids was confirmed by AP-PCR in comparing 
the DNA fingerprints of putative hybrids to parents. Results are shown in Figure 
3.2a, 3.2b and 3.2c for primers of EcoRI ext, ITS5 and TGF respectively. The 
DNA fingerprints of all selected hybrids were different from parents among the three 
primers used and the DNA fingerprints of the hybrids were not combination of those 
of the parents. As only putative hybrid no. 18 possessed faster growth rate than G. 
lucidum and G. tsugae and significantly different DNA fingerprinting pattern from 
parents', it was selected for further tests. 
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Figure 3.2 DNA fingerprinting of parents and some putative hybrids by 
- Arbitrarily-primed polymerase chain reaction using primers (a) EcoRI 
ext; (b) ITS 5; and (c) TGF. PGR was preformed with 2 
low-stringency cycles of 94°C for 2 min, 35°C for 1 min and 72°C for 2 
min, followed by 35 high-stringency cycles of 94°C for 2 min, 55°C for 
1 min and 72°C for 2 min with the last extension time lengthened to 10 
min. 
87 
5.5. Confirmation tests 
3.3.1. Somatic incompatibility test 
The hybrid generated by protoplast fusion was dikaryotic (diploid-equivalent 
condition in lingzhi) and bore clamp connections. Somatic incompatibility in terms 
of barrier reaction between hybrid and G. tsugae was found (Figure 3.3). Table 3.1 
presents the results of somatic incompatibility test. 
Table 3.1 Somatic incompatibility reactions among parents G. lucidum and G. 
tsugae and their hybrid. 
G. lucidum G. tsugae Hybrid 
G. lucidum + - + 
G. tsugae _ + _ 
Hybrid + - + 
+: compatible; -: incompatible. 
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G. tsugae G. lucidum 
Hybrid 
Figure 3.3 Somatic incompatibility test between the parents and their hybrid. 
The two parents and hybrid were inoculated and cultivated on the 
same medium. The culture plate was incubated at 28�C for 5 days 
before observation was made. Colony fusion was found in the hybrid 
and parent G, lucidum and barrier reaction was found between the 
hybrid and parent G. tsugae. 
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3.3.2. DNA fingerprinting by specific polymerase chain reaction 
The nuclear regions of ribosomal DNAs and mitochondrial (MS) of ribosomal 
DNAs of G. lucidum, G. tsugae and hybrid were amplified and resolved in Figure 
3.4a and 3.4b respectively. House keeping gene tubulin was also amplified (Figure 
3.4c). The results of another set of PCR products amplified using primer PSIL 
designed from Pleurotus sajor-caju laccase 1 (Gene bank no. AJ507324) are shown 
in Figure 3.4d. 
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Figure 3.4 Gel electrophoresis of the amplified PGR products using primers of (a) 
ITS; (b) MS 1 and 2; (c) TGF and (d) PSIL as arbitrary primer of 
parents and putative hybrids by specific PGR of 95®C for 1 min; 58°C 
for 1 min and 70°C for 1 min for 39 cycles with the last extension time 
lengthened to 10 min for (a), (b) and (c) whereas annealing 
temperature was lowered to 45�C for (d). 
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The sequence generated by the ABI Prism 3100 Genetic Analyser was 
processed by the software Sequencing Analysis version 3.0 (PE Biosystems). 
Sequences were aligned using web tool ClustalW and UPGMA (unweighted 
pair-group method using arithmetic averages) and neighbor-joining tress provided by 
MEGA (Molecular Evolutionary Genetics Analysis, version 3，2003) were 
constructed. UPGMA tree and neighbor-joining tree of ITS are shown in Figure 3.5 
(a) and (b) and distance is shown in Table 3.2. 
Table 3.2 Similarity index of nuclear region ITS of G. lucidum, G. tsugae and 
hybrid. The numbers in brackets showed the corresponding standard 
error i.e. the pairwise distance for hybrid and G. lucidum is 0.002 
Hybrid G. lucidum G. tsugae 
Hybrid [0.002] [0.014] 
G. lucidum 0.002 [0.015] 














Figure 3.5 Dendrograms of the nuclear ribosomal DNA of G. lucidum, G. tsugae 
and hybrid with nucleotide sequence of 750 bp constructed by (a) 
unweighted pair group method with arithmetic mean (UPGMA) 
clustering and (b) neighbor-joining clustering using MEGA 2.1. 
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MS UPGMA tree and neighbor-joining tree are shown in Figure 3.6 (a) and (b) 
and distance shown in Table 3.3. 
Table 3.3 Similarity index of MS of mitochondrial DNA region of G. lucidum, 
G. tsugae and hybrid. The numbers in brackets showed the 
corresponding standard error i.e. the pairwise distance for hybrid and 
G. lucidum is 0.006. 
Hybrid G. lucidum G. tsugae 
Hybrid [0.006] [0.006] 
G. lucidum 0.020 [0.000] 














Figure 3.6 Dendrograms of the MS of mitochondrial DNA region of G. lucidum, 
G tsugae and hybrid with nucleotide sequence of 2500 bp constructed 
by (a) unweighted pair group method with arithmetic mean (UPGMA) 
clustering and (b) neighbor-joining clustering using MEGA 2.1. 
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Phylogenetic trees of U P G M A and neighbor-joining of house keeping gene 
tubulin are shown in Figure 3.7 (a) and (b) and distance shown in Table 3.4 
correspondently. 
Table 3.4 Similarity index of house keeping gene of G. lucidum, G. tsugae and 
hybrid. The numbers in brackets showed the corresponding standard 
error i.e. the pairwise distance for hybrid and G. lucidum is 0.011 
Hybrid G. lucidum G. tsugae 
Hybrid [0.011] [0.025] 
G. lucidum 0.019 [0.024] 














Figure 3.7 Dendrograms of house keeping gene tubulin of G. lucidum, G tsugae 
and hybrid with nucleotide sequence of 200 bp constructed by (a) 
unweighted pair group method with arithmetic mean (UPGMA) 
clustering and (b) neighbor-joining clustering using M E G A 2.1. 
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For PSIL, genomic D N A s of G. lucidum, G. tsugae and hybrid were amplified 
again by the specific primer. The gel photo is shown in Figure 3.8. Genomic 
D N A of G. tsugae showed negative result in specific PCR using this specific primer 
and the sequences of G. lucidum and hybrid were aligned by web tool ClustalW and 
the distance between two sequence is 0.055 土 0.019 which was calculated by M E G A . 
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Figure 3.8 Gel electrophoresis of the amplified PCR products using specific 
primer designed from sequence of PSIL. G. tsugae shows negative 
result. 
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3,4, Characterisation of selected hybrid 
3.4.1. Scanning electron microscopy 
Specimens of pilei and stipes of G. lucidum, G. tsugae and hybrid were 
prepared and examined under SEM. Both pileus and stipe were cut horizontally 
and longitudinally. The structures of hymenophore, basidia and stipes were 
examined. Long and irregular cavities were distributed in the longitudinal sections of 
the pilei of G. lucidum, G. tsugae and hybrid (Figure 3.9 a, b and c). Cross sections 
showing clamp connection and closely packed hyphae were observed for all three 
specimens in Figure 3.10 a, b and c. Longitudinal sections pilei of G. lucidum, G. 
tsugae and hybrid showed the hymenium with 4-spored basidia (Figure 3.11a, b and 
c). 
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(a) (b) (c) 
Figure 3.9 Scanning electron micrographs showing the hymenophores of the 
parents and the hybrid, (a) surface view of tubes of G. lucidum (xl50); 
(b) longitudinal section of the tubes of G. tsugae (xl50) and (c) surface 
view of tubes of hybrid (x200). 
(a) (b) (c) 
Figure 3.10 Scanning electron micrographs showing the pilei trama of the parents 
and the hybrid, (a) G lucidum (xl500); (b) G tsugae (xlSOO) and (c) 
hybrid (x3500) showing clamp connection and compactly packed 
hyphae. 
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(a) (b) (c) 
m m 
Figure 3.11 Scanning electron micrographs showing the hymenia of the parents and 
the hybrid, (a) G. lucidum showing hymenophore of 4-spored basidum 
(x2000); (b) irregular package ofhymenium showing 4-spored basidum 
of G. tsugae (x3500) and (c) 4-spored basidum of hybrid (x3500). 
(a) (b) (c) 
M H 
Figure 3.12 Scanning electron micrographs showing the cross-sections of stipes of 
the parents and the hybrid, (a) G lucidum (xlOOO); (b) G tsugae (x2000) 
and (c) hybrid (xlOOO) showing compactly packed hyphae. 
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(a) (b) (c) 
Figure 3.13 Scanning electron micrographs showing the longitudinal sections of 
stipes of the parents and the hybrid, (a) G lucidum (xl500); (b) G. 
tsugae (xl500) and (c) hybrid (x2000) showing compactly packed 
hyphae with scattered spore. 
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Tissue organization started with a regular hypodermis in pileus in longitudinal 
section. Hymenophore in the form of tubes was detected (Figure 3.11 a, b and c). 
Basidiospores of G. tsugae are rather round-shaped whereas G. lucidum and hybrid 
basidiospore show oval shaped. 
For stipe, compactly packed hyphae were observed for both cross and 
longitudinal section (Figures 3.12 and 3.13). In addition, clamp connection was 
rarely found in stipe for all specimens of the three samples. 
3.4.2. Temperature effect 
The results of growth of mycelia of G. lucidum, G. tsugae and the selected 
hybrid are shown in Figure 3.14. Generally speaking, two parents and the selected 
hybrid show similar growth pattern as all of them had slow growth rate at 18°C and 
moderate growth rate at 25°C. At 30°C, all three of them showed maximum growth 
and the growth rate of hybrid is significantly higher than the two parents based on 
one-way A N O V A test with p < 0.05. There was a little drop of growth rate for G. 
luciudm at 2>TC but drastic decrease in growth rate for both G. tsugae and hybrid. 
Only little growth for G. lucidum at 40。C and no growth of mycelia observed for G. 
tsugae and hybrid. 
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Figure 3.14 A comparison of the growth rates of the parents G lucidum and G. 
tsugae and their hybrid at temperatures from 18 to 40°C. Growth was 
measured using radius of the mycelial colony after 5 days in darkness. 
Each set of data is represented by the mean 士 standard deviation of 5 
replicates. Ranking of the data at the optimal growth is by Tukey test 
at 5% probability with “a” and "A" of the highest ranks. 
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3.4.3. Submerged fermentation 
The fast growing putative hybrid with D N A fingerprint different from parents' 
was brought to submerged fermentation. The yield of fermenter products is shown 
in Figure 3.15. There was no significant difference between biomass yield but 
freeze-dried filtrate yield of hybrid is significantly higher than the two parents. 
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Figure 3.15 The (a) mycelial biomass gain and (b) culture filtrate yield of G. 
lucidum, G tsugae and their hybrid from submerged fermentation. 
Each set of data is represented by the mean 士 standard deviation of 
triplicates. Ranking is by Tukey test at 5% probability with “a” of the 
highest ranking. 
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3.4.4. Fruiting test 
The selected hybrid was fertile in producing basidiomes and basidiospores 
(Figure 3.16) and the yield of fruiting test is shown in Figure 3.17. No significant 
difference was found among parents and hybrid. 
107 
(a) (b) (c) 
Figure 3.16 Basidiomes of (a) G lucidum，(b) G tsugae and (c) their hybrid under 
artificial cultivation in the mushroom cultivation complex, The 
Chinese University of Hong Kong. 
3 0 � 
25 -
^^In n i 
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Figure 3.17 The fruiting yield of G lucidum, G tsugae and their hybrid. Each set 
of data is represented by the mean 士 standard deviation of triplicates. 
Ranking is by Tukey test at 5% probability. No significant difference 
found. 
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3.5. Bioactive components of G. lucidum, G tsugae and hybrid 
3.5.1. Lingzhi polysaccharide 
The yields of extracted lingzhi polysaccharide from biomass and pileus are 
shown in Figure 3.18a. Also, the amount of lingzhi polysaccharide in 1 mg/ml 
water extract of biomass or pileus was also shown in Figure 3.18b. Lingzhi 
polysaccharide amount extracted from biomass was generally higher than pileus and 
water extracts whereas G. lucidum and G. tsugae biomass were higher than those of 
hybrid. Lingzhi polysaccharide amounts extracted from both biomass and pileus of 
G. lucidum and G. tsugae are higher than hybrid but in water extracts of biomass and 
pileus, there was no significant difference between them. 
3.5.2. Terpenes 
The yields of extracted terpenes from biomass and pileus are shown in Figure 
3.19a. The amount of terpenes prepared from 1 mg/ml biomass or pileus extract was 
also shown in Figure 3.19b. No significant difference was observed from the 
amount of terpenes extracted from biomass and pileus of G. luciudm, G. tsugae and 
hybrid. Terpenes content of hybrid biomass extract was found to be higher than G. 
tsugae biomass extract but no significant difference from G. lucidum. On the 
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Figure 3.18 The lingzhi polysaccharide yields from (a) freeze-dried biomass and 
pileus and (b) the water extracts of G lucidum, G tsugae and their 
hybrid. Each set of data is represented by the mean 士 standard 
deviation of triplicates. Ranking is by Tukey test at 5% probability 
with ‘‘a，’ of the highest ranking. 
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Figure 3.19 The terpene yields from (a) freeze-dried biomass and pileus and (b) 
the water extracts of G lucidum, G tsugae and their hybrid. Each set 
of data is represented by the mean 土 standard deviation of triplicates. 
Ranking is by Tukey test at 5% probability with "a" of the highest 
ranking. 
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Also, G C chiomatograms of G. lucidum biomass, pileus and stipe are shown in 
Figure 3.20a, 3.20b and 3.20c; G. tsugae biomass, pileus and stipe were shown in 
Figure 3.21a, 3.21b and 3.21c and G C chromatograms of hybrid biomass, pileus and 
stipe together with biomass extract and pileus extract are shown in Figure 3.22a, 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































From the chromatograms, the terpenes composition of G. lucidum biomass, 
pileus and stipe were different and the terpenes compositions of the samples of G. 
lucidum were also different from G. tsugae and hybrid. Compounds are only 
putatively identified if each of their similarity indices (S.L) is higher than 90%. 
Similar compounds were identified in G. tsugae biomass, pileus and stipe. 
Erucylamide and terpenes of ergosterol were found in all G. tsugae terpenes 
preparations. Hydrocarbons like octadecane, eicosadiene, docosadiene and 
octadecenamide were also found in all samples of this parent. Octadecenoic acid 
and octadecanal were only found in pileus, and linoleic acid ethyl ester was found 
only in biomass terpenes preparations. Ergosta-5,8,22-trien-3-ol, a derivative of 
and ergosterol, was identified in biomass and stipe terpene preparations only. 
For G. lucidum biomass, pileus and stipe, ergosterol was found in both biomass 
and pileus except in stipe. Another fungal sterol 7-ergostenol was identified instead 
and it is also found in stipe. Hydrocarbons of tetradecyloxirane and 
heptadecyloxirane and benzenedicarboxylica acid and octadecanoic acid were found 
in biomass and pileus terpenes preparations. Ergosta-5,8,22-trien-3-ol, a derivative of 
ergosterol, was identified in pileus and stipe samples. Ergosterols and its 
derivatives were identified in chromatogram of stipe whereas other major peaks 
could not be of certain identities as their S.L values smaller than 90%. 
Hybrid biomass, pileus and stipe contained more hydrocarbons than its parents 
whereas the diversities of hydrocarbons in biomass and pileus were higher than stipe. 
Abundant amounts of docosane, hexadecane, eicosane were found in pileus and 
biomass and on the other hand trace amounts of tetracosane, nonadecane together 
with heptadecenal and octadecanal were also identified in biomass and pileus 
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terpenes preparations. Linoleic acid ethyl ester was only found in biomass. 
Pentacosane, heneicosane and heptacosane were identified in stipe. Ergo sterol was 
identified in biomass and stipe preparations but 7-ergostenol was found in pileus only. 
Lanosta-7,9(l l)-diene, a derivative of ergosterol, was found in hybrid biomass and 
stipe preparations. Also, hybrid pileus and biomass contained 
ergosta-5,8,22-trien-3-ol. Ergosta-7，22-diene-3-ol was only found in pileus 
preparations and was unique among all sample of G. luciudm, G. tsugae and hybrid. 
Hybrid biomass and pileus extracts were also under analysis and G C 
chromatograms are shown in Figure 3.23. The compounds identified in extracts 
were similar to those found in pileus and biomss terpenes preparations except that 
ergosterol was absent in both samples in the presence of lanosta-7,9(l l)-diene. 
Again, pileus extract consisted of higher diversity of hydrocarbons than biomass 
extract. They both had octadecene. Docosene was found in biomass extract. Also， 
squalene was also found in biomass extract and was unique among all other samples. 
Abundant amount of hexadecane was found in pileus extract and trace amounts of 
heneicosane, eicosane, heptacane, docosane tetradcane, nonadecane and pentacoane 
were found in pileus extract. 
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Figure 3.23 G C chromatogram of hybrid (a) biomass and (b) pileus extract. 
Putative identification of resolved peaks is by similarity of mass 
spectra of the resolved compound at the authentic compound in 
database (Wiley 275). The similarity index is higher than 90%. 
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3.6. Effect of extracts against breast cancer cell lines 
3.6.1. Anti-proliferative effect of extracts on MCF-7 cells 
The effects of biomass, pileus, stipe and filtrate extracts on MCF-7 cells were 
studied primarily using M T T assay. The results of treatment using stipe extracts of 
G. lucidum, G. tsugae and hybrid are shown in Figure 3.24a, 3.24b and 3.24c 
respectively. Only G. tsugae stipe extracts displayed anti-proliferative effect with 
maximum 17.83 土 2.22o/o at concentration of 1 mg/ml whereas G. lucidum and 
hybrid stipe extracts showed mitogenic effect instead. Dosage-response curve of 
cytotoxicity of stipe extracts is shown in Figure 3.25. The percentage of inhibition 
was independent of the water extract concentration which was displayed by the 
curve. 
The results of the effect of medium extracts of G. lucidum, G. tsugae and hybrid 
are shown in Figure 3.26a, 3.26b and 3.26c respectively. All three samples 
demonstrated anti-proliferative effect of MCF-7 cells but only in a small percentage 
of inhibition with maximum of 19.52 土 IITA which was obtained with G. tsugae 
medium extracts. Figure 3.27 demonstrates the dosage-response curve of 
cytotoxicity effect of medium extracts. Again, the effect is concentration 
independence which was similar to the cytotoxicity of stipe extracts. 
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Figure 3.24 Cytotoxicities of the aqueous stipe extracts of (a) G. lucidum; (b) G. 
tsugae and (c) their hybrid against breast cancer cells MCF-7 using 
M T T assay. MCF-7 cells of cell density 3 x 10^  cells per well were 
seeded and incubated. Cells were harvested at 24, 48, 72 and 96 
hours. Each data is represented by the mean 士 standard deviation of 5 
replicates. Ranking is by Tukey test at 5% probability. 
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Figure 3.25 Dose-response curve of cytotoxicities of the aqueous stipe extracts of 
G. lucidum; G. tsugae and their hybrid against breast cancer cells 
MCF-7 using M T T assay. MCF-7 cells of cell density 3 x ICP cells 
per well were seeded and incubated. Cells were harvested at 24, 48， 
72 and 96 hours. Each data is represented by the mean 士 standard 
deviation of 5 replicates. Ranking is by Tukey test at 5% probability 
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Figure 3.26 Cytotoxicities of medium extracts of (a) G lucidum., (b) G. tsugae and 
(c) hybrid against breast cancer cells MCF-7 cells using M T T assay. 
MCF-7 cells of cell density 3 x 10^  cells per well were seeded and 
incubated. Cells were harvested at 24, 48, 72 and 96 hours. Each 
data is represented by the mean 士 standard deviation of 5 replicates. 
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Figure 3.27 Dose-response curve of cytotoxicities of the medium extracts of G. 
lucidum; G. tsugae and their hybrid against breast cancer cells MCF-7 
using M T T assay. MCF-7 cells of cell density 3 x 10^  cells per well 
were seeded and incubated. Cells were harvested at 24，48, 72 and 
96 hours. Each data is represented by the mean 士 standard deviation 
of 5 replicates. Ranking is by Tukey test at 5% probability. 
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The study of MCF-7 cells treated with biomass extracts of G. lucidum by M T T 
assay, cell viability assay and BrdU assay are shown in Figure 3.28a, 3.28b and 3.28c 
respectively. G. lucidum biomass extracts treated MCF-7 cells showed proliferative 
effect upon 24 and 48 hour incubation but displayed anti-proliferation at 72 hour. 
Percentage of inhibition reached maxima when cells were treated up to 96 hours by 
both M T T and BrdU assay. For cell viability assay, maxima percentage of 
inhibition was also achieved at 96 hour incubation but unlike M T T and BrdU assay, 
no mitogenic effect was observed at 24 and 48 hour incubation. Anti-proliferation 
was observed starting from 24 hour incubation except for concentration of 0.5 
mg/ml. 
For concentration of 1 mg/ml G. lucidum biomass extract, it exerted 
significantly higher percentage of inhibition of 57.29 土 1.17o/o which were higher 
than the lower concentrations. Also, concentration dependent maimer was observed 
and it is shown in Figure 3.31 
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Figure 3.28 Anti-proliferative effects of biomass extracts of G. lucidum against 
breast cancer cells MCF-7 cells by (a) M T T assay (b) cell viability 
assay with tryphan blue (c) BrdU assay. MCF-7 cells of cell density 3 
X 10^  cells per well were seeded and incubated. Cells were harvested 
at 24, 48, 72 and 96 hours. Each data is represented by the mean 士 
standard deviation of 5 replicates. Ranking is by Tukey test at 5% 
probability with "a" of the highest ranking. 
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The results of MCF-7 cells treated with G. tsugae biomass extracts using MTT, 
cell viability assay and BrdU assay are shown in Figure 3.29a，3.29b and 3.29c 
respectively. The results were similar to G. lucidum biomass extracts treated cancer 
cell with the highest percentage of inhibition at 96 hour incubation for the three 
assays used. However, mitogenie effect was observed in M T T and BrdU assay at 
24 and 48 hour incubation for all concentrations but proliferative effect was observed 
starting from 24 hour incubation only for 1 and 0.25 mg/ml in the cell viability assay. 
For concentrations of 1 and 0.5 mg/ml G. tsugae biomass extract, it induced 
significantly higher percentage of inhibition of 62.43 土 1.05o/o and 50.67 土 3.26o/o 
than the lower concentrations did and again just like G. lucidum biomass extract 




70 - a 
60 - a 
^ 40 : - … ; ^ I + GT 0.0625 m g ^ 
^ 30 - / - « — G T 0.125 mg/ml 
I 20 - / y d -lir-GT 0.25 m g / m l 
I Ig ]l a d — —GT0.5 mg/ml 
-10,) % l + _ _ 
-30 - ^ ^ 
-40 L 
Treatment period (hours) 
(b) 
90 r a i: 
- 5 0 - / j GT 0.0625 mg/ml 
I 30 : Z ： / ^ — — c " ^ G T 0.125 mg/ml 
I 20 - l ^d - ^ G T 0.25 mg/ml 
. I g � ^ _ _ , , _ . GTO.5 mg/ml 
-10 0 ；1 ； ^ ^ G T I mg/ml 
io t 
Treatment period (hours) 
(C) a 
a 
40 - ^ 
^^^ 、 1 丨• •• • 
^ 20 - b I - ^ G T 0.0625 mg/ml f b 0.125 mg/ml 
:B 0 � — — ‘ ‘ — — T x C ^ ‘ GT 0.25 mg/ml 
I 48 96 —-…GTO.5 mg/ml 
_ - ^ G T l mg/ml 
4 0 - ^ ^ ^ ^ ^  
-60 L 
Treatment period (hours) 
Figure 3.29 Anti-proliferative effects of biomass extracts of G. tsugae against breast 
cancer cells MCF-7 cells using (a) M T T assay (b) cell viability assay 
with tryphan blue (c) BrdU assay. MCF-7 cells of cell density 3 x 10^  
cells per well were seeded and incubated. Cells were harvested at 24， 
48, 72 and 96 hours. Each data is represented by the mean 士 standard 
deviation of 5 replicates. Ranking is by Tukey test at 5% probability 
with "a" of the highest ranking. 
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The results of MCF-7 cells treated with hybrid biomass extracts using MTT, cell 
viability assay and BrdU assay are shown in Figure 3.30a，3.30b and 3.30c 
respectively. The results were similar to MCF-7 cells treated with G. lucidum and 
G. tsugae biomass extracts. The highest percentage of inhibition was observed at 
96 hour incubation for the three assays used. However, proliferative effect was 
observed in M T T and BrdU assay at 24 and 48 hour incubation for all concentrations 
but mitogenic effect was observed from 24 hour incubation only for 0.5 mg/ml in the 
cell viability assay. For concentrations of 1 mg/ml hybrid biomass extract, it 
induced significantly higher percentage of inhibition of 67.35 土 2.80o/o than the lower 
concentrations of 0.5，0.25，0.125 and 0.0625 mg/ml and just like G. lucidum and G. 
tsugae biomass extract treated cells, concentration dependent manner was observed 
which is shown in Figure 3.31. 
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Figure 3.30 Anti-proliferative effects of biomass extracts of hybrid against breast 
cancer cells MCF-7 cells (a) M T T assay (b) cell viability assay with 
tryphan blue (c) BrdU assay. MCF-7 cells of cell density 3 x 10^  
cells per well were seeded and incubated. Cells were harvested at 24, 
48，72 and 96 hours Each data is represented by the mean 士 standard 
deviation of 5 replicates. Ranking is by Tukey test at 5% probability 
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Figure 3.31 Dose-response curve of cytotoxicities of the aqueous biomass extracts 
of G. lucidum; G. tsugae and their hybrid against breast cancer cells 
MCF-7 using M T T assay. MCF-7 cells of cell density 3 x 10^  cells 
per well were seeded and incubated. Cells were harvested at 24, 48， 
72 and 96 hours. Each data is represented by the mean 士 standard 
deviation of 5 replicates. Ranking is by Tukey test at 5% probability 
with "a" of the highest ranking. 
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The study of MCF-7 cells treated with pileus extracts of G. lucidum by M T T 
assay, cell viability assay and BrdU assay are shown in Figure 3.32a, 3.32b and 3.32c 
respectively. The time effect was similar to the cells treated with biomass extracts 
and when different concentrations of pileus extracts were added to the cells, G. 
lucidum pileus extracts treated MCF-7 cells displayed mitogenic effect upon 24 and 
48 hour incubation but anti-proliferation at 72 hour was observed and percentage of 
inhibition reached maxima when cells were treated up to 96 hours in both M T T and 
BrdU assays for all concentrations. For cell viability assay, maximal percentage of 
inhibition was also achieved at 96 hour incubation but unlike M T T and BrdU assays, 
mitogenic effect was observed at 24 and 48 hour incubation for 0.0625 mg/ml. For 
concentration of 1 mg/ml G. lucidum pileus extract, it exerted significantly higher 
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Figure 3.32 Anti-proliferative effects of pileus extracts of G lucidum against breast 
cancer cells MCF-7 cells (a) M T T assay (b) cell viability assay with 
tryphan blue (c) BrdU assay. MCF-7 cells of cell density 3 x 10^  
cells per well were seeded and incubated. Cells were harvested at 24, 
48，72 and 96 hours. Each data is represented by the mean 士 standard 
deviation of 5 replicates. Ranking is by Tukey test at 5% probability 
with “a，，of the highest ranking. 
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The results of MCF-7 cells treated with G. tsugae pileus extracts using MTT, 
cell viability assay and BrdU assay are shown in Figure 3.33a，3.33b and 3.33c 
respectively. The results were similar to MCF-7 cells treated with G. lucidum 
pileus extracts with the highest percentage of inhibition at 96 hour incubation for the 
three assays used. However, mitogenic effect was observed in M T T and BrdU 
assay at 24 and 48 hour incubation for all concentrations but proliferative effect was 
observed starting from 24 hour incubation in the cell viability assay. For 
concentrations of 1 mg/ml G. tsugae pileus extract, it exerted significantly higher 
percentage of inhibition of 44.44 土 3.16o/o than the lower concentrations did. 
Percentage of inhibition of G. tsugae pileus extract treated MCF-7 cells showed 
concentration dependent manner at concentrations of 1 mg/ml to 0.25 mg/ml but 
similar to biomass extracts, there was no significant difference at concentrations of 
0.125 mg/ml and 0.0625 mg/ml. 
133 
(a) fo f 
60 -_ 50 - j f a GT 0.0625 mg/ml 
f fo ： b - ^ G T 0.125 mg/ml 
20 - c 一一GT0.25 mg/ml 
1 a - ^ G T 0.5 mg/ml 
：绍 I) 72 96 l + GTl mg/ml__ 
"-40 t 




^ 50 : I-^GT0.0625 mg/ml 
S ffi • fee -»-GT 0.125 mg/ml 
I 20 - be ""^GT 0.25 mg/ml 
i 10 j I , — —— GT 0.5 mg/ml 
^ -绍(i ^T 48 12 % l + GTl mg/ml__ 
-30 --40 L Treatment period (hours)  
(c)  
？n , 
一器： ^ a - • — G T 0 . 0 6 2 5 mg/ml 
f 绍： - ^ G T 0.125 mg/ml 
20 - b� - ^ G T 0.25 mg/ml 
2 —— — 一— GT 0.5 mg/ml 
占：绍 96 l-^GTlmg/ml 
4 0 匕 
Treatment period (hours) 
Figure 3.33 Anti-proliferative effects of pileus extracts of G. tsugae against breast 
cancer cells MCF-7 cells using (a) M T T assay (b) cell viability assay 
with tryphan blue (c) BrdU assay. MCF-7 cells of cell density 3 x 10^  
cells per well were seeded and incubated. Cells were harvested at 24, 
48, 72 and 96 hours. Each data is represented by the mean 士 standard 
deviation of 5 replicates. Ranking is by Tukey test at 5% probability 
with "a" of the highest ranking. 
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The results of MCF-7 cells treated with hybrid pileus extracts using MTT, cell 
viability assay and BrdU assay are shown in Figure 3.34a，3.34b and 3.34c 
respectively. The results were similar to MCF-7 cells treated with G. lucidum and 
G. tsugae pileus extracts. At 96 hour incubation, the highest percentage of 
inhibition was observed for the three assays. Proliferative effect was observed in 
M T T and BrdU assay at 24 and 48 hour treatment but mitogenic effect was observed 
from 24 hour incubation in the cell viability assay. For concentration of 1 mg/ml 
hybrid pileus extract, it induced significantly higher percentage of inhibition of 66.48 
土 2.28o/o than the lower concentrations. Just similar to G. lucidum and G. tsugae 
pileus extract treated cells, concentration dependent manner was observed at 
concentrations of 1 mg/ml to 0.25 mg/ml but similar to biomass extracts, there was 
no significant difference at concentrations of 0.125 mg/ml and 0.0625 mg/ml. 
Dosage-response curve is shown in Figure 3.35. 
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Figure 3.34 Anti-proliferative effects of pileus extracts of hybrid against breast 
cancer cells MCF-7 cells using (a) M T T assay (b) cell viability assay 
with tryphan blue (c) BrdU assay. MCF-7 cells of cell density 3 x 10^  
cells per well were seeded and incubated. Cells were harvested at 24， 
48, 72 and 96 hours. Each data is represented by the mean 士 standard 
deviation of 5 replicates. Ranking is by Tukey test at 5% probability. 
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Figure 3.35 Dose-response curves of cytotoxicities of the aqueous pileus extracts 
of G. lucidum', G. tsugae and their hybrid against breast cancer cells 
MCF-7 using M T T assay. MCF-7 cells of cell density 3 x 10^  cells 
per well were seeded and incubated. Cells were harvested at 24，48， 
72 and 96 hours. Each data is represented by the mean 土 standard 
deviation of 5 replicates. Ranking is by Tukey test at 5% probability 
with “a，, of the highest ranking. 
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The value of IC50 were calculated and are shown in Table 3.5. From the 
calculated IC50, biomass and pileus extracts possessed the lowest IC50 value. IC50 
value of hybrid biomass extract was 0.200 mg/ml and hybrid pileus extract was 0.313 
mg/ml. From the results, biomass and pileus extracts would be used to treat MCF-7 
cells using trypan blue cell viability assay and BrdU assay for further study of 
anti-proliferative effect. 
Table 3.5 The anti-proliferative effect of filtrate, stipe, biomass and pileus 
extracts of G. lucidum, G. tsugae and hybrid on MCF-7 cells. 
IC50 (mg/ml) 95% Confidence limit 
Lower Upper 
G. tsugae Filtrate 38.577 N A N A 
G. lucidum Filtrate 46.338 N A N A 
Hybrid Filtrate 10.601 N A N A 
G. tsugae Stipe 28.424 N A N A 
G. lucidum Stipe Cannot be calculated as % of inhibition does not reach 50% 
Hybrid Stipe 
G. tsugae Biomass 0.510 0.418 0.651 
G. luciudm Biomass 0.313 0.256 0.391 
Hybrid Biomass 0.321 0.242 0.443 
G. tsugae Pileus 1.318 0.944 2.206 
G. lucidum Pileus 1.435 1.018 2.456 
Hybrid Pileus 0.399 0.322 0.514 
> IC50 w a s calculated b y E P A Probit analysis p r o g r a m m e used for ca lculat ing L C / E C values 
v e r s i o n 1.5. 
> N . A . : not appl icable . 
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3.6.2. Study of medium effect of biomass and pileus extracts on MCF-7 cells 
As the correlations of M T T assay against cell viability assay and BrdU assay 
were above 0.8，MTT assay would be used for other experiments. MCF-7 cells 
were first treated with biomass extracts for two days. Then the medium was 
collected and filter sterilized. The filter sterilized medium was then added to newly 
seeded MCF-7 cell again to study for the anti-proliferative effect. This time, 
anti-proliferation was observed starting from 24 hour treatment which was entirely 
different from the mitogenic effect when the cells was treated with fresh extracts in 
medium (Figure 3.36). Also, drastic increase in percentage of inhibition was found 
when cells were treated with 1 mg/ml extracts of G. lucidum, G. tsugae and hybrid 
which were significantly higher than treatment of other concentrations. 
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Figure 3.36 The effect of cultured medium on cytotoxities of biomass extracts of (a) 
G lucidum; (b) G tsugae and (c) hybrid on MCF-7 cells using M T T 
assay. MCF-7 cells of cell density 3 x 10^  cells per well were seeded 
and incubated. Cells were harvested at 24, 48, 72 and 96 hours. Each 
data is represented by the mean 士 standard deviation of 5 replicates. 
Ranking is by Tukey test at 5% probability with “a” of the highest 
ranking. 
140 
For cells treated with filter sterilized pileus extracts with medium, the results 
were similar to those of biomass extracts (Figure 3.37). Drastic increase in % of 
inhibition was observed from 24 hour treatment when cells were treated with 1 
mg/ml extracts of G. lucidum, G. tsugae and hybrid which were significantly higher 
than treatment of other concentrations. 
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Figure 3.37 The effect of cultured medium on cytotoxities of pileus extracts of (a) G 
lucidum; (b) G. tsugae and (c) hybrid on MCF-7 by M T T assay. MCF-7 
cells of cell density 3 x 10^  cells per well were seeded and incubated. 
Cells were harvested at 24, 48, 72 and 96 hours. Each data is 
represented by the mean 士 standard deviation of 5 replicates. Ranking 
is by Tukey test at 5% probability with “a” of the highest ranking. 
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3.6.3. mRNA expression assay (RT-PCR) 
To determine the effects of biomass and pileus extracts on the expression of p53， 
Bcl-2 and Bax m R N A in MCF-7 cells, RT-PCR was performed. Concentration of 1 
mg/ml G. lucidum, G. tsugae and hybrid biomass and pileus extracts increased Bax 
levels in MCF-7 cells after 96 hours exposure (Figure 3.38 (a) and (b); (e) and (f) for 
biomass extracts and Figure 3.39 (a) and (b); (e) and (f) for pileus extracts) and 
decreased the Bcl-2 m R N A levels compared to control (Figure 3.38 (c) and (d) for 
biomass extracts and Figure 3.39 (c) and (d) for pileus extracts). Furthermore, 
Bax/Bcl-2 ratio for MCF-7 cell treated with both biomass and pileus extract were 
up-regulated (Figure 3.38 (h) for biomass extracts and Figure 3.39 (h) for pileus 
extracts). For MCF-7 cells treated with biomass extracts, cells treated with G. 
tsugae increased the Bax/Bcl-2 ratio by 2-fold, G. lucidum increased by 7-fold and 
their hybrid by 3-fold. For cells treated with pileus extracts, the ratio was 5-fold 
increased for G. tsugae, 8-fold increased for G. lucidum and 10-fold increased for 
hybrid. Also, MCF-7 cells treated with 1 mg/ml hybrid pileus up-regulated Bax and 
down-regulated Bcl-2 m R N A levels in a time-dependent manner from 0 to 96 hour 
treatment (Figure 3.40). Bax/^cl-2 ratio for MCF-7 cells treated with hybrid pileus 
extract was also enhanced. 
Expression of p53 m R N A level was determined. As shown in Figure 3.38 (a) 
and (b) for biomass extracts and Figure 3.39 (a) and (b), no significant differences 
were observed in p53 m R N A levels between control and treated MCF-7 cells. 
Expression of p53 levels was enhanced from 0 hour treatment to 24 hour treatment of 
MCF-7 cells treated with hybrid pileus extracts but no significant difference was 
found from 24 hour treatment to 96 hour treatment (Figure 3.40 (a) and (b)). 
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Figure 3.38 Differential regulation of the biomass extracts of G. lucidum, G. tsugae 
and their hybrid on expression of (a & b) p53 gene, (c & d) Bcl-2 gene, 
(e & f) Bax gene and (g) actin gene of breast cancer cells MCF-7. 
Gene expression is expressed as normalized ratio to the expression of 
housekeeping gene actin as shown in (b, d, f). Graph (h) is the 
expression ratio of Bcl-2/Bax. Each data is represented by the mean 士 
standard deviation of triplicates. Ranking is by Tukey test at 5% 
probability. 
144 
？ p p « ？ p p w 
& « C ^ 3 J? ^ 
s C O H C n 
^ ^ B： ^ a I g： ^ 
“ I “ I 
(a) I ^ ^ H H H (b) r ^ 
T pX, rtl • • • _ 11 a 
： : ： ! A b b im^m^ i^ 0 LH__hi__r^  _ 
(e) (f) rz a 
m ^ ^ ^ ^ M _ _ 露 
G 一 ^ £2!： Ml 錢— 
(g) S H H H H (h) 
ab 工 _ ^^ H^IHH rn F _ 
0 — I I 邏I I IM I 丨激 I 
Figure 3.39 Differential regulation of the pileus extracts of G. lucidum, G. tsugae 
and their hybrid biomass extracts on of (a & b) p53 gene, (c & d) Bcl-2 
gene, (e & f) Bax gene and (g) actin gene of breast cancer cells MCF-7. 
Gene expression is expressed as normalized ratio to the expression of 
housekeeping gene actin as shown in (b，d, f). Graph (h) is the 
expression ratio ofBcl-2/Bax. Each data is represented by the mean 士 
standard deviation of triplicates. Ranking is by Tukey test at 5% 
probability. 
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Expression of m R N A levels of cells in study of medium effect was also 
investigated. Similar to the results of pileus extract of hybrid, no difference was 
found in p53 levels. Bax m R N A levels were elevated. Bcl-2 levels were 
significantly down-regulated, and so, Bax/Bcl-2 ratio was increased drastically 
compared to cells in normal treatment of hybrid pileus extract. 
Morphology of MCF-7 cells treated with G. lucidum, G. tsugae and hybrid 
biomass and pileus are shown in Figure 3.41 and 3.42 respectively. MCF-7 cells 
treated with G. lucidum, G. tsugae and hybrid biomass and pileus extract showed 
similar morphology. MCF-7 cells showed a marked change in morphology after 
treatment with biomass and pileus extracts including shrinkage, irregular shape and 
condensed chromatin in the nuclei. On the other hand, control cells without 
treatment displayed typical epithelial patterns, i.e. a cluster of cells growing in a 
polygonal shape. 
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Figure 3.41 Phase contrast light micrographs of MCF-7 cells treated with (a) PBS 





( C ) ( d ) 
Figure 3.42 Phase contrast light micrographs of MCF-7 cells treated with (a) PBS 
as control and pileus extracts of (b) G. lucidum, (c) G. tsugae and (c) 
their hybrid. 
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3.6.4. Effect of biomass and pileus lingzhi polysaccharides and terpenes on 
MCF-7 cells 
Lingzhi polysaccharides extracted from biomass and pileus of G. lucidum, G. 
tsugae and hybrid were used to treat MCF-7 cells (Figures 3.43 and 3.44 
respectively). The amounts of lingzhi polysaccharides used were equivalent to the 
amounts determined in the extracts. This enables to study whether the lingzhi 
polysaccharide was the active component contributed to the anti-proliferative effect 
of the biomass and pileus extracts. 
From the results, biomass lingzhi polysaccharide of G. lucidum (Figure 3.45a), 
G. tsugae (Figure 3.43b) and hybrid (Figure 3.43c); pileus lingzhi polysaccharide of 
G. lucidum (Figure 3.44a), G. tsugae (Figure 3.46b), hybrid (Figure 3.44c) showed 
concentration dependent effect at 96 hour treatment. Also from Tables 3.6, IC50 
values of lingzhi polysaccharide were lower than the water extracts of biomass and 
pileus of the two parents and hybrid. 
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Figure 3.43 Cytotoxicities of the lingzhi polysaccharide preparation from biomass 
extracts of (a) G lucidum, (b) G. tsugae and (c) their hybrid against 
breast cancer cells MCF-7 using M T T assay. The amounts of lingzhi 
polysaccharide (equivalent to 1 x mg/ml in the graph) prepared from 
biomass extracts were (g/g): G. lucidum, 0.0146; G tsugae, 0.0130 and 
their hybrid, 0.0307. MCF-7 cells of cell density 3x 10^  cells per well 
were seeded and incubated. Cells were harvested at 24, 48, 72 and 96 
hours Each data is represented by the mean 士 standard deviation of 5 
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Figure 3.44 Cytotoxicities of the lingzhi polysaccharide preparation from pileus 
extracts of (a) G lucidum, (b) G tsugae and (c) hybrid against breast 
cancer cells MCF-7 using M T T assay. The amounts of lingzhi 
polysaccharide (equivalent to 1 x mg/ml in the graph) prepared from 
pileus extracts were (g/g): G. lucidum, 0.0182; G tsugae, 0.0224 and 
their hybrid, 0.0462. MCF-7 cells of cell density 3x 10^  cells per well 
were seeded and incubated. Cells were harvested at 24, 48，72 and 96 
hours Each data is represented by the mean 士 standard deviation of 5 
replicates. Ranking is by Tukey test at 5% probability with “a” of 
highest ranking. 
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Table 3.6 The anti-proliferative effect of lingzhi polysaccharide extracted from 
biomass and pileus extracts of G. lucidum, G. tsugae and hybrid on 
MCF-7 cells. 
Lingzhi IC5o(mg/ml) 95% Confidence limit 
polysaccharide Lower Upper 
G. tsugae Biomass 0.394 0.262 0.712 
G. luciudm Biomass 0.142 0.021 0.294 
Hybrid Biomass 0.101 0.066 0.136 
G. tsugae Pileus 1.006 N.A. N.A. 
G. lucidum Pileus 0.392 0.278 0.625 
Hybrid Pileus 0.310 0.245 0.408 
> IC50 w a s ca lcu lated b y E P A Probit analysis p r o g r a m m e used for ca lculat ing L C / E C values 
v e r s i o n 1 .5 . 
> N . A . : not appl icable . 
Terpenes extracted from biomass and pileus of G. lucidum, G. tsugae and 
hybrid were used to treat MCF-7 cells (Figure 3.45 and Figure 3.46). The amounts 
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Figure 3.45 Cytotoxicities of the terpene preparation from biomass extracts of (a) G 
lucidum, (b) G tsugae and (c) hybrid against breast cancer cells MCF-7 
using M T T assay. The amounts of terpenes (equivalent to 1 x mg/ml in 
the graph) prepared from biomass extracts were (g/g): G lucidum, 
0.0171; G tsugae, 0.0224 and their hybrid, 0.0301. MCF-7 cells of cell 
density 3 x 10^  cells per well were seeded and incubated. Cells were 
harvested at 24, 48, 72 and 96 hours Each data is represented by the 
mean 士 standard deviation of 5 replicates. Ranking is by Tukey test at 
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Figure 3.46 Cytotoxicities of the terpene preparation from pileus extracts of (a) G. 
lucidum, (b) G. tsugae and (c) hybrid against breast cancer cells 
MCF-7 using M T T assay. The amounts of terpenes (equivalent to 1 x 
mg/ml in the graph) prepared from pileus extracts were (g/g): G. 
lucidum, 0.0140; G. tsugae, 0.0240 and their hybrid, 0.0280. MCF-7 
cells of cell density 3 x 10^  cells per well were seeded and incubated. 
Cells were harvested at 24, 48, 72 and 96 hours Each data is 
represented by the mean 士 standard deviation of 5 replicates. 
Ranking is by Tukey test at 5% probability with "a" of the highest 
ranking. 
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From the results, biomass terpenes of G. lucidutn (Figure 3.45a)，G. tsugae 
(Figure 3.45b), hybrid (Figure 3.45c), pileus terpenes of G. lucidum (Figure 3.46a)， 
G. tsugae (Figure 3.46b)，hybrid (Figure 3.46c) showed concentration dependent 
effect at 96 hour treatment. Unlike the results of lingzhi polysaccharide, IC50 of 
cells treated with terpenes were greater than the water extracts ofbiomass and pileus 
of the two parents and hybrid (Tables 3.7). 
Table 3.7 The anti-proliferative effect of terpenes extracted from biomass and 
pileus extracts of G. lucidum, G. tsugae and hybrid on MCF-7 cells. 
Terpenes IC5o(mg/ml) 95% Confidence limit 
Lower Upper 
G. tsugae Biomass N.A. N.A. N. A. 
G. luciudm Biomass N.A. N.A. N.A. 
Hybrid Biomass N.A. N.A. N.A. 
G. tsugae Pileus N.A. N.A. N.A. 
G. lucidum Pileus 0.694 0.387 2.971 
Hybrid Pileus N.A. N.A. N.A. 
> IC50 w a s ca lculated b y E P A Probit analysis p r o g r a m m e used for calculat ing L C / E C values 
v e r s i o n 1 .5 . 
> N . A . : not appl icable . 
Lingzhi polysaccharide and terpenes were used together to study for any 
additive effect on inhibition of MCF-7 cells. From the results of lingzhi 
polysaccharide and terpenes of biomass and pileus (Figure 3.47a and Figure 3.47b 
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respectively), the % of inhibition was enhanced compared to crude extracts but 
similar to lingzhi polysaccharide of Ix concentration alone for all samples. 
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Figure 3.47 Cytotoxicities of the reconstituted terpene preparation and lingzhi 
polysaccharide preparation from (a) biomass extracts and (b) pileus 
extracts of G. lucidum, G. tsugae and their hybrid against breast 
cancer cells MCF-7 using M T T assay. In (a), the amounts of terpenes 
and lingzhi polysaccharides used were (mg/ml and mg/ml): G. 
lucidum, 0.0171 and 0.0146; G. tsugae, 0.0224 and 0.0130; hybrid, 
0.0301 and 0.0307，respectively. In (b), the amounts of terpenes and 
lingzhi polysaccharides used were (mg/ml and mg/ml): G. lucidum, 
0.0140 and 0.0182; G. tsugae, 0.0240 and 0.0224; hybrid, 0.0280 and 
0.0462，respectively. MCF-7 cells of cell density 3 x 10^  cells per 
well were seeded and incubated. Cells were harvested at 24, 48, 72 
and 96 hours Each data is represented by the mean 士 standard 
deviation of 5 replicates. Ranking is by Tukey test at 5% probability 
with “a，，of highest ranking. 
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3.6.5. Effect of biomass and pileus extracts on MDA-MB-231 cells 
The effects of pileus and biomass extracts on MDA-MB-231 were also studied 
using M T T assay and cell viability assay. Results of MDA-MB-231 cells treated 
with G. lucidum (Figure 3.48 (a) and (b)), G. tsugae (Figure 3.49 (a) and (b)) and 
hybrid (Figure 3.50 (a) and (b)) biomass extract using M T T and cell viability assay 
are shown. Similar results obtained from M T T assay and cell viability assays with 
no obvious anti-proliferative effect was observed for G. lucidum, G. tsugae and 
hybrid biomass extracts. 
For pileus extracts of G. lucidum (Figure 3.51 (a) and (b))，G. tsugae (Figure 
3.52 (a) and (b)) and hybrid (Figure 3.53 (a) and (b)) using M T T and cell viability 
assay are shown. Similar results obtained from G. lucidum and G. tsugae pileus 
extract treated MDA-MB-231 cells with significantly higher percentage of inhibition 
resulted using M T T assay but no significant different observed when using cell 
viability assays. About 20% of inhibition was shown by treatment with 1 mg/ml 
extracts of G. lucidum, G. tsugae and hybrid. 
159 
(a) ‘ 




40 - I - ^ G L 0.0625 mg/ml I 
: 3 0 - ~ « ~ G L 0.125 mg/ml 
:| 20 - -A t-GL 0.25 mg/ml 
10 - - GL 0.5 mg/ml 
^ 0 It X l - ^ G L l m g / m l 
.10 a 24 48 ‘ 
- 2 0 -
-30 -
-40 L 
Treatment period (hours) 
(b) 




40 _ - ^ G L 0.0625 mg/ml 
£ 30 - - «—GL 0.125 mg/ml 
I 20 - T- - ^ G L O . 2 5 mg/ml 
1 ^^  f ^ ： ： ： ^ ^ ^ ^ — G L a 5 m _ 
〜〜工 GL Img/ml 
-10 (T 24 、 ^ , , 72 ^  
-20 - \、各,' 、 
-30 -
-40 L 
Treatment period (hours) 
Figure 3.48 Anti-proliferative effects of biomass extracts of G lucidum against 
breast cancer cells MDA-MB-231 cells using (a) M T T assay (b) cell 
viability assay with tryphan blue. MCF-7 cells of cell density 3 x 10^  
cells per well were seeded and incubated. Cells were harvested at 24， 
48, 72 and 96 hours Each data is represented by the mean 士 standard 
deviation of 5 replicates. Ranking is by Tukey test at 5% probability 
with "a，，of the highest ranking. 
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Figure 3.49 Anti-proliferative effects of biomass extracts of G. tsugae against 
breast cancer cells MDA-MB-231 cells using (a) M T T assay (b) cell 
viability assay with tryphan blue. MCF-7 cells of cell density 3 x 
10 cells per well were seeded and incubated. Cells were harvested 
at 24, 48, 72 and 96 hours Each data is represented by the mean 土 
standard deviation of 5 replicates. Ranking is by Tukey test at 5% 
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Figure 3.50 Anti-proliferative effects of biomass extracts of hybrid against breast 
cancer cells MDA-MB-231 cells using (a) M T T assay (b) cell 
viability assay with tryphan blue. MCF-7 cells of cell density 3 x 
10^  cells per well were seeded and incubated. Cells were harvested 
at 24，48, 72 and 96 hours Each data is represented by the mean 士 
standard deviation of 5 replicates. Ranking is by Tukey test at 5% 
probability with “a，，of highest ranking. 
162 
(a) ‘ 




40 - a  � a —•—GL 0.0625 mg/ml 
函 30 -^ J -«—GL 0.125 mg/ml 
. 2 0 - .. 本 —A—GL 0.25 mg/ml i 10 .： [ ^ -I b - GL 0.5 mg/ml 
^ ,, I � Z ^ ^ r b Img/ml 
0 IE  
.10 24 48 72 96 b 
- 2 0 -
-30 -
4n 
Treatment period (hours) 




_ 40 - I - - • — G L 0.0625 mg/ml I 
£ 30 - - T I - » - G L 0.125 mg/ml 
I 20 - - ^ G L 0.25 mg/ml 
I 1 0 - .一― GL 0.5 mg/ml 
- _ - ^ G L Img/ml 
OH 义 ‘ ‘ 
0 24 72 96 
-20 -
-30 -
4 0 L 
Treatment period (hours) 
Figure 3.51 Anti-proliferative effects ofpileus extracts of G lucidum against breast 
cancer cells MDA-MB-231 cells using (a) M T T assay (b) cell viability 
assay with tryphan blue. MCF-7 cells of cell density 3 x 10^  cells per 
well were seeded and incubated. Cells were harvested at 24, 48, 72 
and 96 hours Each data is represented by the mean 士 standard deviation 
of 5 replicates. Ranking is by Tukey test at 5% probability with “a” of 
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Figure 3.52 Anti-proliferative effects of pileus extracts of G tsugae against breast 
cancer cells MDA-MB-231 cells using (a) M T T assay (b) cell viability 
assay with trypan blue. MCF-7 cells of cell density 3 x 10^  cells per 
well were seeded and incubated. Cells were harvested at 24, 48, 72 
and 96 hours Each data is represented by the mean 士 standard deviation 
of 5 replicates. Ranking is by Tukey test at 5% probability with “a，，of 
the highest ranking. 
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Figure 3.53 Anti-proliferative effects of pileus extracts of hybrid against breast 
cancer cells MDA-MB-231 cells using (a) M T T assay (b) cell viability 
assay with tryphan blue. MCF-7 cells of cell density 3 x 10^  cells per 
well were seeded and incubated. Cells were harvested at 24, 48, 72 
and 96 hours. Each data is represented by the mean 士 standard 
deviation of 5 replicates. Ranking is by Tukey test at 5% probability 
with “a，，of the highest ranking. 
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i . 7. Estrogenicity assay 
3.7.1. E-screen assay on biomass and pileus extracts 
In E-screen assay, maximum cell proliferation was observed with 0.25 mg/ml 
(i.e. 10 nM) of /3 -estradial (E2). The proliferative effect of extracts relative to E2 
(0.25 mg/ml as 100%) was represented as relative proliferative effect (RPE) (Figure 
3.54a). Hybrid pileus extract significantly stimulated the proliferation of MCF-7 
cells compared with others. At 20 mg/ml, hybrid pileus extract had maximal cell 
proliferation (RPE二 71.41 土 3.68o/o). Other samples also showed proliferation of 
MCF-7 cells with RPE of 56.92 土 3.49o/o，51.26 土 0.93o/o，49.49 土 4.20%，44.38 土 
4.82% and 41.98 土 1.71% of biomass extract of G. lucidum, G. tsugae and hybrid 
and G. lucidum, G. tsugae pileus extract. G. lucidum, G. tsugae and hybrid biomass 
and pileus showed estrogenicity in a concentration-dependent manner. No 
significant difference among the pileus extracts of the two parents and hybrid. No 
significant difference was also observed among biomass extracts of G. lucidum, G. 
tsugae and hybrid. 
3.7.2. E-screen assay on biomass and pileus terpenes and lingzhi polysaccharide 
Different concentrations of biomass and pileus terpenes and lingzhi 
polysaccharide were tested for estrogenic activity by E-screen assay (Figure 3.54c). 
The results showed that both biomass and pileus terpens displayed proliferative 
effect of MCF-7 cells which were similar to the estrogenicity of G. lucidum, G. 
tsugae and hybrid biomass and pileus extract. At concentration of 2Ox, maximum 
cell proliferation was observed in G. tsugae pileus terpenes with PRE of 86.16 土 
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4.07%. G. lucidum and hybrid pileus terpenes also showed rather high RPE of 82.14 
土 5.50% and 82.89 土 14.46o/o respectively. On the other hand, terpenes extracted 
from biomass of G. lucidum, G. tsugae and hybrid were comparatively lower than 
those extracted from pileus. The RPE of biomass terpenes of G. lucidum was 52.31 土 
1.32%; G. tsugae was 50.26 土 0.83% and hybrid of 56.47 土 2.79% and also, 
concentration dependent response was found. No obvious proliferation was 
observed from cells treated with lingzhi polysaccharide as shown in Figure 3.54b. 
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Figure 3.54 Relative proliferative effects of (a) biomass and pileus extract (b) 
lingzhi polysaccharide preparations and (c) terpenes preparations on of 
MCF-7 cells. 
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3.7.3. Estrogen receptor competitor binding assay 
In estrogen receptor competitor binding assay a，pileus extract effectively 
displaced the estrogen ligand from the ER/Fluormone™ EL Red complex except G. 
lucidum pileus extracts. The lowest IC50 of hybrid pileus extract was 79.215 mg/ml. 
The IC50 of G. lucidum, G. tsugae and hybrid biomass in this assay (Table 3.8) were 
too high and the binding affinity to the complex were considered to be low (Figure 
3.55a). 
Table 3.8 The binding affinity to estrogen receptor a of estrogen of biomass and 
pileus extracts of G. lucidum, G. tsugae and hybrid. 
EC50 (mg/ml) 950/0 Confidence limit 
Lower Upper 
Estrogen 0.050 0.031 0.088 
Water G. tsugae Biomass N.A. N.A. N.A. 
extract G. lucidum Biomass N.A. N.A. N.A. 
Hybrid Biomass N.A. N.A. N.A. 
G. tsugae Pileus 86.019 33.896 835.838 
G. lucidum Pileus N.A. N.A. N.A. 
Hybrid Pileus 79.215 28.257 1570.310 
> Binding affinity was expressed in EC50 which was calculated by EPA Probit analysis 
programme used for calculating LC/EC values version 1.5. 
> N.A.: not applicable. 
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For estrogen receptor competitor binding assay p，biomass and pileus extracts 
(Figure 3.55b) effectively displaced the estrogen ligand from the ER/Fluormone™ 
EL Red complex with lowest EC50 of hybrid pileus extract of 57.142 mg/ml (Table 
3.9). 
Table 3.9 The binding affinity to estrogen receptor (3 of estrogen, biomass and 
pileus water extracts and terpenes extracted from biomass and pileus 
of G. lucidum, G. tsugae and hybrid. 
EC5o(mg/ml) 95% Confidence limit 
Lower Upper 
Estrogen 0.058 0.037 0.099 
Water G. tsugae Biomass 320.923 87.581 11934.157 
extract G. lucidum Biomass 127.932 47.066 1416.056 
Hybrid Biomass 73.188 26.962 1250.366 
G. tsugae Pileus 65.093 24.269 1170.435 
G. lucidum Pileus 88.952 37.053 649.409 
Hybrid Pileus 57.142 21.678 1060.767 
> Binding affinity was expressed in I C 5 0 which was calculated by EPA Probit analysis programme 
used for calculating LC/EC values version 1.5. 
> N.A.: not applicable. 
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Figure 3.55 The competitive binding assays for (a) estrogen receptor alpha and (b) 
estrogen receptor beta with biomass and pileus extracts of G lucidum, 
G tsugae and their hybrid and estrogen, the positive control. 
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Terpenes extracted from biomass and pileus were tested to show estrogenicity in 
E-screen assay and therefore, they were put for estrogen receptor competitor binding 
assays in order to study for their binding affinity to estrogen receptor. From the 
results of estrogen receptor competitor binding a (Figure 3.56a and Table 3.10), 
biomass and pileus extracts effectively displaced the estrogen ligand from the 
ER/Fluormone™ EL Red complex with lowest IC50 of hybrid pileus extract of 
50.787 mg/ml (Table 3.10). 
Table 3.10 The binding affinities to estrogen receptor a of estrogen, and terpenes 
prepared from biomass and pileus extracts of G. lucidum, G. tsugae 
and hybrid. 
EC50 (mg/ml) 95% Confidence limit 
Lower Upper 
Estrogen 0.050 0.031 0.088 
Terpenes G. tsugae Biomass 139.097 75.205 405.609 
G. lucidum Biomass 447.378 150.635 4669.796 
Hybrid Biomass 758.044 194.804 19829.783 
G. tsugae Pileus 66.797 38.542 167.051 
G. lucidum Pileus 78.885 48.048 174.053 
Hybrid Pileus 50.787 29.983 121.940 
> Binding affinity was expressed in I C 5 0 -which was calculated by EPA Probit analysis programme 
used for calculating LC/EC values version 1.5. 
> N.A.: not applicable. 
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From the results of estrogen receptor competitor binding (3 (Figure 3.56b and 
Table 3.11)，biomass and pileus extract effectively displaced the estrogen ligand 
from the ER/Fluormone™ EL Red complex with lowest IC50 of hybrid pileus extract 
of 41.096 mg/ml (Table 3.11). 
Table 3.11 The binding affinities to estrogen receptor P of estrogen, and terpenes 
prepared from biomass and pileus extracts of G. lucidum, G. tsugae 
and hybrid. 
IC50 (mg/ml) 95% Confidence limit 
Lower Upper 
Estrogen 0.058 0.037 0.099 
Terpenes G. tsugae Biomass 81.527 50.905 171.813 
G. lucidum Biomass 100.312 60.618 229.067 
Hybrid Biomass 81.543 49.373 182.248 
G. tsugae Pileus 51.439 34.162 94.982 
G. lucidum Pileus 56.015 35.194 115.793 
Hybrid Pileus 41.096 27.711 73.554 
> Binding affinity was expressed in I C 5 0 which was calculated by EPA Probit analysis programme 
used for calculating LC/EC values version 1.5. 
> N.A.: not applicable. 
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Figure 3.56 The competitive binding assays for (a) estrogen receptor alpha and (b) 
estrogen receptor beta with the terpene preparations from G. lucidum, 
G. tsugae and their hybrid and estrogen, the positive control. 
174 
3.7.4. pS2 mRNA expression assay 
Cells treated with /3 -estradiol and 1 mg/ml pileus extract of G. lucidum, G. 
tsugae and hybrid and also biomass extract of hybrid up-regulated the expression of 
pS2 m R N A significantly when compared with the unexposed control (Figure 3.57). 
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Figure 3.57 The effects of pileus extracts of G. lucidum, G. tsugae and hybrid on 
expression of (a) actin and (b) pS2 of MCF-7 cells. The expression 
of pS2 is normalized with that of actin as shown in (c). Each data is 
represented by the mean 士 standard deviation of triplicates. Ranking 
is by Tukey test at 5% probability. MCF-7 cells were cultured in 
steroid depleted medium for 2 two days and seeded with cell density 
of 3 X per ml cells supplemented with charcoal dextran treated 
FBS. Medium was removed on the next day and replaced with fresh 
medium with pileus extracts or estrogen as positive control. 
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3.8. DNA Microarray analysis 
A gene highlighted with a red or green square indicates a 4-fold or above 
difference in expression which are shown in Figures 3.61 and 3.63. The scatterplots 
of gene expressions in control against hybrid biomass and pileus extracts treatment 
are also shown in Figures 3.62 and 3.64. Again, red spots show the up-regulated 
gene while green ones show the down-regulated genes. The list of these 
up-regulated or down-regulated genes with 4 or more fold difference is summarized 
in table form (Table 3.10 and 3.11). For hybrid biomass treatment, the highest 
up-regulated gene was growth arrest and D N A damage-inducible, alpha gene 
(GADD45A) with 4.92 fold up-regulation, and the second one is bone 
moiphogenetic protein 4 (BMP-4). The results of MCF-7 cells treated with hybrid 
pileus extract was similar to those treated with biomass extracts with genes of WNT2, 
HSPCA, TNFSFIO, WSBl, TF and C D K N 2 D down-regulated. BMP-4, G A D D 4 5 A 
and HSPA5 were also up-regulated in MCF-7 cells treated with pileus extract while 
BMP-4 and G A D D 4 5 A were the first and second highest gene being up-regulated. 
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Figure 3.58 Slides of D N A microarray showing the differential regulation on 
expression profiles of the signal transduction pathways of MCF-7 
breast cancer cells by (a) control and (b) hybrid biomass treatment. 
The gene with a red square indicates that there are at least 4-folds 
up-regulation and green square for down-regulation in gene 
expression analyzed by GEArray Expression Analysis Suite. 
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Figure 3.59 Scatter plot of the gene expressions in MCF-7 cancer cells between 
control and hybrid biomass treatment. Red spots indicate genes 
which are at least 4-folds up-regulated expression compared to control 
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Table 3.12 Summary of genes with 4-fold expression difference compared to 
control in MCF-7 cancer cells with treatment of hybrid biomass 
extract. 
Gene Name Up Down 
regulation regulation 
Growth arrest and DNA-damage-inducible, alpha 4.92 
(GADD45A) 
Bone moiphogenetic protein 4 (BMP-4) 4.62 
Heat shock 70kDa protein 5 (glucose-regulated protein, 4.38 
78kDa) (HSPA5) 
Wingless-type M M T V integration site family member 
13.47 
2 (WNT2) 
Cyclin-dependent kinase inhibitor 2D (pi9，inhibits 
7.73 
CDK4) (CDKN2D) 
Heat shock 90kDa protein 1，alpha (HSPCA) 7.50 
W D repeat and SOCS box-containing 1 (WSB-1) 6.55 
Transferrin (TF) 4.16 
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Figure 3.60 Slides of D N A microarray showing the differential regulation on 
expression profiles of the signal transduction pathways of MCF-7 
breast cancer cells by (a) control and (b) hybrid pileus treatment. 
The gene with a red square indicates that there are at least 4-folds 
up-regulation and green square for down-regulation in gene 
expression analyzed by GEArray Expression Analysis Suite. 
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Figure 3.61 Scatter plot of the gene expressions in MCF-7 cancer cells between 
control and hybrid pileus treatment. Red spots indicate genes which 
are at least 4-folds up-regulated expression compared to control 
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Table 3.13 Summary of genes with 4-fold expression difference compared to 
control in MCF-7 cancer cells with treatment of hybrid pileus extract. 
Gene Name Up D o w n 
regulation regulation 
Bone morphogenetic protein 4 (BMP-4) 8.53 
Growth arrest and DNA-damage-inducible, alpha 7.65 
(GADD45A)  
Baculoviral LAP repeat-containing 1 (BIRCl) 6.06 
Interleukin 4 receptor (IL4R) 5.82 
Heat shock 70kDa protein 5 (glucose-regulated protein, 4.09 
78kDa) (HSPA5)  
Wingless-type M M T V integration site family member ^^ ^ ^ 
2 (WNT2) . 
Heat shock 90kDa protein 1，alpha  
Tumor necrosis factor (ligand) superfamily, member 10 
4.61 
(TNFSFIQ)  
W D repeat and SOCS box-containing 1 (WSB-1) ^  
Transferrin (TF) ^  
Cyclin-dependent kinase inhibitor 2D (pi9，inhibits 
4.09 
CDK4) (CDKN2D)  
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4. Discussion 
4.1. Artificial hybridisation of Ganoderma tsugae and G lucidium 
4.1.1. Protoplast isolation and fusion of Ganoderma tsugae and G lucidum 
Two studies investigated the application of interspecific hybridization by 
protoplast fusion involving Ganoderma lucidum. The first one was Yanai et al. 
(1995) employing G. luciudm and Pleurotus ostreatus and the other report was G. 
lucidum and Grifola umbelleta (Yoo et al., 2002). No fertile basidoimes were 
produced in the claimed hybrids in both studies and only the hybrid of G. lucidum 
and P. florida was detected by random amplified polymorphic D N A markers (Yoo et. 
al. 2002). This is the first report about the application of interspecific protoplast 
fusion of Ganoderma spp. and this study provided a new approach for producing 
fertile lingzhi hybrids of two Ganoderma species discriminated by somatic 
incompatibility, growth rate, growth temperature range, nuclear and mitochondrial 
ribosomal D N A sequences beside the basidome morphology. When G. tsugae was 
confronted with G. luciudm in agar media, somatic incompatibility occurred by 
forming barrier between the two mycelial colonies. 
4.1.2. Screening and selection of hybrid 
Temperature screening was employed as a primary screening approach because 
it allowed fast and simple selection of putative hybrids. Due to the difference in 
growth rate of the two parents, isolates with significantly different growth 
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performance could be chosen. A diversity of non-parental progeny was obtained. 
Barrier was found between one parent and delimitation found between another one 
suggested that the selected hybrid is a new isolate in somatic incompatibility test. A 
low level of variation was found in amplified ITS region of ribosomal D N A and 
Mt-rDNA fragments in the hybrid from the two parents. The genetically close 
relationship of the hybrid to its parent G. lucidum may actually be the result of the 
selection criteria for expanding the growth temperature ranges and fast growth rates. 
The success of the protoplast fusion may be correlated with the evolutionary 
relationship among these species. 
For PSIL which was designed for laccase gene of fungus Pleurotus sajor-caju 
laccase 1，genomic D N A s of G. lucidum, G. tsugae and hybrid were amplified by the 
specific primer set but no PCR product was obtained from G. tsugae. There were 
15 base pair difference were found between the amplified sequences of G. lucidum 
and hybrid. Thus somatic recombination might have occurred during protoplast 
fusion of G. lucidum and G. tsugae in the formation of the hybrid. 
4.1.3. Characterisation of the selected hybrid 
Scanning electron microscopy is a microscopic characterization of the hybrid. 
The basidiospores of hybrid were similar to those of parent G. lucidum which were 
oval-shaped whereas basidiospores of G. tsugae was round-shaped but all of them 
were smooth-walled but the surface became rough after drying stage indicating the 
fragile outer wall in Ganoderma spp. 
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G. lucidum, G. tsugae and their hybrid showed similar growth pattern and 
maximum growth rate was observed at 30°C. Normal cultivation temperature for 
lingzhi is 28°C (Stametes, 1993) which is autumn and spring in Hong Kong. This 
hybrid acquired better growth performance by possessing the ability to tolerate 
higher temperatures. As mycelial growth of hybrid is significantly higher than 
parents, cultivation of lingzhi could also be carried out in summer which will in turn 
lower the cultivation cost. 
The amount of freeze-dried filtrate of hybrid was significantly higher than those 
of the two parents for the same incubation period of submerged fermentation. One 
component of filtrate is water-soluble polysaccharide (Chen and Chen, 2003). 
Polysaccharides exist abundantly in fungi and are the major component of fungal cell 
wall. Polysaccharides have been recognised as effective anti-tumor substances 
which have drawn special research attention in correlation with immunomodulatory 
effects (Kim et al., 1999; Mizushina et al., 1999; Wasser and Weiss, 1999). Also, 
research has been intensively conducted in studying immunostimulatory effect of 
polysaccharides (Habijanic et al., 2001). Ganoderma lucidum polysaccharides 
could stimulate host immune functions through activation of macrophages and 
lymphocytes to secret anti-tumor cytokines such as TNF-a and interferon-y (Cao and 
Lin, 2004). Lingzhi polysaccharide is actually ethanol-soluble polysaccharide. 
This fraction of polysaccharide was obtained rather than the water-soluble one 
because this fraction used 85% ethanol for extraction and this fraction consisted of 
more components that are responsible for immunostimulatory and cancer therapy 
(Habijani et a l , 2001; Berovic et al., 2003). Lingzhi polysaccharide extracted from 
biomass is generally higher than pileus because polysaccharide of glucan was 
metabolized when fruiting bodies are formed (Carlile et al.，2001). 
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Unlike polysaccharide, terpenes are specifically found in Ganoderma spp. but 
not all fungi (Nishitoba et al., 1986). Over one hundred triterpenoids have been 
isolated form Ganoderma. It contributed to the antioxidant activity of Ganoderma 
spp. (Zhu et a l , 1999) and anti-tumor effect (Noda et al” 1997; Gan et al,, 1998; Min 
et al., 2000). Terpenes amounts extracted from biomass and pileus of G. lucidum, 
G. tsugae and hybrid were similar. However, from the chromatograms, different 
strains of Ganoderma spp. consisted of different bioactive compounds as expected. 
The terpene profiles are listed in Table 4.1. 
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Table 4.1 Terpene profiles of G. lucidum, G. tsugae and hybrid. 
G. hiddum G. tsugae Hybrid 
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A "V" denoted the presence of compound in the sample and compounds which are unique in certain 
samples are coloured grey. 
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Different parts and stage of lingzhi consisted of different terpene profiles. For 
G. lucidum, tetradecyloxirane and benzenedicarboxylic acid were only found in 
biomass, and heptadecyloxirane was only found in pileus. For G. tsugae, 
octadecanol was uniquely found in biomass. For hybrid samples, docosene and 
hexadecane were found only in biomass and octacosane, docosane and eicosane 
together with ergosta-7,22-diene-3-ol were uniquely present in pileus. Hydrocarbons 
of heneicosane, heptacosane and pentacosane were only identified in stipe of hybrid. 
Ergosterol was also found in the terpene preparations. Ergosterol is the major 
sterol of plasma membrane of fungi (Carlile et al., 2002). Conversion of ergosterol 
to vitamin D2 would be carried out under sunlight or heated in a mechanical drying 
process. Vitamin D2 has the advantageous effect to lessen the danger of bone loss 
(Jasinghe and Perera, 2005; Kac et al., 1984). Ergosterol derivatives have found to 
be potent anti-tumor agents (Gan et al., 1998). However analysis has reported that 
the main component of the steroid faction is ergosta-7，22-diene-3-ol whereas 
ergosterol and other derivatives are subcomponents (Kac et al., 1984) but 
bioactivities of the ergosterol derivatives have not yet reported. 
4.1.4. Nature of hybrid, mutant and variant 
The generated organism from protoplast fusion is named “hybrid” with genetic 
materials come from both parents. Mendes-da-Gloria et al. (2000) demonstrated 
complementary genetic profile was obtained from both parents in protoplast fusion of 
Caipira sweet orange and Rangpur lime. However, mutant will be generated when 
mutation occurs which is caused by copying errors of genetic materials. Instability 
189 
and rate of cell death were increased when green alga cells undergo mutation 
(Zamora and Marshall, 2005), and variant is an organism that comes across genetic 
variation with alteration of the genotype. These variants possess a number of 
particular sites which are coinherited from one or both parents (Broeckel and Schork, 
2003). 
In this study, the claimed hybrid after protoplast fusion may be classified as a 
"variant" rather than a "hybrid". This is because the selection force allowed the 
choice of putative hybrid in biased to one parent with expanded growth temperature 
range together with faster growth rate. This resulted in selection of a variant with 
alternation of a few regions of genetic materials which is different from one parent 
and at the same time, similar to another. 
4,2, Effect of extracts against breast cancer cell lines 
4.2.1. Anti-proliferative effect of extracts on MCF-7 cells 
G. lucidum, G. tsugae and hybrid biomass and pileus extracts demonstrated 
anti-proliferative effect in estrogen-dependent MCF-7 breast cancer cells in a time-
and concentration-dependent by MTT, cell viability and BrdU assays. The 
correlation of the results of the M T T assay and cell viability assay was above 0.8 and 
so, experiments were monitored by M T T assay in the first place. 
Morphologies of MCF-7 cells treated with G. lucidum, G. tsugae and hybrid 
biomass and pileus were recorded. From the morphology observed, cells treated 
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with both parents and hybrid biomass and pileus were undergoing apoptosis with 
shrunken cells, irregular shaped cells, etc. 
Ganoderma spp. have been commonly used as traditional Chinese medicine and 
at present consumed as an anticancer and tonic agent for many years. Jiang et al. 
(2004a) reported that water extracts of Ganoderma lucidum down-regulated Bcl-2 
and up-regulated Bax protein expression levels in human prostate cancer cells. 
Many bioactive components have been identified from its fruiting bodies, mycelia, 
stipe and culture media (Furusawa et al., 1992). Polysaccharides and triterpenes are 
two major categories of the bioactive ingredients (Lieu et al., 1993). 
Polysaccharides from G. lucidum were extensively reported to inhibit cell 
proliferation (Cheung et al.’ 2000). Triterpenes extracted from Ganoderma spp. 
were reported to induce cytotoxic activity against tumor cells (Gan et a l , 1998; Min 
et a l , 2000; Noda et al., 1997; Zhu et al., 1999). Therefore these two bioactive 
components are believed to contribute to anti-proliferative activities in cancer cells as 
polysaccharides and terpenes possess anti-tumor effects. Ergosterol found in 
terpenes preparation also reported to have anti-tumor effect (Gan et al., 1998) and 
these compounds may also contribute to the anti-proliferation. In the present study, 
the effects of G. lucidum, G. tsugae and hybrid on the proliferation of MCF-7 breast 
cancer cells were examined. Here the results showed that the biomass and pileus 
extracts effectively inhibited the growth of MCF-7 cells but not stipe or medium 
extracts. As there was no significant difference in contents of major anti-tumor 
agents, polysaccharide and terpenes of parents and hybrids, the difference in 
anti-proliferation may be due to the different terpene profiles of pileus and biomass 
which were shown in G C chromatograms and/or the actual chemical composition of 
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their lingzhi polysaccharides. For medium extracts, the quantities of terpenes were 
extremely low which may account for their ineffectiveness in anti-proliferative effect 
in MCF-7 cells. 
In order to verify the contribution of terpenes and polysaccharides of their 
anti-proliferative effect, terpenes and lingzhi polysaccharides were isolated from the 
extracts of two parents and hybrid and these preparations were used to treat MCF-7 
cells again. The amounts of lingzhi polysaccharides and terpenes used for treatment 
were quantified so that they were equal to the amounts present in biomass and pileus 
extracts. 
No significant difference between percentage of inhibition was observed when 
terpenes and lingzhi polysaccharides extracted from biomass and pileus of G. 
lucidum, G. tsugae and hybrid compared to treatment of biomass and pileus water 
extracts. This indicates that different terpenes profile does not correlate with the 
difference in anti-proliferation of MCF-7 cells. It has been reported that certain 
components in extracts were speculated to exert different percentages of inhibition of 
cell proliferation in crude extracts (Wilasnimee et al., 2002) but further investigation 
is required for verification. 
On the other hand, percentage of inhibition of MCF-7 cells was enhanced when 
lingzhi polysaccharides extracted from biomass and pileus of G. lucidum, G. tsugae 
and hybrid instead of water extracts were used for treatment. These results match 
with the studies about anti-cancer potency of polysaccharides (Gan et al,, 1998; Kim 
et a l , 1999; Min et al； 2000; Mizushina et al” 1999; Noda et al； 1997; Wasser and 
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Weiss, 1999; Zhu et al., 1999). Moreover, interaction of terpenes and lingzhi 
polysaccharides were studied. Enhanced percentage of inhibition of lingzhi 
polysaccharides was observed but it was similar to those of lingzhi polysaccharides 
alone. This may indicate that lingzhi polysaccharide may be the major component 
that contributes to anti-proliferation against MCF-7 cells. 
4.2.2. Study of effect of cultured medium of biomass and pileus extracts on 
MCF-7 cells 
Mitogenic effect of MCF-7 cells treated with various extracts upon 24 and 48 
hour treatments may be due to presence of growth factors or analogues in the extracts. 
These substances may stimulate cell proliferation. Therefore another experiment 
was conducted for confirmation of this hypothesis. Medium together with extracts 
were used to treat MCF-7 cells for 2 days. After 2 day treatment, medium would be 
recovered and filter sterilized and added to new MCF-7 cells to see whether the 
inhibitory effect started upon 24 hour treatment. From the results, mitogenic effect 
was eliminated as anti-proliferation was observed starting from 24 hour treatment. 
— Proliferative effect on 24 and 48 hour incubation of MCF-7 cells upon treatment with 
biomass and pileus extracts were thus due to presence of growth factor or analogues. 
Inhibition of cell growth was observed on 72 and 96 hour treatment. After 
enhanced proliferation of cell growth, cell may release some kind of factors that may 
inhibit cell growth. Accumulation of these certain factor may result in cell growth 
inhibition. 
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4.2.3. Effect of biomass and pileus extracts on MDA-MB-231 cells 
In vitro studies have demonstrated that G. lucidum inhibits the proliferative 
activity of a number of mammalian cells (Hu et al., 2002; Jiang et al., 2004a). A 
previous study reported by Sliva et al. (2002) suggested that Ganoderma lucidum 
was able to suppress motility of MDA-MB-231 but unable to exert anti-proliferative 
effect on the cells. Results obtained in this study imply that pileus extracts not 
biomass extracts of G. lucidum, G. tsugae and their hybrid induced inhibitory effect 
on proliferation of MDA-MB-231, an estrogen-independent human breast carcinoma 
cells. This may be due to strain differences. Cells exposed to 1 mg/ml pileus 
extracts lost their capability to proliferate after 96 hour treatment but negative results 
was observed for MDA-MB-231 cells treated with biomass extracts. It has been 
reported that MCF-7 human breast cancer cells express both ER a and (3 while only 
E R p is expressed in MDA-MB-231 cells (Dotzlaw et al., 1996; Burow et a!” 2000). 
The inhibitory effect of pileus and biomass extracts of G. lucidum, G. tsugae and 
hybrid in MCF-7 cells may then be mediated by estrogen receptors whereas 
anit-proliferative effect observed in MDA-MB-231 cells by pileus but not biomass 
extracts were suggested to be mediated by estrogen-receptor-independent pathway. 
Inhibitory effect ofpileus extracts of two parents and hybrid against MDA-MB-231 
may be due to certain compound present in the crude extracts which require further 
investigation (Wilasnimee et a l , 2002). Jiang et al (2004b) reported that 
MDA-MB-231 cells were inhibited by downregulation of Akt/NF-kappaB signaling 
which suppresses phosphorylation of Akt on Ser473 and downregulates the 
expression of Akt by Ganoderma lucidum extract. This resulted in the inhibition of 
NF-kappaB activity in MDA-MB-231 cells. Cell cycle arrest at GO/Gl was induced 
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by the effect of Ganoderma lucidum and in turn resulted in downregulation of 
expression ofNF-kappaB-regulated cyclin D1 followed by the inhibition of cdk4. 
4.2.4. mRNA expression assay (RT-PCR) 
Bcl-2 plays an important role in inhibition of apoptosis stimulated by various 
factors such as irradiation, chemotherapeutic drugs and withdrawal of growth factors 
(Miysashita and Reed, 1994; Germain et al., 1993). Whether cells enter apoptosis 
is determined by the ratio of pro-apoptotic: anti-apoptotic factors. Increased 
expression of Bax can induce apoptosis while Bcl-2 protects cells from death (Cory 
and Adams, 2002). Bax is a pro-apoptotic Bcl-2 family member which binds to 
anti-apoptotic Bcl-2 protein that can antagonize its function to block apoptosis 
(Oltvai et al., 1993). Cytochrome c release from mitochondria followed by 
induction of Bax and this is inhibited by anti-apoptotic Bcl-2 family members 
(RosseA et al., 1998). The ratio of Bax/Bcl-2 plays a major role in determining 
whether cells will undergo apoptosis. Expression of Bcl-2 was down-regulated in 
MCF-7 cells after cultured with 1 mg/ml G. lucidum, G. tsugae and hybrid biomass 
and pileus extracts but Bax was up-regulated. Also, hybrid pileus extract lowered 
Bcl-2 and elevated Bax m R N A levels in a time-dependent manner. In the study of 
medium effect to MCF-7 cells, m R N A levels were found similar to cells treated with 
normal treatment of hybrid pileus extract except drastic decrease in Bcl-2 levels of 
MCF-7 cells. Further apoptotic assays like D N A fragmentation has to be carried 
out for confirmation. 
Bcl-2 expression may be down-regulated by p53 through binding to silencer of 
BC1-2 and after treatment with cytotoxic agents or irradiation (Haldar et al., 1994) 
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and p53 plays a critical role in apoptosis (Zhang et al., 1999). In order to 
investigate whether down-regulation of Bcl-2 was mediated via a p53-mediated 
pathway, p53 m R N A expression was studied. However, no differences were found 
in expression level of p53 although many studies reported that p53 has been found to 
increase several folds after treatment with cytotoxic agents (Gaelics et al., 1994). 
On the other hand the Bax gene is transcriptionally regulated by p53 during induction 
of apoptosis (Buckbinder et al., 1995; Miyashita and Reed, 1995). Therefore, bax 
up-regulation is one mechanism whereby p53 induces apoptosis. From the results, 
extracts-induced apoptosis was probably not caused by altering p53 levels. 
Amellem et al. (1997) and Zhang et al (1999) also reported that no change in p53 
were found with control MCF-7 cells and cells treated with tamoxifen or hypoxia. 
p53 acts as a tumour-suppressor protein that induces apoptotic cell death in response 
to oncogenic stress (Vousden and Lu, 2002). However, transcriptionally 
independent activities of p53 can also contribute to the apoptotic response (Vousden 
and Lu, 2002). Previous studies found that p53 caused apoptosis initiated by D N A 
damage can occur in the presence of actinomycin D or cycloheximide which blocks 
R N A or protein synthesis (Caelles et al., 1994). From the results of BrdU assay, 
D N A synthesis was found to be lowered in treated cells compared to control. p53 
may be involved in D N A damage or cell cycle arrest but no differences were found 
in p53 levels of cells treated with extracts. Taken together with the results, 
p53-induced apoptosis might not be involved. 
Bcl-2 expression has been shown to be a favorable prognostic factor and 
predictor of response to endocrine therapy in breast cancers (Gee et al., 1994; 
Silvestrini et al., 1996; Zhang et al., 1997). Enhanced response to endocrine 
therapy in cancers with Bci-2 response positive tumors might be the result of 
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down-regulation of Bcl-2 by antiestrogen agents (Zhang et al., 1999). These might 
be the case that G. lucidum, G. tsugae and hybrid biomass and pileus extracts can 
trigger apoptosis by down-regulating Bcl-2 levels together with elevating Bax levels 
and inhibiting proliferation of cancer cells. 
Estrogen has been shown to inhibit cytotoxic drug-induced apoptosis through 
up-regulating Bcl-2 levels in MCF-7 cells in previous studies (Teixeira et al., 1995; 
Huang et al； 1997). The down-regulation of Bcl-2 may be able to cause agonistic 
or antagonistic estrogenic effects (Oh and Chung, 2003; Zhang et al, 1999). Such 
an effect can be mediated by interaction with estrogen receptor (Zhang et al., 1999). 
MCF-7 breast cancer cells was reported to express both ER a and p (Dotzlaw et al., 
1996; Burow et al., 2000). 
Growth of breast cancer cells MDA-MB-231 was inhibited by downregulation 
of Akt/NF-kappaB signaling and induction of cell cycle arrest at GO/Gl was resulted 
by the effect of Ganoderma lucidum (Jiang et al., 2004b). Alcholic extract of 
Ganoderma lucidum may consist of potential anti-tumor agents via up-regulation of 
p21 and down-regulation of cyclin D1 together with enhanced expression of Bax (Hu 
et al., 2002). In addition, Ganoderma lucidum also exerts anti-angiogenic activities 
on breast cancer cells (Lu et al., 2004). In the present study, growth inhibition of 
MCF-7 cells was mediated by up-regulation of Bax and down-regulated Bcl-2 
through p53-independent pathway. This suggested that anti-tumor effect of 
Ganoderma spp. is mediated by multiple pathways (Cao and Lin, 2004; Hseu et al” 
2003; Hu and Lin, 1999; Jiang et al., 2004a and b). Moreover, strain and 
physiological stages affect the efficacy of the anti-proliferative effect a lot. 
Therefore, further investigation on basic studies of application on lingzhi as 
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anti-tumor drug or supplement in chemo or radio therapy of cancer are needed. 
4.3. Estrogenicity 
4.3.1. E-screen assay 
Estrogen plays an important role in biological activities like reproduction and 
physiological processes in a number of tissues including liver, bone, brain, blood 
vessels, adipose tissue etc. (Ciocca and Roig，1995). The action of estrogen is 
mediated through the intracellular estrogen receptors (Beato et al., 1995). Severe 
consequences may result from deficiency of estrogen such as menopausal symptoms 
like hot flushes, vaginal dryness etc., cardiovascular disease and osteoporosis 
(Ciocca and Roig, 1995). The major causes of estrogen deficiency are 
postmenopausal and surgical operation (Brzezinski and Debi, 1999; This et aL, 2001). 
Substances which act like estrogen may serve as a hormone alternative. Besides 
treating menopausal symptoms, these substances may also be able to lower the risk 
of cancer (Ito, 1999). These substances are commonly found from plant and named 
as phytoestrogens. These are manufactured by algae and fungi (Buck, 1996). 
In this study, it was confirmed that G. lucidum, G. tsugae and hybrid biomass 
and pileus extracts showed estrogenic effect in the estrogenicity screening assay 
(E-screen test). The bioactive compounds terpenes and lingzhi polysaccharides 
were then be tested by this. Negative results obtained from lingzhi polysaccharides 
but on the other hand, terpenes induced cell proliferation in the E-screen assay. 
Terpenes contribute to the estrogenicity in the biomass and pileus extracts. The 
estrogenicities of pileus extracts were generally higher than those of the biomass 
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extracts of G. lucidum, G. tsugae and hybrid. From the terpene contents, there were 
no significant difference between biomass and pileus extracts but the terpene profiles 
of these six extracts were different. Therefore different terpene profiles may 
account for the difference in estrogenicity. 
4.3.2. Estrogen receptor competitor binding assay 
For both estrogen receptor competitor binding assays a and ft pileus extracts 
effectively displaced the estrogen ligand from the ER/Fluoraione™ EL Red complex 
except G. lucidum pileus extracts in estrogen receptor competitor binding assay a 
On the other hand biomass extracts of G. lucidum, G. tsugae and hybrid were able to 
bind directly to estrogen receptor fi but not estrogen receptor a. The IC50 of pileus 
extract to ER-jS was lower than ER-a, indicating that the binding affinity to ER-jS 
was higher than ER-a. For biomass extracts, they only worked effectively with 
ER'fi but not ER-a. For terpenes extracted from pileus, the samples showed the 
same effects to pileus extracts for both E R a and 13. This suggests that E R binding 
affinity of G. lucidum, G. tsugae and hybrid were caused by their bioactive 
components terpenes. For biomass extracts, although the affinity of biomass extract 
to ER-a was low, they still showed affinitiy to E R This results match with 
biomass terpenes in the 2 estrogen receptor competitor binding assays. E R a has 
been widely studied for its important role in reproduction whereas E R 13 for its 
marked role in the central nervous system, bone, cardiovascular system, immune 
system (Arts et al., 1997; Enmark et al., 1997; Kuiper et al., 1998 a and b; Lindner et 
al； 1998; Osterlund et al” 1998). E R was reported for contribution to the cellular 
defense mechanism against hypeiproliferation, initiation and progression of 
neoplasmic transformation (Gustafsson, 1999). The dual action on E R a and ER 0 
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of pileus extracts and the higher binding affinity for the E R suggest that the pileus 
extracts could cause the agonistic or antagonistic effects dependent on target organs 
(Oh and Chung, 2004). These results suggest that biomass and pileus extracts from 
G. lucidum, G. tsugae and hybrid possessed weak estrogenic activities such that the 
action of estrogens is antagonized by anti-estrogens that binds to E R in a competitive 
manner against E2 (Wakeling and Bowler, 1988; Berry et al., 1990，Jordan and 
Murphy, 1990; Montano et al” 1996). Also, the observed effect was induced 
through a classical estrogen response pathway by interaction with the estrogen 
receptors. 
4.3.3. pS2 mRNA expression assay 
Pileus and biomass extracts of G. lucidum, G. tsugae and hybrid showed 
induction of pS2 gene expression. No significant difference was found in induction 
of pS2 expression by estrogen and hybrid biomass extracts together with pileus 
extracts of two parents and hybrid. The hybrid preparation was of higher effective 
than G. lucidum and G. tsugae biomass extracts. pS2 gene is an estrogen-responsive 
gene which only expressed in breast cancer cells but not in normal mammary cells 
(Jakowlew et al., 1984; Rio et al., 1987). Exposure of MCF-7 cells to estrogen 
activates transcription of this gene and resulted in increased levels of pS2 m R N A 
expression (Jakowlew et al； 1984; Masuakowski et a l , 1982). This is an ideal 
model to study the mechanism of estrogenic activity (Brown et al., 1984). 
Expression of pS2 gene has been widely used as a marker of estrogen responsiveness 
in ER-containing breast cancer cells which acts like an indicator of disease 
progression and a predictor of success of anti-estrogen therapy in breast cancer 
patients (Nunez et al., 1989). pS2 protein possessed a signal peptide together with 
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high contents of cysteine residue like some growth factors, but it does not show 
growth promoting activity towards any cells. pS2 gene expression can be increased 
by estrogen and inhibited by antiestrogen (Masiakowski et al., 1982). 
4.3.4. Ganoderma spp. as hormonal therapy 
Most women suffer from estrogen-deficiency in menopausal period which will 
in turn cause diseases such as cardiovascular disease etc. (This et a l , 2001). 
However, it is well documented that estrogen could enhance cell proliferation in 
estrogen-dependent breast cancer cells (Heish et a\., 1998) but on the other hand, 
Adlercreutz (1990)，Barnes et al (1990) and Setchell et al. (1984) demonstrated that 
estrogen and estrogen agonists such as genistein chemiopreventive agents which is 
able to inhibit mammary tumors. From the results, Ganoderma spp. show weak 
estrogenicity at high concentration with estrogen receptor binding affinity and ability 
to induce pS2 m R N A expression, which indicated that Ganoderma spp. may act as 
agonist action which could be a potent hormonal therapy substance for menopausal 
women and chemiopreventive agents for mammary tumors. 
4,4, DNA microarray analysis 
D N A microarray analyses were carried out to detect the signal transduction 
pathways affected by the treatment of lingzhi extracts on the breast cancer cells 
MCF-7. Both pileus extract and biomass extract affected similar profiles of the 
genes. Among them, the most affected expression belongs to genes GADD45a and 
BMP-4. G A D D 4 5 A is an apoptotic gene whereas BMP-4 takes part in induction of 
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apoptosis in addition to stimulation of bone formation (Yokouchi et al., 1996). 
Wingless-type M M T V integration site family member 2 (WNT2) gene was 
down-regulated to the greatest extent in which this gene plays an important role in 
tumor development. Down-regulation of this gene will in turn hinder 
carcinogenesis (Mazieres et al, 2005). Cyclin-dependent kinase inhibitor 2D (pi9， 
inhibits CDK4) (CDKN2D) was observed with 7.73 fold down-regulation which 
suggested cell death was triggered as pl9 plays an important role in D N A repair 
(Ceruti et al., 2005). Another down-regulated gene in treatment of hybrid biomass 
extract is Heat shock 90kDa protein 1，alpha (HSPCA). This gene is involved in 
regulation of steroid receptors including estrogen receptors by binding to those 
receptor molecules and furthermore, it is associated with cell proliferation (Yano et 
al., 1999). Down-regulation of this gene suggested that cell proliferation is 
prohibited. WSB-1, a SOCS-box-containing WD-40 protein, is of unknown 
function in Hh signaling and no literature information available about the 
relationship between WSB-1 and cancers (Dentice et al., 2005). Transferrin (TF) is 
an essential growth factor of cell proliferation, differentiation and cell function. It 
is also being regulated in reproductive organs in vivo and reported to be expressed in 
MCF-7 breast cancer cells (Bradshaw & White，1985; Schaeffer et al., 1989; 
Vandewalle et al., 1989). Newbold et al. (1992) and Teng (1995) reported that this 
gene is estrogen-responsive in rodent reproductive tract. Down-regulation of this 
gene indicated that cell growth was inhibited which may be through estrogen 
receptor pathway. Heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) 
(HSPA5) plays a general role in helping proteins adopt and maintain native 
conformations. It also acts in cellular processes during which proteins are partially 
folded such as translation and transport across membranes, and protects cells from 
stress by preventing protein aggregation (Song and Masison, 2005). Apoptosis 
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inducer Tumor necrosis factor (ligand) superfamily, member 10 (TNFSFIO) was 
down-regulated by hybrid biomass extract which suggested that cell growth 
inhibition was TNFSF10-independent. 
The results of MCF-7 cells treated with hybrid pileus extract was similar to 
those treated with biomass extracts with genes of WNT2, HSPCA, TNFSFIO, WSBl, 
TF and C D K N 2 D down-regulated. BMP-4 and G A D D 4 5 A were also up-regulated in 
MCF-7 cells treated with pileus extract while they were the first and second highest 
gene being up-regulated. Baculoviral lAP repeat-containing 1 (BIRCl) gene was 
also up-regulated which suggested that inhibitory apoptotic protein may not be 
involved in apoptosis of MCF-7 cells induced by hybrid pileus extract. Interleukin 
4 receptor (IL4R) was up-regulated but the significance of expression of IL-4R on 
cancer cells is unknown. However, these receptors are able to mediate biological 
responses in cancer cells such as regulation of intercellular adhesion molecule-1 and 
major histocompatibility complex antigen expression, inhibition of cell growth, and 
induction of apoptosis (Beseth et al., 2004). 
Together with other analyses carried out in this study, lingzhi extracts affected 
estrogen pathway through estrogen responsive gene TF and pS2. Under the influence 
of lingzhi extract in the incubation medium of MCF-7 cells, apoptotic pathway was 
induced through up-regulation of Bax/Bcl-2 ratio (detected by reverse-transcriptase 
PGR) together with G A D D 4 5 A (detected by D N A microarray). Inhibition of cell 
proliferation (with the phenotype of decrease in viable cell counts) was mediated by 
down-regulation of HSPCA. 
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4.5. Further investigation 
The present study is the first research conducted on biotechnological breeding 
by protoplast fusion of Ganoderma spp. Anti-proliferative effect of breast cancer 
cell lines were evaluated and in vivo studies on the anti-tumor effect should be 
carried out for investigation of physiological response in animal. Certain 
compounds may also possesses anti-proliferative effect in crude extracts of 
Ganoderma spp. Isolation of these compounds is essential and anti-proliferative 
effect should be studied for verification. D N A fragmentation assay and flow 
cytometry should be carried out for investigation of induction of apoptosis by G. 
lucidum, G. tsugae and hybrid. 
This is the first report about the estrogenicity of G. lucidum, G. tsugae and 
hybrid. In vivo estrogenicity assay is essential to study for the physiological effect 
in animal in response to estrogenicity of the extracts. Lingzhi could be useful as 
hormone alternatives but further investigation are required to assess the physiological 
significance in animals and human. 
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5. Conclusion 
This is the first report on biotechnological breeding by interspecific protoplast 
fusion of Ganoderma spp. The hybrid strain was improved in terms of extended 
growth temperature range, growth rates and anti-proliferative effect on breast cancer 
cells. Different physiological stages of lingzhi were prepared in this study. Biomass 
and pileus extracts of G. lucidum, G. tsugae and their hybrid exhibited inhibitory 
effect on proliferation of estrogen-dependent breast cancer cell line MCF-7. The 
hybrid had better performance than its parents. Besides, pileus extracts also 
inhibited estrogen-independent breast cancer cell line MDA-MB-231 to a lesser 
extent. 
This is also the first report demonstrating that G, lucidum’ G. tsugae and hybrid 
biomass and pileus extracts show weak estrogenicity. Estrogenicity of pileus 
extracts were mediated by ER a and p where biomass extracts acted only via ER p. 
This may correlate with the initial proliferative phase of MCF-7 cells observed in the 
presence of lingzhi extracts. However, the anti-proliferation of breast cancer cells 
occurred at day 3 onwards. G. lucidum, G. tsugae and hybrid biomass and pileus 
extracts induced apoptosis by modulating Bcl-2 and Bax m R N A levels. Lingzhi 
polysaccharides and terpenes extracted from biomass and pileus showed anti-cancer 
efficacies. Synergic effect was observed in reconstitution of lingzhi 
polysaccharides and terpenes but similar to the effect on addition of polysaccharides 
in treating the MCF-7 cell. Polysaccharides seem to be the major bioactive 
component for anti-tumor effect in Ganoderma spp. Thus in addition to the 
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beneficial anti-cancer property, of Ganoderma spp. might have potency in hormonal 
therapy for menopausal women and hormonal related cancers. 
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